

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
1	Baxheinrich, 2012, 22894911	2010 (approx)	Germany	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
2	Baxheinrich, 2012, 22894911	2010 (approx)	Germany	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
3	Baxheinrich, 2012, 22894911	2010 (approx)	Germany	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
4	Baxheinrich, 2012, 22894911	2010 (approx)	Germany	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
5	Baxheinrich, 2012, 22894911	2010 (approx)	Germany	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
6	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
7	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
8	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
9	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
10	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
11	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
12	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
13	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
14	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
15	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
16	Bosch, 2012, 22686415	2003	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
1	Baxheinrich, 2012, 22894911	Diabetes and/or metabolic syndrome	81
2	Baxheinrich, 2012, 22894911	Diabetes and/or metabolic syndrome	81
3	Baxheinrich, 2012, 22894911	Diabetes and/or metabolic syndrome	81
4	Baxheinrich, 2012, 22894911	Diabetes and/or metabolic syndrome	81
5	Baxheinrich, 2012, 22894911	Diabetes and/or metabolic syndrome	81
6	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
7	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
8	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
9	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
10	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
11	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
12	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
13	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
14	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
15	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536
16	Bosch, 2012, 22686415	Diabetes and/or metabolic syndrome ; Hypertension ; Cardiac disease ; Cerebrovascular disease ; Peripheral vascular disease ; Arrhythmia	12536

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
1	Baxheinrich, 2012, 22894911	50.3 (9.8)	nd	nd
2	Baxheinrich, 2012, 22894911	50.3 (9.8)	nd	nd
3	Baxheinrich, 2012, 22894911	50.3 (9.8)	nd	nd
4	Baxheinrich, 2012, 22894911	50.3 (9.8)	nd	nd
5	Baxheinrich, 2012, 22894911	50.3 (9.8)	nd	nd
6	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
7	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
8	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
9	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
10	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
11	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
12	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
13	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
14	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
15	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd
16	Bosch, 2012, 22686415	63.6 (7.9)	64.7	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
1	Baxheinrich, 2012, 22894911	140.1 (12.4)/90.2 (7.7)
2	Baxheinrich, 2012, 22894911	140.1 (12.4)/90.2 (7.7)
3	Baxheinrich, 2012, 22894911	140.1 (12.4)/90.2 (7.7)
4	Baxheinrich, 2012, 22894911	140.1 (12.4)/90.2 (7.7)
5	Baxheinrich, 2012, 22894911	140.1 (12.4)/90.2 (7.7)
6	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
7	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
8	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
9	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
10	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
11	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
12	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
13	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
14	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
15	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)
16	Bosch, 2012, 22686415	146.0 (21.8)/84.2 (12.1)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
1	Baxheinrich, 2012, 22894911	[5.49 (1.09)]/[3.49 (0.92)]/[1.43 (0.34)]/[1.64 (1.02)]
2	Baxheinrich, 2012, 22894911	[5.49 (1.09)]/[3.49 (0.92)]/[1.43 (0.34)]/[1.64 (1.02)]
3	Baxheinrich, 2012, 22894911	[5.49 (1.09)]/[3.49 (0.92)]/[1.43 (0.34)]/[1.64 (1.02)]
4	Baxheinrich, 2012, 22894911	[5.49 (1.09)]/[3.49 (0.92)]/[1.43 (0.34)]/[1.64 (1.02)]
5	Baxheinrich, 2012, 22894911	[5.49 (1.09)]/[3.49 (0.92)]/[1.43 (0.34)]/[1.64 (1.02)]
6	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
7	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
8	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
9	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
10	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
11	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
12	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
13	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
14	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
15	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)
16	Bosch, 2012, 22686415	190 (47)/112 (40)/46 (12)/median 140 (97, 195)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
1	Baxheinrich, 2012, 22894911	35.2 (5.1)/99.4 (16.2)	nd	nd
2	Baxheinrich, 2012, 22894911	35.2 (5.1)/99.4 (16.2)	nd	nd
3	Baxheinrich, 2012, 22894911	35.2 (5.1)/99.4 (16.2)	nd	nd
4	Baxheinrich, 2012, 22894911	35.2 (5.1)/99.4 (16.2)	nd	nd
5	Baxheinrich, 2012, 22894911	35.2 (5.1)/99.4 (16.2)	nd	nd
6	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
7	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
8	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
9	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
10	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
11	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
12	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
13	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
14	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
15	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd
16	Bosch, 2012, 22686415	29.9 (5.2)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
1	Baxheinrich, 2012, 22894911	ALA vs ALA	g/d	Trial: Randomized Parallel	HDL-c
2	Baxheinrich, 2012, 22894911	ALA vs ALA	g/d	Trial: Randomized Parallel	LDL-c
3	Baxheinrich, 2012, 22894911	ALA vs ALA	g/d	Trial: Randomized Parallel	Tg
4	Baxheinrich, 2012, 22894911	ALA vs Placebo	g/d	Trial: Randomized Parallel	SBP
5	Baxheinrich, 2012, 22894911	ALA vs Placebo	g/d	Trial: Randomized Parallel	DBP
6	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Death, all cause
7	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Death, CVD (total)
8	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Myocardial infarction
9	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Revascularization
10	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Stroke
11	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Sudden cardiac death
12	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
13	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
14	Bosch, 2012, 22686415	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
15	Bosch, 2012, 22686415	ALA+DHA+EPA vs Placebo	g/d	Trial: Randomized Factorial Design	SBP
16	Bosch, 2012, 22686415	ALA+DHA+EPA vs Placebo	g/d	Trial: Randomized Factorial Design	DBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
1	Baxheinrich, 2012, 22894911	2.32 (-2.95, 7.59)	2.68	0.8656716
2	Baxheinrich, 2012, 22894911	1.93 (-11.97, 15.83)	2.68	0.7201493
3	Baxheinrich, 2012, 22894911	-22.12 (-59.01, 14.76)	2.68	-8.253732
4	Baxheinrich, 2012, 22894911	-1.8 (-8.3, 4.7)	3.46	-0.5202312
5	Baxheinrich, 2012, 22894911	-3.9 (-8.1, 0.3)	3.46	-1.127168
6	Bosch, 2012, 22686415	Adj HR 0.98 (0.89, 1.07)	0.84	0.976236
7	Bosch, 2012, 22686415	HR 0.98 (0.87, 1.10)	0.84	0.976236
8	Bosch, 2012, 22686415	Adj HR 1.09 (0.93, 1.27)	0.84	1.10804
9	Bosch, 2012, 22686415	HR 0.96 (0.87, 1.05)	0.84	0.9525644
10	Bosch, 2012, 22686415	HR 0.92 (0.79, 1.08)	0.84	0.9055038
11	Bosch, 2012, 22686415	OR 1.11 (0.94, 1.32)	0.63	1.180161
12	Bosch, 2012, 22686415	0.10 (-0.73, 0.93)	0.465	0.2150538
13	Bosch, 2012, 22686415	0.60 (-1.62, 2.82)	0.465	1.290323
14	Bosch, 2012, 22686415	-14.50 (-22.82, -6.18)	0.84	-17.26191
15	Bosch, 2012, 22686415	0.1 (-0.6, 0.9)	0.84	0.1190476
16	Bosch, 2012, 22686415	0.1 (-0.3, 0.5)	0.84	0.1190476

Causality Table: Comparative Studies

Row	Study	Outcome classification
1	Baxheinrich, 2012, 22894911	Secondary (per registry record DRKS00006232)
2	Baxheinrich, 2012, 22894911	Secondary (per registry record DRKS00006232)
3	Baxheinrich, 2012, 22894911	Secondary (per registry record DRKS00006232)
4	Baxheinrich, 2012, 22894911	Secondary (per registry record DRKS00006232)
5	Baxheinrich, 2012, 22894911	Secondary (per registry record DRKS00006232)
6	Bosch, 2012, 22686415	Secondary
7	Bosch, 2012, 22686415	Secondary; Primary in registry record (NCT00069784)
8	Bosch, 2012, 22686415	Primary (stated)
9	Bosch, 2012, 22686415	Secondary; Primary in registry record (NCT00069784)
10	Bosch, 2012, 22686415	Secondary; Primary in registry record (NCT00069784)
11	Bosch, 2012, 22686415	Secondary
12	Bosch, 2012, 22686415	Secondary
13	Bosch, 2012, 22686415	Secondary
14	Bosch, 2012, 22686415	Secondary
15	Bosch, 2012, 22686415	Secondary
16	Bosch, 2012, 22686415	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
17	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
18	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
19	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
20	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
21	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
22	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
23	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
24	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
25	Brinton, 2013, 23835245	nd	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
26	Brouwer, 2006, 16772624	2001	Germany, Netherlands, Sweden, UK, Poland, Czech Republic, Belgium, Austria	Secondary Prevention (history of CVD event)
27	Brouwer, 2006, 16772624	2001	Germany, Netherlands, Sweden, UK, Poland, Czech Republic, Belgium, Austria	Secondary Prevention (history of CVD event)
28	Brouwer, 2006, 16772624	2001	Germany, Netherlands, Sweden, UK, Poland, Czech Republic, Belgium, Austria,	Secondary Prevention (history of CVD event)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
17	Brinton, 2013, 23835245	nd	687
18	Brinton, 2013, 23835245	nd	687
19	Brinton, 2013, 23835245	nd	687
20	Brinton, 2013, 23835245	nd	687
21	Brinton, 2013, 23835245	nd	687
22	Brinton, 2013, 23835245	nd	687
23	Brinton, 2013, 23835245	nd	687
24	Brinton, 2013, 23835245	nd	687
25	Brinton, 2013, 23835245	nd	687
26	Brouwer, 2006, 16772624	Arrhythmia (at least 1 true, confirmed, spontaneous VT or VF in the preceding year, and either had and ICD or were about to receive one)	546
27	Brouwer, 2006, 16772624	Arrhythmia (at least 1 true, confirmed, spontaneous VT or VF in the preceding year, and either had and ICD or were about to receive one)	546
28	Brouwer, 2006, 16772624	Arrhythmia (at least 1 true, confirmed, spontaneous VT or VF in the preceding year, and either had and ICD or were about to receive one.)	546

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
17	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
18	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
19	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
20	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
21	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
22	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
23	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
24	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
25	Brinton, 2013, 23835245	61.2 (10.05)	62	96 white
26	Brouwer, 2006, 16772624	62.4 (11.4)	84	nd
27	Brouwer, 2006, 16772624	62.4 (11.4)	84	nd
28	Brouwer, 2006, 16772624	62.4 (11.4)	84	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
17	Brinton, 2013, 23835245	nd
18	Brinton, 2013, 23835245	nd
19	Brinton, 2013, 23835245	nd
20	Brinton, 2013, 23835245	nd
21	Brinton, 2013, 23835245	nd
22	Brinton, 2013, 23835245	nd
23	Brinton, 2013, 23835245	nd
24	Brinton, 2013, 23835245	nd
25	Brinton, 2013, 23835245	nd
26	Brouwer, 2006, 16772624	121.2 (18.5)/74.2 (9.1)
27	Brouwer, 2006, 16772624	121.2 (18.5)/74.2 (9.1)
28	Brouwer, 2006, 16772624	121.2 (18.5)/74.2 (9.1)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
17	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
18	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
19	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
20	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
21	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
22	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
23	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
24	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
25	Brinton, 2013, 23835245	median 168.0 (IQR 38.0)/median 84.0 (27)/median 37 (12)/median 259.0 (81)
26	Brouwer, 2006, 16772624	nd
27	Brouwer, 2006, 16772624	nd
28	Brouwer, 2006, 16772624	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
17	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
18	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
19	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
20	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
21	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
22	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
23	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
24	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
25	Brinton, 2013, 23835245	33.0 (5.04)	nd	nd
26	Brouwer, 2006, 16772624	26.86 (4.01)	nd	nd
27	Brouwer, 2006, 16772624	26.86 (4.01)	nd	nd
28	Brouwer, 2006, 16772624	26.86 (4.01)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
17	Brinton, 2013, 23835245	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
18	Brinton, 2013, 23835245	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
19	Brinton, 2013, 23835245	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
20	Brinton, 2013, 23835245	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
21	Brinton, 2013, 23835245	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
22	Brinton, 2013, 23835245	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
23	Brinton, 2013, 23835245	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
24	Brinton, 2013, 23835245	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
25	Brinton, 2013, 23835245	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
26	Brouwer, 2006, 16772624	EPA + DHA vs Placebo	g/d	Trial: Randomized Parallel	Arrhythmia composite
27	Brouwer, 2006, 16772624	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
28	Brouwer, 2006, 16772624	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, cardiac

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
17	Brinton, 2013, 23835245	-5.00 (-8.80, -1.20)	4	-1.25
18	Brinton, 2013, 23835245	-2.30 (-5.59, 0.98)	2	-1.15
19	Brinton, 2013, 23835245	-1.00 (nd)	2	-0.5
20	Brinton, 2013, 23835245	-3.80 (-8.97, 1.37)	2	-1.9
21	Brinton, 2013, 23835245	-6.30 (-11.61, 0.99)	4	-1.575
22	Brinton, 2013, 23835245	-4.00 (nd)	2	-2
23	Brinton, 2013, 23835245	-23.20 (-34.89, -11.51)	4	-5.8
24	Brinton, 2013, 23835245	-9.80 (-17.26, -2.34)	2	-4.9
25	Brinton, 2013, 23835245	-34.40 (nd)	2	-17.2
26	Brouwer, 2006, 16772624	0.86 (0.6, 1.23)	0.84	0.8356453
27	Brouwer, 2006, 16772624	OR 0.52 (0.22, 1.25)	0.799	0.4411232
28	Brouwer, 2006, 16772624	OR 0.45 (0.17, 1.20)	0.799	0.3681062

Causality Table: Comparative Studies

Row	Study	Outcome classification
17	Brinton, 2013, 23835245	Secondary
18	Brinton, 2013, 23835245	Secondary
19	Brinton, 2013, 23835245	Secondary
20	Brinton, 2013, 23835245	Secondary
21	Brinton, 2013, 23835245	Secondary
22	Brinton, 2013, 23835245	Secondary
23	Brinton, 2013, 23835245	Primary (stated)
24	Brinton, 2013, 23835245	Primary (stated)
25	Brinton, 2013, 23835245	Primary (stated)
26	Brouwer, 2006, 16772624	Secondary
27	Brouwer, 2006, 16772624	Secondary
28	Brouwer, 2006, 16772624	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
29	Brouwer, 2006, 16772624	2001	Germany, Netherlands, Sweden, UK, Poland, Czech Republic, Belgium, Austria	Secondary Prevention (history of CVD event)
30	Burr, 1989, 2571009	1987 (Approx)	UK	Secondary Prevention (history of CVD event)
31	Burr, 1989, 2571009	1987 (Approx)	UK	Secondary Prevention (history of CVD event)
32	Burr, 1989, 2571009	1987 (Approx)	UK	Secondary Prevention (history of CVD event)
34	Burr, 1989, 2571009	1987 (Approx)	UK	Secondary Prevention (history of CVD event)
35	Burr, 1989, 2571009	1987 (Approx)	UK	Secondary Prevention (history of CVD event)
36	Burr, 2003, 12571649, UK	1990	UK	Secondary Prevention (history of CVD event)
37	Burr, 2003, 12571649, UK	1990	UK	Secondary Prevention (history of CVD event)
38	Carrepeiro, 2011, 21561620	2008 (approx)	Brazil	Primary Prevention, Healthy
39	Carrepeiro, 2011, 21561620	2008 (approx)	Brazil	Primary Prevention, Healthy
40	Carrepeiro, 2011, 21561620	2008 (approx)	Brazil	Primary Prevention, Healthy
41	Carrepeiro, 2011, 21561620	2008 (approx)	Brazil	Primary Prevention, Healthy
42	Carrepeiro, 2011, 21561620	2008 (approx)	Brazil	Primary Prevention, Healthy
43	Carrepeiro, 2011, 21561620	2008 (approx)	Brazil	Primary Prevention, Healthy
44	Carter, 2012, 22707560	2010 (Approx)	US	Primary Prevention, Healthy
45	Carter, 2012, 22707560	2010 (Approx)	US	Primary Prevention, Healthy
46	Carter, 2012, 22707560	2010 (Approx)	US	Primary Prevention, Healthy
47	Carter, 2012, 22707560	2010 (Approx)	US	Primary Prevention, Healthy
48	Carter, 2012, 22707560	2010 (Approx)	US	Primary Prevention, Healthy
49	Carter, 2012, 22707560	2010 (Approx)	US	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
29	Brouwer, 2006, 16772624	Arrhythmia (at least 1 true, confirmed, spontaneous VT or VF in the preceding year, and either had and ICD or were about to receive one)	546
30	Burr, 1989, 2571009	Cardiac disease (Previous MI)	2033
31	Burr, 1989, 2571009	Cardiac disease (Previous MI)	2033
32	Burr, 1989, 2571009	Cardiac disease (Previous MI)	2033
34	Burr, 1989, 2571009	Cardiac disease (Previous MI)	2033
35	Burr, 1989, 2571009	Cardiac disease (Previous MI)	2033
36	Burr, 2003, 12571649, UK	Cardiac disease (Angina)	3114
37	Burr, 2003, 12571649, UK	Cardiac disease (Angina)	3114
38	Carrepeiro, 2011, 21561620	na	43
39	Carrepeiro, 2011, 21561620	na	43
40	Carrepeiro, 2011, 21561620	na	43
41	Carrepeiro, 2011, 21561620	na	43
42	Carrepeiro, 2011, 21561620	na	43
43	Carrepeiro, 2011, 21561620	na	43
44	Carter, 2012, 22707560	na	67
45	Carter, 2012, 22707560	na	67
46	Carter, 2012, 22707560	na	67
47	Carter, 2012, 22707560	na	67
48	Carter, 2012, 22707560	na	67
49	Carter, 2012, 22707560	na	67

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
29	Brouwer, 2006, 16772624	62.4 (11.4)	84	nd
30	Burr, 1989, 2571009	56.4	100	nd
31	Burr, 1989, 2571009	56.4	100	nd
32	Burr, 1989, 2571009	56.4	100	nd
34	Burr, 1989, 2571009	56.4	100	nd
35	Burr, 1989, 2571009	56.4	100	nd
36	Burr, 2003, 12571649, UK	61	100	nd
37	Burr, 2003, 12571649, UK	61	100	nd
38	Carrepeiro, 2011, 21561620	61.3 (7.8)	0	65 white, 14 black, 5 Asian, 16 American lian
39	Carrepeiro, 2011, 21561620	61.3 (7.8)	0	65 white, 14 black, 5 Asian, 16 American lian
40	Carrepeiro, 2011, 21561620	61.3 (7.8)	0	65 white, 14 black, 5 Asian, 16 American lian
41	Carrepeiro, 2011, 21561620	61.3 (7.8)	0	65 white, 14 black, 5 Asian, 16 American lian
42	Carrepeiro, 2011, 21561620	61.3 (7.8)	0	65 white, 14 black, 5 Asian, 16 American lian
43	Carrepeiro, 2011, 21561620	61.3 (7.8)	0	65 white, 14 black, 5 Asian, 16 American lian
44	Carter, 2012, 22707560	24 (SE 2)	90	nd
45	Carter, 2012, 22707560	24 (SE 2)	90	nd
46	Carter, 2012, 22707560	24 (SE 2)	90	nd
47	Carter, 2012, 22707560	24 (SE 2)	90	nd
48	Carter, 2012, 22707560	24 (SE 2)	90	nd
49	Carter, 2012, 22707560	24 (SE 2)	90	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
29	Brouwer, 2006, 16772624	121.2 (18.5)/74.2 (9.1)
30	Burr, 1989, 2571009	130.1 (21.0)/80.2 (12.5)
31	Burr, 1989, 2571009	130.1 (21.0)/80.2 (12.5)
32	Burr, 1989, 2571009	130.1 (21.0)/80.2 (12.5)
34	Burr, 1989, 2571009	130.1 (21.0)/80.2 (12.5)
35	Burr, 1989, 2571009	130.1 (21.0)/80.2 (12.5)
36	Burr, 2003, 12571649, UK	141.6/84.6
37	Burr, 2003, 12571649, UK	141.6/84.6
38	Carrepeiro, 2011, 21561620	nd
39	Carrepeiro, 2011, 21561620	nd
40	Carrepeiro, 2011, 21561620	nd
41	Carrepeiro, 2011, 21561620	nd
42	Carrepeiro, 2011, 21561620	nd
43	Carrepeiro, 2011, 21561620	nd
44	Carter, 2012, 22707560	normotensive: 107 (SE 2)/65 (SE 1), prehypertensive:
45	Carter, 2012, 22707560	normotensive: 107 (SE 2)/65 (SE 1), prehypertensive:
46	Carter, 2012, 22707560	normotensive: 107 (SE 2)/65 (SE 1), prehypertensive:
47	Carter, 2012, 22707560	normotensive: 107 (SE 2)/65 (SE 1), prehypertensive:
48	Carter, 2012, 22707560	normotensive: 107 (SE 2)/65 (SE 1), prehypertensive:
49	Carter, 2012, 22707560	normotensive: 107 (SE 2)/65 (SE 1), prehypertensive:

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
29	Brouwer, 2006, 16772624	nd
30	Burr, 1989, 2571009	nd
31	Burr, 1989, 2571009	nd
32	Burr, 1989, 2571009	nd
34	Burr, 1989, 2571009	nd
35	Burr, 1989, 2571009	nd
36	Burr, 2003, 12571649, UK	6.4/nd/nd/nd
37	Burr, 2003, 12571649, UK	6.4/nd/nd/nd
38	Carrepeiro, 2011, 21561620	208 (36.8)/134.8 (34.1)/50.1 (12.4)/117.5 (48.5)
39	Carrepeiro, 2011, 21561620	208 (36.8)/134.8 (34.1)/50.1 (12.4)/117.5 (48.5)
40	Carrepeiro, 2011, 21561620	208 (36.8)/134.8 (34.1)/50.1 (12.4)/117.5 (48.5)
41	Carrepeiro, 2011, 21561620	208 (36.8)/134.8 (34.1)/50.1 (12.4)/117.5 (48.5)
42	Carrepeiro, 2011, 21561620	208 (36.8)/134.8 (34.1)/50.1 (12.4)/117.5 (48.5)
43	Carrepeiro, 2011, 21561620	208 (36.8)/134.8 (34.1)/50.1 (12.4)/117.5 (48.5)
44	Carter, 2012, 22707560	nd
45	Carter, 2012, 22707560	nd
46	Carter, 2012, 22707560	nd
47	Carter, 2012, 22707560	nd
48	Carter, 2012, 22707560	nd
49	Carter, 2012, 22707560	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
29	Brouwer, 2006, 16772624	26.86 (4.01)	nd	nd
30	Burr, 1989, 2571009	26	nd	nd
31	Burr, 1989, 2571009	26	nd	nd
32	Burr, 1989, 2571009	26	nd	nd
34	Burr, 1989, 2571009	26	nd	nd
35	Burr, 1989, 2571009	26	nd	nd
36	Burr, 2003, 12571649, UK	28.1	EPA 3.19 (1.75) mg/dl	plasma
37	Burr, 2003, 12571649, UK	28.1	EPA 3.19 (1.75) mg/dl	plasma
38	Carrepeiro, 2011, 21561620	28.2 (4.8)	nd	nd
39	Carrepeiro, 2011, 21561620	28.2 (4.8)	nd	nd
40	Carrepeiro, 2011, 21561620	28.2 (4.8)	nd	nd
41	Carrepeiro, 2011, 21561620	28.2 (4.8)	nd	nd
42	Carrepeiro, 2011, 21561620	28.2 (4.8)	nd	nd
43	Carrepeiro, 2011, 21561620	28.2 (4.8)	nd	nd
44	Carter, 2012, 22707560	normotensive: 24 (SE 1)/70 (SE 2), prehypertensive 27 (SE 1)/87 (SE 2)	nd	nd
45	Carter, 2012, 22707560	normotensive: 24 (SE 1)/70 (SE 2), prehypertensive 27 (SE 1)/87 (SE 2)	nd	nd
46	Carter, 2012, 22707560	normotensive: 24 (SE 1)/70 (SE 2), prehypertensive 27 (SE 1)/87 (SE 2)	nd	nd
47	Carter, 2012, 22707560	normotensive: 24 (SE 1)/70 (SE 2), prehypertensive 27 (SE 1)/87 (SE 2)	nd	nd
48	Carter, 2012, 22707560	normotensive: 24 (SE 1)/70 (SE 2), prehypertensive 27 (SE 1)/87 (SE 2)	nd	nd
49	Carter, 2012, 22707560	normotensive: 24 (SE 1)/70 (SE 2), prehypertensive 27 (SE 1)/87 (SE 2)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
29	Brouwer, 2006, 16772624	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
30	Burr, 1989, 2571009	EPA vs EPA	g/d	Trial: Randomized Factorial Design	Death, all cause
31	Burr, 1989, 2571009	EPA vs EPA	mg/dl	Trial: Randomized Factorial Design	Death, cardiac
32	Burr, 1989, 2571009	EPA vs EPA	g/d	Trial: Randomized Factorial Design	Myocardial infarction
34	Burr, 1989, 2571009	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	SBP
35	Burr, 1989, 2571009	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	DBP
36	Burr, 2003, 12571649, UK	EPA+DHA vs EPA	g/d	Trial: Randomized Factorial Design	Death, all cause
37	Burr, 2003, 12571649, UK	EPA vs. EPA	g/d	Trial: Randomized Factorial Design	Death, cardiac
38	Carrepeiro, 2011, 21561620	EPA+DHA + Statin vs Placebo + Statin	g/d	Trial: Randomized Cross-over	HDL-c
39	Carrepeiro, 2011, 21561620	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
40	Carrepeiro, 2011, 21561620	EPA+DHA + Statin vs Placebo + Statin	g/d	Trial: Randomized Cross-over	LDL-c
41	Carrepeiro, 2011, 21561620	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
42	Carrepeiro, 2011, 21561620	EPA+DHA + Statin vs Placebo + Statin	g/d	Trial: Randomized Cross-over	Tg
43	Carrepeiro, 2011, 21561620	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
44	Carter, 2012, 22707560	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
45	Carter, 2012, 22707560	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
46	Carter, 2012, 22707560	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
47	Carter, 2012, 22707560	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
48	Carter, 2012, 22707560	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP
49	Carter, 2012, 22707560	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
29	Brouwer, 2006, 16772624	OR 0.33 (0.03, 3.20)	0.799	0.2496831
30	Burr, 1989, 2571009	Adj HR 0.95 (0.85, 1.07)	0.25	0.8145062
31	Burr, 1989, 2571009	Adj HR 0.92 (0.80, 1.07)	0.25	0.7163929
32	Burr, 1989, 2571009	Adj RR 0.84 (0.66, 1.07)	0.25	0.4978714
34	Burr, 1989, 2571009	0.40 (-1.33, 2.13)	0.357	1.120448
35	Burr, 1989, 2571009	0.19 (-0.88, 1.26)	0.357	0.5322129
36	Burr, 2003, 12571649, UK	Adj HR 1.19 (0.92, 1.54)	NA	
37	Burr, 2003, 12571649, UK	Adj HR 0.92 (0.80, 1.07)	0.25	0.7163929
38	Carrepeiro, 2011, 21561620	1.85 (nd)	2.4	0.7708333
39	Carrepeiro, 2011, 21561620	-1.34 (nd)	2.4	-0.5583333
40	Carrepeiro, 2011, 21561620	-1.54 (-3.52, 0.44)	2.4	-0.6416667
41	Carrepeiro, 2011, 21561620	-0.79 (-2.76, 1.18)	2.4	-0.3291667
42	Carrepeiro, 2011, 21561620	-1.96 (-3.95, 0.03)	2.4	-0.8166667
43	Carrepeiro, 2011, 21561620	-1.79 (-3.77, 0.19)	2.4	-0.7458333
44	Carter, 2012, 22707560	-3 (-7, 1)	2.7	-1.111111
45	Carter, 2012, 22707560	1 (-4.2, 6.2)	2.7	0.3703704
46	Carter, 2012, 22707560	-1.0 (-3.6, 1.6)	2.7	-0.3703704
47	Carter, 2012, 22707560	0 (-5.2, 5.2)	2.7	0
48	Carter, 2012, 22707560	-1 (-3.8, 1.8)	2.7	-0.3703704
49	Carter, 2012, 22707560	1 (-3.8, 5.8)	2.7	0.3703704

Causality Table: Comparative Studies

Row	Study	Outcome classification
29	Brouwer, 2006, 16772624	Secondary
30	Burr, 1989, 2571009	Secondary
31	Burr, 1989, 2571009	Secondary
32	Burr, 1989, 2571009	Primary (stated)
34	Burr, 1989, 2571009	Secondary
35	Burr, 1989, 2571009	Secondary
36	Burr, 2003, 12571649, UK	Primary (stated)
37	Burr, 2003, 12571649, UK	Secondary
38	Carrepeiro, 2011, 21561620	Secondary
39	Carrepeiro, 2011, 21561620	Secondary
40	Carrepeiro, 2011, 21561620	Secondary
41	Carrepeiro, 2011, 21561620	Secondary
42	Carrepeiro, 2011, 21561620	Secondary
43	Carrepeiro, 2011, 21561620	Secondary
44	Carter, 2012, 22707560	Primary (stated)
45	Carter, 2012, 22707560	Primary (stated)
46	Carter, 2012, 22707560	Primary (stated)
47	Carter, 2012, 22707560	Primary (stated)
48	Carter, 2012, 22707560	Primary (stated)
49	Carter, 2012, 22707560	Primary (stated)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
50	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
51	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
52	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
53	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
54	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
55	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
56	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
57	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
50	Caslake, 2008, 18779276	na	312
51	Caslake, 2008, 18779276	na	312
52	Caslake, 2008, 18779276	na	312
53	Caslake, 2008, 18779276	na	312
54	Caslake, 2008, 18779276	na	312
55	Caslake, 2008, 18779276	na	312
56	Caslake, 2008, 18779276	na	312
57	Caslake, 2008, 18779276	na	312

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
50	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
51	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
52	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
53	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
54	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
55	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
56	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
57	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
50	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
51	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
52	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
53	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
54	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
55	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
56	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
57	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
50	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
51	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
52	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
53	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
54	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
55	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
56	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
57	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
50	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
51	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
52	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
53	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
54	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
55	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
56	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
57	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
50	Caslake, 2008, 18779276	EPA+DHA vs Placebo	% FA	Trial: Randomized Cross-over	HDL-c
51	Caslake, 2008, 18779276	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
52	Caslake, 2008, 18779276	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Cross-over	HDL-c
53	Caslake, 2008, 18779276	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
54	Caslake, 2008, 18779276	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
55	Caslake, 2008, 18779276	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Cross-over	LDL-c
56	Caslake, 2008, 18779276	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
57	Caslake, 2008, 18779276	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	Tg

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
50	Caslake, 2008, 18779276	2.32 (0.18, 4.46)	1.8	1.288889
51	Caslake, 2008, 18779276	2.32 (0.18, 4.46)	0.7	3.314286
52	Caslake, 2008, 18779276	0.00 (-2.14, 2.14)	1.1	0
53	Caslake, 2008, 18779276	2.70 (-2.96, 8.37)	1.8	1.5
54	Caslake, 2008, 18779276	2.70 (-2.65, 8.05)	0.7	3.857143
55	Caslake, 2008, 18779276	0.00 (-5.66, 5.66)	1.1	0
56	Caslake, 2008, 18779276	-1.42 (-23.50, -4.82)	1.8	-0.788889
57	Caslake, 2008, 18779276	-8.00 (-17.34, 1.34)	0.7	-11.42857

Causality Table: Comparative Studies

Row	Study	Outcome classification
50	Caslake, 2008, 18779276	Secondary
51	Caslake, 2008, 18779276	Secondary
52	Caslake, 2008, 18779276	Secondary
53	Caslake, 2008, 18779276	Primary (power analysis)
54	Caslake, 2008, 18779276	Primary (power analysis)
55	Caslake, 2008, 18779276	Primary (power analysis)
56	Caslake, 2008, 18779276	Primary (power analysis)
57	Caslake, 2008, 18779276	Primary (power analysis)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
58	Caslake, 2008, 18779276	2003	UK	Primary Prevention, Healthy
59	Damsgaard, 2008, 18492834	2005	Denmark	Primary Prevention, Healthy
60	Damsgaard, 2008, 18492834	2005	Denmark	Primary Prevention, Healthy
61	Damsgaard, 2008, 18492834	2005	Denmark	Primary Prevention, Healthy
62	Damsgaard, 2008, 18492834	2005	Denmark	Primary Prevention, Healthy
63	Damsgaard, 2008, 18492834	2005	Denmark	Primary Prevention, Healthy
64	Damsgaard, 2008, 18492834	2005	Denmark	Primary Prevention, Healthy
65	Derosa, 2009, 19397392	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
66	Derosa, 2009, 19397392	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
67	Derosa, 2009, 19397392	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
68	Derosa, 2009, 19397392	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
69	Derosa, 2009, 19397392	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
70	Earnest, 2012, 22811376	2009 (Approx)	US	Primary Prevention, Healthy; Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
71	Ebrahimi, 2009, 19593941	2007 (Approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
72	Ebrahimi, 2009, 19593941	2007 (Approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
73	Ebrahimi, 2009, 19593941	2007 (Approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
74	Ebrahimi, 2009, 19593941	2007 (Approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
58	Caslake, 2008, 18779276	na	312
59	Damsgaard, 2008, 18492834	na	64
60	Damsgaard, 2008, 18492834	na	64
61	Damsgaard, 2008, 18492834	na	64
62	Damsgaard, 2008, 18492834	na	64
63	Damsgaard, 2008, 18492834	na	64
64	Damsgaard, 2008, 18492834	na	64
65	Derosa, 2009, 19397392	Dyslipidemia (total cholesterol (TC) > 200 mg/dl and triglycerides (Tg) > 200 mg/dl)	333
66	Derosa, 2009, 19397392	Dyslipidemia (total cholesterol (TC) > 200 mg/dl and triglycerides (Tg) > 200 mg/dl)	333
67	Derosa, 2009, 19397392	Dyslipidemia (total cholesterol (TC) > 200 mg/dl and triglycerides (Tg) > 200 mg/dl)	333
68	Derosa, 2009, 19397392	Dyslipidemia (total cholesterol (TC) > 200 mg/dl and triglycerides (Tg) > 200 mg/dl)	333
69	Derosa, 2009, 19397392	Dyslipidemia (total cholesterol (TC) > 200 mg/dl and triglycerides (Tg) > 200 mg/dl)	333
70	Earnest, 2012, 22811376	Diabetes and/or metabolic syndrome; Hypertension ; Dyslipidemia	92
71	Ebrahimi, 2009, 19593941	Diabetes and/or metabolic syndrome	89
72	Ebrahimi, 2009, 19593941	Diabetes and/or metabolic syndrome	89
73	Ebrahimi, 2009, 19593941	Diabetes and/or metabolic syndrome	89
74	Ebrahimi, 2009, 19593941	Diabetes and/or metabolic syndrome	89

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
58	Caslake, 2008, 18779276	45 (SE 0.7)	47.76	nd
59	Damsgaard, 2008, 18492834	25.5 (4.4)	100	nd
60	Damsgaard, 2008, 18492834	25.5 (4.4)	100	nd
61	Damsgaard, 2008, 18492834	25.5 (4.4)	100	nd
62	Damsgaard, 2008, 18492834	25.5 (4.4)	100	nd
63	Damsgaard, 2008, 18492834	25.5 (4.4)	100	nd
64	Damsgaard, 2008, 18492834	25.5 (4.4)	100	nd
65	Derosa, 2009, 19397392	50.7 (6.8)	49.7	nd
66	Derosa, 2009, 19397392	50.7 (6.8)	49.7	nd
67	Derosa, 2009, 19397392	50.7 (6.8)	49.7	nd
68	Derosa, 2009, 19397392	50.7 (6.8)	49.7	nd
69	Derosa, 2009, 19397392	50.7 (6.8)	49.7	nd
70	Earnest, 2012, 22811376	52.9 (10.7) [range 30, 70]	55	77 white, 13 black, 10 Hispanic
71	Ebrahimi, 2009, 19593941	52.3 (11.1)	nd	nd
72	Ebrahimi, 2009, 19593941	52.3 (11.1)	nd	nd
73	Ebrahimi, 2009, 19593941	52.3 (11.1)	nd	nd
74	Ebrahimi, 2009, 19593941	52.3 (11.1)	nd	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
58	Caslake, 2008, 18779276	126 (SE 2)/74 (SE 2)
59	Damsgaard, 2008, 18492834	115 (6)/nd
60	Damsgaard, 2008, 18492834	115 (6)/nd
61	Damsgaard, 2008, 18492834	115 (6)/nd
62	Damsgaard, 2008, 18492834	115 (6)/nd
63	Damsgaard, 2008, 18492834	115 (6)/nd
64	Damsgaard, 2008, 18492834	115 (6)/nd
65	Derosa, 2009, 19397392	129.6 (6.8)/81.4 (7.1)
66	Derosa, 2009, 19397392	129.6 (6.8)/81.4 (7.1)
67	Derosa, 2009, 19397392	129.6 (6.8)/81.4 (7.1)
68	Derosa, 2009, 19397392	129.6 (6.8)/81.4 (7.1)
69	Derosa, 2009, 19397392	129.6 (6.8)/81.4 (7.1)
70	Earnest, 2012, 22811376	nd
71	Ebrahimi, 2009, 19593941	129.6 (19.8)/78.3 (13.4)
72	Ebrahimi, 2009, 19593941	129.6 (19.8)/78.3 (13.4)
73	Ebrahimi, 2009, 19593941	129.6 (19.8)/78.3 (13.4)
74	Ebrahimi, 2009, 19593941	129.6 (19.8)/78.3 (13.4)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
58	Caslake, 2008, 18779276	[5.12 (SE 0.06)]/[3.22 (SE 0.05)]/[1.42 (SE 0.02)]/[1.26 (SE 0.03)]
59	Damsgaard, 2008, 18492834	[4.12 (SE 0.20)]/[2.71 (SE 0.18)]/[1.50 (SE 0.09)]/[median 1.01]
60	Damsgaard, 2008, 18492834	[4.12 (SE 0.20)]/[2.71 (SE 0.18)]/[1.50 (SE 0.09)]/[median 1.01]
61	Damsgaard, 2008, 18492834	[4.12 (SE 0.20)]/[2.71 (SE 0.18)]/[1.50 (SE 0.09)]/[median 1.01]
62	Damsgaard, 2008, 18492834	[4.12 (SE 0.20)]/[2.71 (SE 0.18)]/[1.50 (SE 0.09)]/[median 1.01]
63	Damsgaard, 2008, 18492834	[4.12 (SE 0.20)]/[2.71 (SE 0.18)]/[1.50 (SE 0.09)]/[median 1.01]
64	Damsgaard, 2008, 18492834	[4.12 (SE 0.20)]/[2.71 (SE 0.18)]/[1.50 (SE 0.09)]/[median 1.01]
65	Derosa, 2009, 19397392	227.5 (16.3)/149.9 (7.5)/39.7 (5.1)/189.3 (41.8)
66	Derosa, 2009, 19397392	227.5 (16.3)/149.9 (7.5)/39.7 (5.1)/189.3 (41.8)
67	Derosa, 2009, 19397392	227.5 (16.3)/149.9 (7.5)/39.7 (5.1)/189.3 (41.8)
68	Derosa, 2009, 19397392	227.5 (16.3)/149.9 (7.5)/39.7 (5.1)/189.3 (41.8)
69	Derosa, 2009, 19397392	227.5 (16.3)/149.9 (7.5)/39.7 (5.1)/189.3 (41.8)
70	Earnest, 2012, 22811376	[4.77 (0.99)]/[2.72 (0.83)]/[1.48 (0.51)]/1.25 (0.57)
71	Ebrahimi, 2009, 19593941	[5.75 (1.04)]/[3.71 (0.72)]/[1.12 (0.19)]/5.75 (1.04)
72	Ebrahimi, 2009, 19593941	[5.75 (1.04)]/[3.71 (0.72)]/[1.12 (0.19)]/5.75 (1.04)
73	Ebrahimi, 2009, 19593941	[5.75 (1.04)]/[3.71 (0.72)]/[1.12 (0.19)]/5.75 (1.04)
74	Ebrahimi, 2009, 19593941	[5.75 (1.04)]/[3.71 (0.72)]/[1.12 (0.19)]/5.75 (1.04)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
58	Caslake, 2008, 18779276	25.2 (SE 0.19)/73.0 (SE 0.8)	EPA: 1.6 (SEM 0.04) % FA, DPA: 1.09 (0.01)% FA, DHA: 4.41 (0.07)% FA, EPA+DPA+DHA: 7.17 (0.11) % FA	plasma phosphatidylcholine fatty acid
59	Damsgaard, 2008, 18492834	23.3 (1.9)/79.3 (9.3)	nd	nd
60	Damsgaard, 2008, 18492834	23.3 (1.9)/79.3 (9.3)	nd	nd
61	Damsgaard, 2008, 18492834	23.3 (1.9)/79.3 (9.3)	nd	nd
62	Damsgaard, 2008, 18492834	23.3 (1.9)/79.3 (9.3)	nd	nd
63	Damsgaard, 2008, 18492834	23.3 (1.9)/79.3 (9.3)	nd	nd
64	Damsgaard, 2008, 18492834	23.3 (1.9)/79.3 (9.3)	nd	nd
65	Derosa, 2009, 19397392	26.0 (1.1)	nd	nd
66	Derosa, 2009, 19397392	26.0 (1.1)	nd	nd
67	Derosa, 2009, 19397392	26.0 (1.1)	nd	nd
68	Derosa, 2009, 19397392	26.0 (1.1)	nd	nd
69	Derosa, 2009, 19397392	26.0 (1.1)	nd	nd
70	Earnest, 2012, 22811376	26.3 (4.4)	nd	nd
71	Ebrahimi, 2009, 19593941	30.4 (6.1)/69.5 (14.6)	nd	nd
72	Ebrahimi, 2009, 19593941	30.4 (6.1)/69.5 (14.6)	nd	nd
73	Ebrahimi, 2009, 19593941	30.4 (6.1)/69.5 (14.6)	nd	nd
74	Ebrahimi, 2009, 19593941	30.4 (6.1)/69.5 (14.6)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
58	Caslake, 2008, 18779276	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Cross-over	Tg
59	Damsgaard, 2008, 18492834	EPA+DHA + high LA vs Placebo + high LA	g/d	Trial: Randomized Factorial Design	HDL-c
60	Damsgaard, 2008, 18492834	EPA+DHA + low LA vs Placebo + low LA	g/d	Trial: Randomized Factorial Design	HDL-c
61	Damsgaard, 2008, 18492834	EPA+DHA + high LA vs Placebo + high LA	g/d	Trial: Randomized Factorial Design	LDL-c
62	Damsgaard, 2008, 18492834	EPA+DHA + low LA vs Placebo + low LA	g/d	Trial: Randomized Factorial Design	LDL-c
63	Damsgaard, 2008, 18492834	EPA+DHA + high LA vs Placebo + high LA	g/d	Trial: Randomized Factorial Design	Tg
64	Damsgaard, 2008, 18492834	EPA+DHA + low LA vs Placebo + low LA	g/d	Trial: Randomized Factorial Design	Tg
65	Derosa, 2009, 19397392	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
66	Derosa, 2009, 19397392	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
67	Derosa, 2009, 19397392	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
68	Derosa, 2009, 19397392	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
69	Derosa, 2009, 19397392	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
70	Earnest, 2012, 22811376	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
71	Ebrahimi, 2009, 19593941	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
72	Ebrahimi, 2009, 19593941	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
73	Ebrahimi, 2009, 19593941	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
74	Ebrahimi, 2009, 19593941	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
58	Caslake, 2008, 18779276	-6.19 (-15.04, 2.65)	1.1	-5.627273
59	Damsgaard, 2008, 18492834	0.39 (-5.67, 6.44)	3.1	0.1258065
60	Damsgaard, 2008, 18492834	3.09 (-7.83, 14.00)	3.1	0.9967742
61	Damsgaard, 2008, 18492834	3.47 (-8.98, 15.93)	3.1	1.119355
62	Damsgaard, 2008, 18492834	5.41 (-15.10, 25.91)	3.1	1.745161
63	Damsgaard, 2008, 18492834	1.70 (nd)	3.1	0.5483871
64	Damsgaard, 2008, 18492834	43.40 (nd)	3.1	14
65	Derosa, 2009, 19397392	3.90 (2.73, 5.07)	2.4	1.625
66	Derosa, 2009, 19397392	0.70 (-0.83, 2.23)	2.4	0.2916667
67	Derosa, 2009, 19397392	-59.20 (-67.35, -51.05)	2.4	-24.66667
68	Derosa, 2009, 19397392	0 (-1.4, 1.4)	2.4	0
69	Derosa, 2009, 19397392	0.2 (-1.3, 1.7)	2.4	0.0833333
70	Earnest, 2012, 22811376	82.30 (-66.53, 231.13)	2	41.15
71	Ebrahimi, 2009, 19593941	-0.39 (-13.01, 12.23)	0.3	-1.3
72	Ebrahimi, 2009, 19593941	5.41 (-50.63, 61.44)	0.3	18.03333
73	Ebrahimi, 2009, 19593941	-7.08 (nd)	0.3	-23.6
74	Ebrahimi, 2009, 19593941	-5.3 (-13.5, 2.9)	0.3	-17.66667

Causality Table: Comparative Studies

Row	Study	Outcome classification
58	Caslake, 2008, 18779276	Primary (power analysis)
59	Damsgaard, 2008, 18492834	Primary (implied)
60	Damsgaard, 2008, 18492834	Primary (implied)
61	Damsgaard, 2008, 18492834	Primary (implied)
62	Damsgaard, 2008, 18492834	Primary (implied)
63	Damsgaard, 2008, 18492834	Primary (implied)
64	Damsgaard, 2008, 18492834	Primary (implied)
65	Derosa, 2009, 19397392	Secondary
66	Derosa, 2009, 19397392	Secondary
67	Derosa, 2009, 19397392	Secondary
68	Derosa, 2009, 19397392	Secondary
69	Derosa, 2009, 19397392	Secondary
70	Earnest, 2012, 22811376	Secondary
71	Ebrahimi, 2009, 19593941	Secondary
72	Ebrahimi, 2009, 19593941	Secondary
73	Ebrahimi, 2009, 19593941	Secondary
74	Ebrahimi, 2009, 19593941	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
75	Ebrahimi, 2009, 19593941	2007 (Approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
76	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
77	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
78	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
79	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
80	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
81	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
82	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
75	Ebrahimi, 2009, 19593941	Diabetes and/or metabolic syndrome	89
76	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
77	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
78	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
79	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
80	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
81	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
82	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
75	Ebrahimi, 2009, 19593941	52.3 (11.1)	nd	nd
76	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
77	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
78	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
79	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
80	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
81	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
82	Einvik, 2010, 20389249	69.7 (3.0)	100	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
75	Ebrahimi, 2009, 19593941	129.6 (19.8)/78.3 (13.4)
76	Einvik, 2010, 20389249	147 (20)/83 (11)
77	Einvik, 2010, 20389249	147 (20)/83 (11)
78	Einvik, 2010, 20389249	147 (20)/83 (11)
79	Einvik, 2010, 20389249	147 (20)/83 (11)
80	Einvik, 2010, 20389249	147 (20)/83 (11)
81	Einvik, 2010, 20389249	147 (20)/83 (11)
82	Einvik, 2010, 20389249	147 (20)/83 (11)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
75	Ebrahimi, 2009, 19593941	[5.75 (1.04)]/[3.71 (0.72)]/[1.12 (0.19)]/5.75 (1.04)
76	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
77	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
78	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
79	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
80	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
81	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
82	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
75	Ebrahimi, 2009, 19593941	30.4 (6.1)/69.5 (14.6)	nd	nd
76	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
77	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
78	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
79	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
80	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
81	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
82	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
75	Ebrahimi, 2009, 19593941	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
76	Einvik, 2010, 20389249	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Death, all cause
77	Einvik, 2010, 20389249	EPA+DHA + diet intervention vs placebo (Corn oil)	g/d	Trial: Randomized Factorial Design	Death, CVD (total)
78	Einvik, 2010, 20389249	EPA+DHA + diet intervention vs Placebo + diet intervention	g/d	Trial: Randomized Factorial Design	MACE
79	Einvik, 2010, 20389249	EPA+DHA +/- diet intervention vs Placebo +/- diet intervention	g/d	Trial: Randomized Factorial Design	MACE
80	Einvik, 2010, 20389249	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
81	Einvik, 2010, 20389249	EPA+DHA + diet intervention vs Placebo + diet intervention	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
82	Einvik, 2010, 20389249	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
75	Ebrahimi, 2009, 19593941	-4.5 (-9, 0)	0.18	-25
76	Einvik, 2010, 20389249	Adj HR 0.53 (0.27, 1.04)	4.41	0.8659195
77	Einvik, 2010, 20389249	OR 0.62 (0.24, 1.64)	2.02	0.7892664
78	Einvik, 2010, 20389249	HR 0.89 (0.55, 1.44)	2.4	0.9526042
79	Einvik, 2010, 20389249	OR 1.00 (0.56, 1.78)	2.4	1
80	Einvik, 2010, 20389249	-0.3 (-0.8, 0.2)	2.4	-0.125
81	Einvik, 2010, 20389249	-0.3 (-0.7, 0.1)	2.4	-0.125
82	Einvik, 2010, 20389249	2.70 (-2.45, 7.85)	2.4	1.125

Causality Table: Comparative Studies

Row	Study	Outcome classification
75	Ebrahimi, 2009, 19593941	Secondary
76	Einvik, 2010, 20389249	Secondary
77	Einvik, 2010, 20389249	Secondary
78	Einvik, 2010, 20389249	Secondary
79	Einvik, 2010, 20389249	Secondary
80	Einvik, 2010, 20389249	Secondary
81	Einvik, 2010, 20389249	Secondary
82	Einvik, 2010, 20389249	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
83	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
84	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
85	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
86	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
87	Einvik, 2010, 20389249	1997	Norway	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
88	Eritslund, 1996, 8540453	1989	Norway	Secondary Prevention (history of CVD event)
89	Eritslund, 1996, 8540453	1989	Norway	Secondary Prevention (history of CVD event)
90	Eritslund, 1996, 8540453	1989	Norway	Secondary Prevention (history of CVD event)
91	Eritslund, 1996, 8540453	1989	Norway	Secondary Prevention (history of CVD event)
92	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
93	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
83	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
84	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
85	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
86	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
87	Einvik, 2010, 20389249	Dyslipidemia (hypercholesterolemia (> 6.45 mmol/l))	563
88	Eritslund, 1996, 8540453	Cardiac disease (coronary artery bypass grafting without concomitant cardiac surgery)	511
89	Eritslund, 1996, 8540453	Cardiac disease (coronary artery bypass grafting without concomitant cardiac surgery)	511
90	Eritslund, 1996, 8540453	Cardiac disease (coronary artery bypass grafting without concomitant cardiac surgery)	511
91	Eritslund, 1996, 8540453	Cardiac disease (coronary artery bypass grafting without concomitant cardiac surgery)	511
92	Finnegan, 2003, 12663273	Dyslipidemia	119
93	Finnegan, 2003, 12663273	Dyslipidemia	119

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
83	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
84	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
85	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
86	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
87	Einvik, 2010, 20389249	69.7 (3.0)	100	nd
88	Eritslund, 1996, 8540453	59.4 (8.8)	87.6	nd
89	Eritslund, 1996, 8540453	59.4 (8.8)	87.6	nd
90	Eritslund, 1996, 8540453	59.4 (8.8)	87.6	nd
91	Eritslund, 1996, 8540453	59.4 (8.8)	87.6	nd
92	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
93	Finnegan, 2003, 12663273	55 (SE 2)	60	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
83	Einvik, 2010, 20389249	147 (20)/83 (11)
84	Einvik, 2010, 20389249	147 (20)/83 (11)
85	Einvik, 2010, 20389249	147 (20)/83 (11)
86	Einvik, 2010, 20389249	147 (20)/83 (11)
87	Einvik, 2010, 20389249	147 (20)/83 (11)
88	Eritslund, 1996, 8540453	146/88
89	Eritslund, 1996, 8540453	146/88
90	Eritslund, 1996, 8540453	146/88
91	Eritslund, 1996, 8540453	146/88
92	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
93	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
83	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
84	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
85	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
86	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
87	Einvik, 2010, 20389249	[6.3 (1.0)]/[4.1 (1.0)]/[1.4 (0.4)]/1.7 (0.9)
88	Eritsland, 1996, 8540453	[6.55 (1.16)]/[4.61 (1.09)]/[1.00 (0.27)]/2.09 (1.07)
89	Eritsland, 1996, 8540453	[6.55 (1.16)]/[4.61 (1.09)]/[1.00 (0.27)]/2.09 (1.07)
90	Eritsland, 1996, 8540453	[6.55 (1.16)]/[4.61 (1.09)]/[1.00 (0.27)]/2.09 (1.07)
91	Eritsland, 1996, 8540453	[6.55 (1.16)]/[4.61 (1.09)]/[1.00 (0.27)]/2.09 (1.07)
92	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
93	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m2/Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
83	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
84	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
85	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
86	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
87	Einvik, 2010, 20389249	26.7 (3.7)	ALA: 0.59 (0.20)% FA, EPA: 2.18 (1.7)% FA, DHA: 2.98 (1.2)% FA, Total n-3 FA: 6.0 (3.0)% FA	serum
88	Eritsland, 1996, 8540453	25.5 (2.8)	EPA: 33.5 (19.9) mg/L, DHA: 111.4 (30.8) mg/L, Total n-3 FA: 170.3 (51.4) mg/L	serum
89	Eritsland, 1996, 8540453	25.5 (2.8)	EPA: 33.5 (19.9) mg/L, DHA: 111.4 (30.8) mg/L, Total n-3 FA: 170.3 (51.4) mg/L	serum
90	Eritsland, 1996, 8540453	25.5 (2.8)	EPA: 33.5 (19.9) mg/L, DHA: 111.4 (30.8) mg/L, Total n-3 FA: 170.3 (51.4) mg/L	serum
91	Eritsland, 1996, 8540453	25.5 (2.8)	EPA: 33.5 (19.9) mg/L, DHA: 111.4 (30.8) mg/L, Total n-3 FA: 170.3 (51.4) mg/L	serum
92	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
93	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
83	Einvik, 2010, 20389249	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
84	Einvik, 2010, 20389249	EPA+DHA (no diet intervention) vs Placebo (no diet intervention)	g/d	Trial: Randomized Factorial Design	SBP
85	Einvik, 2010, 20389249	EPA+DHA (diet intervention) vs Placebo (diet intervention)	g/d	Trial: Randomized Factorial Design	SBP
86	Einvik, 2010, 20389249	EPA+DHA (no diet intervention) vs Placebo (no diet intervention)	% FA	Trial: Randomized Factorial Design	DBP
87	Einvik, 2010, 20389249	EPA+DHA (diet intervention) vs Placebo (diet intervention)	g/d	Trial: Randomized Factorial Design	DBP
88	Eritsland, 1996, 8540453	EPA+DHA vs Placebo	mg/L	Trial: Randomized Factorial Design	Death, all cause
89	Eritsland, 1996, 8540453	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
90	Eritsland, 1996, 8540453	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
91	Eritsland, 1996, 8540453	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
92	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
93	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
83	Einvik, 2010, 20389249	-15.04 (-41.14, 11.06)	2.4	-6.266667
84	Einvik, 2010, 20389249	1 (-5.4, 7.4)	2.4	0.416667
85	Einvik, 2010, 20389249	3 (-3.5, 9.5)	2.4	1.25
86	Einvik, 2010, 20389249	0 (-3.9, 3.9)	4.41	0
87	Einvik, 2010, 20389249	-1.1 (-5, 3)	4.41	-0.2494331
88	Eritslund, 1996, 8540453	OR 1.24 (0.42, 3.61)	3.32	1.066938
89	Eritslund, 1996, 8540453	0.77 (-4.62, 6.16)	3.4	0.2264706
90	Eritslund, 1996, 8540453	4.00 (-3.83, 11.83)	3.4	1.176471
91	Eritslund, 1996, 8540453	-32.00 (-49.61, -14.39)	3.4	-9.411765
92	Finnegan, 2003, 12663273	0.77 (-5.42, 6.97)	4.5	0.1711111
93	Finnegan, 2003, 12663273	3.09 (-3.68, 9.86)	0.8	3.8625

Causality Table: Comparative Studies

Row	Study	Outcome classification
83	Einvik, 2010, 20389249	Secondary
84	Einvik, 2010, 20389249	Secondary
85	Einvik, 2010, 20389249	Secondary
86	Einvik, 2010, 20389249	Secondary
87	Einvik, 2010, 20389249	Secondary
88	Eritsland, 1996, 8540453	Secondary; Primary in registry record (NCT01422317)
89	Eritsland, 1996, 8540453	Secondary
90	Eritsland, 1996, 8540453	Secondary
91	Eritsland, 1996, 8540453	Secondary
92	Finnegan, 2003, 12663273	Secondary
93	Finnegan, 2003, 12663273	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
94	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
95	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
96	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
97	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
98	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
99	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
100	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
101	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
102	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
103	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
104	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
105	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
106	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
107	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
108	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
109	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
110	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
111	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
112	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
113	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
114	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
115	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
116	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
117	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
118	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
119	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
120	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
121	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
122	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
123	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
124	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
125	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
126	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy
127	Finnegan, 2003, 12663273	1998	UK	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
94	Finnegan, 2003, 12663273	Dyslipidemia	119
95	Finnegan, 2003, 12663273	Dyslipidemia	119
96	Finnegan, 2003, 12663273	Dyslipidemia	119
97	Finnegan, 2003, 12663273	Dyslipidemia	119
98	Finnegan, 2003, 12663273	Dyslipidemia	119
99	Finnegan, 2003, 12663273	Dyslipidemia	119
100	Finnegan, 2003, 12663273	Dyslipidemia	119
101	Finnegan, 2003, 12663273	Dyslipidemia	119
102	Finnegan, 2003, 12663273	Dyslipidemia	119
103	Finnegan, 2003, 12663273	Dyslipidemia	119
104	Finnegan, 2003, 12663273	Dyslipidemia	119
105	Finnegan, 2003, 12663273	Dyslipidemia	119
106	Finnegan, 2003, 12663273	Dyslipidemia	119
107	Finnegan, 2003, 12663273	Dyslipidemia	119
108	Finnegan, 2003, 12663273	Dyslipidemia	119
109	Finnegan, 2003, 12663273	Dyslipidemia	119
110	Finnegan, 2003, 12663273	Dyslipidemia	119
111	Finnegan, 2003, 12663273	Dyslipidemia	119
112	Finnegan, 2003, 12663273	Dyslipidemia	119
113	Finnegan, 2003, 12663273	Dyslipidemia	119
114	Finnegan, 2003, 12663273	Dyslipidemia	119
115	Finnegan, 2003, 12663273	Dyslipidemia	119
116	Finnegan, 2003, 12663273	Dyslipidemia	119
117	Finnegan, 2003, 12663273	Dyslipidemia	119
118	Finnegan, 2003, 12663273	Dyslipidemia	119
119	Finnegan, 2003, 12663273	Dyslipidemia	119
120	Finnegan, 2003, 12663273	Dyslipidemia	119
121	Finnegan, 2003, 12663273	Dyslipidemia	119
122	Finnegan, 2003, 12663273	Dyslipidemia	119
123	Finnegan, 2003, 12663273	Dyslipidemia	119
124	Finnegan, 2003, 12663273	Dyslipidemia	119
125	Finnegan, 2003, 12663273	Dyslipidemia	119
126	Finnegan, 2003, 12663273	Dyslipidemia	119
127	Finnegan, 2003, 12663273	Dyslipidemia	119

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
94	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
95	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
96	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
97	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
98	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
99	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
100	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
101	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
102	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
103	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
104	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
105	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
106	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
107	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
108	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
109	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
110	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
111	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
112	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
113	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
114	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
115	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
116	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
117	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
118	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
119	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
120	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
121	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
122	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
123	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
124	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
125	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
126	Finnegan, 2003, 12663273	55 (SE 2)	60	nd
127	Finnegan, 2003, 12663273	55 (SE 2)	60	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
94	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
95	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
96	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
97	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
98	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
99	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
100	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
101	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
102	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
103	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
104	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
105	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
106	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
107	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
108	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
109	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
110	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
111	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
112	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
113	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
114	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
115	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
116	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
117	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
118	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
119	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
120	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
121	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
122	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
123	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
124	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
125	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
126	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)
127	Finnegan, 2003, 12663273	123.2 (SE 3.7)/76 (SE 1.6)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
94	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
95	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
96	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
97	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
98	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
99	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
100	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
101	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
102	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
103	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
104	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
105	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
106	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
107	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
108	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
109	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
110	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
111	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
112	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
113	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
114	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
115	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
116	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
117	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
118	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
119	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
120	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
121	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
122	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
123	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
124	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
125	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
126	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]
127	Finnegan, 2003, 12663273	[5.8 (SE 0.17)]/[3.63 (SE 0.16)]/[1.35 (SE 0.06)]/[1.69 (SE 0.11)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
94	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
95	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
96	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
97	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
98	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
99	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
100	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
101	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
102	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
103	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
104	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
105	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
106	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
107	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
108	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
109	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
110	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
111	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
112	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
113	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
114	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
115	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
116	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
117	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
118	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
119	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
120	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
121	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
122	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
123	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
124	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
125	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
126	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd
127	Finnegan, 2003, 12663273	25.8 (SE 0.6)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
94	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
95	Finnegan, 2003, 12663273	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
96	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	HDL-c
97	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	HDL-c
98	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
99	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
100	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
101	Finnegan, 2003, 12663273	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
102	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	LDL-c
103	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	LDL-c
104	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	Tg
105	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
106	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
107	Finnegan, 2003, 12663273	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
108	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	Tg
109	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	Tg
110	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	SBP
111	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	SBP
112	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
113	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
114	Finnegan, 2003, 12663273	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	SBP
115	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	SBP
116	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	SBP
117	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	SBP
118	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	SBP
119	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	DBP
120	Finnegan, 2003, 12663273	ALA vs Placebo	g/d	Trial: Randomized Parallel	DBP
121	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
122	Finnegan, 2003, 12663273	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
123	Finnegan, 2003, 12663273	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	DBP
124	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	DBP
125	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	DBP
126	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	DBP
127	Finnegan, 2003, 12663273	EPA+DHA vs ALA	g/d	Trial: Randomized Parallel	DBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
94	Finnegan, 2003, 12663273	2.32 (-4.78, 9.42)	1.7	1.364706
95	Finnegan, 2003, 12663273	-0.77 (-8.56, 7.02)	0.9	-0.8555555
96	Finnegan, 2003, 12663273	2.32 (-4.66, 9.29)	NA	
97	Finnegan, 2003, 12663273	1.54 (-5.75, 8.84)	NA	
98	Finnegan, 2003, 12663273	-1.93 (-16.80, 12.94)	4.5	-0.4288889
99	Finnegan, 2003, 12663273	0.00 (-17.32, 17.32)	0.8	0
100	Finnegan, 2003, 12663273	12.74 (-3.22, 28.71)	1.7	7.494118
101	Finnegan, 2003, 12663273	12.74 (-4.76, 30.25)	0.9	14.15556
102	Finnegan, 2003, 12663273	1.93 (-14.58, 18.44)	NA	
103	Finnegan, 2003, 12663273	14.67 (-0.41, 29.75)	NA	
104	Finnegan, 2003, 12663273	23.01 (-8.88, 54.90)	4.5	5.113333
105	Finnegan, 2003, 12663273	6.19 (-23.50, 35.88)	0.8	7.7375
106	Finnegan, 2003, 12663273	-9.73 (-38.13, 18.66)	1.7	-5.723529
107	Finnegan, 2003, 12663273	-15.93 (-46.91, 15.05)	0.9	-17.7
108	Finnegan, 2003, 12663273	-16.81 (-51.02, 17.40)	NA	
109	Finnegan, 2003, 12663273	-32.74 (-65.84, 0.35)	NA	
110	Finnegan, 2003, 12663273	0 (-8.7, 8.7)	1.7	0
111	Finnegan, 2003, 12663273	5.2 (-3.9, 14.3)	4.5	1.155556
112	Finnegan, 2003, 12663273	0.5 (-8.3, 9.3)	1.7	0.2941177
113	Finnegan, 2003, 12663273	3.7 (-6.4, 13.8)	0.8	4.625
114	Finnegan, 2003, 12663273	-3.2 (-12.5, 6.1)	0.9	-3.555556
115	Finnegan, 2003, 12663273	0.5 (-7.3, 8.3)	NA	
116	Finnegan, 2003, 12663273	-4.7 (-12.9, 3.5)	NA	
117	Finnegan, 2003, 12663273	3.7 (-5.5, 12.9)	NA	
118	Finnegan, 2003, 12663273	-1.5 (-11.1, 8.1)	NA	
119	Finnegan, 2003, 12663273	-0.2 (-5.5, 5.1)	1.7	-0.1176471
120	Finnegan, 2003, 12663273	0.7 (-4.7, 6.1)	4.5	0.1555556
121	Finnegan, 2003, 12663273	-0.5 (-5.7, 4.7)	1.7	-0.2941177
122	Finnegan, 2003, 12663273	2.1 (-2.8, 7)	0.8	2.625
123	Finnegan, 2003, 12663273	-2.6 (-8, 2.8)	0.9	-2.888889
124	Finnegan, 2003, 12663273	-0.3 (-6.1, 5.5)	NA	
125	Finnegan, 2003, 12663273	-1.2 (-7.1, 4.7)	NA	
126	Finnegan, 2003, 12663273	2.3 (-3.3, 7.9)	NA	
127	Finnegan, 2003, 12663273	1.4 (-4.3, 7.1)	NA	

Causality Table: Comparative Studies

Row	Study	Outcome classification
94	Finnegan, 2003, 12663273	Secondary
95	Finnegan, 2003, 12663273	Secondary
96	Finnegan, 2003, 12663273	Secondary
97	Finnegan, 2003, 12663273	Secondary
98	Finnegan, 2003, 12663273	Secondary
99	Finnegan, 2003, 12663273	Secondary
100	Finnegan, 2003, 12663273	Secondary
101	Finnegan, 2003, 12663273	Secondary
102	Finnegan, 2003, 12663273	Secondary
103	Finnegan, 2003, 12663273	Secondary
104	Finnegan, 2003, 12663273	Secondary
105	Finnegan, 2003, 12663273	Secondary
106	Finnegan, 2003, 12663273	Secondary
107	Finnegan, 2003, 12663273	Secondary
108	Finnegan, 2003, 12663273	Secondary
109	Finnegan, 2003, 12663273	Secondary
110	Finnegan, 2003, 12663273	Secondary
111	Finnegan, 2003, 12663273	Secondary
112	Finnegan, 2003, 12663273	Secondary
113	Finnegan, 2003, 12663273	Secondary
114	Finnegan, 2003, 12663273	Secondary
115	Finnegan, 2003, 12663273	Secondary
116	Finnegan, 2003, 12663273	Secondary
117	Finnegan, 2003, 12663273	Secondary
118	Finnegan, 2003, 12663273	Secondary
119	Finnegan, 2003, 12663273	Secondary
120	Finnegan, 2003, 12663273	Secondary
121	Finnegan, 2003, 12663273	Secondary
122	Finnegan, 2003, 12663273	Primary (power analysis)
123	Finnegan, 2003, 12663273	Primary (power analysis)
124	Finnegan, 2003, 12663273	Primary (power analysis)
125	Finnegan, 2003, 12663273	Primary (power analysis)
126	Finnegan, 2003, 12663273	Primary (power analysis)
127	Finnegan, 2003, 12663273	Primary (power analysis)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
128	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
129	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
130	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
131	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
132	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
133	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
134	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
128	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
129	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
130	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
131	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
132	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
133	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
134	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
128	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
129	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
130	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
131	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
132	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
133	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
134	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
128	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
129	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
130	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
131	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
132	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
133	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
134	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
128	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
129	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
130	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
131	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
132	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
133	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
134	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m2/Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
128	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
129	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
130	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
131	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
132	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
133	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
134	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
128	Galan, 2010, 21115589	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
129	Galan, 2010, 21115589	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MACE
130	Galan, 2010, 21115589	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
131	Galan, 2010, 21115589	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Revascularization
132	Galan, 2010, 21115589	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Stroke
133	Galan, 2010, 21115589	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Stroke
134	Galan, 2010, 21115589	EPA + DHA (+/- B vitamin) vs Placebo (+/- B vitamin	g/d	Trial: Randomized Parallel	SBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
128	Galan, 2010, 21115589	Adj HR 1.03 (0.72, 1.48)	0.6	1.050498
129	Galan, 2010, 21115589	HR 1.08 (0.79, 1.47)	0.6	1.136858
130	Galan, 2010, 21115589	Adj HR 0.97 (0.66, 1.42)	0.6	0.9505017
131	Galan, 2010, 21115589	HR 0.97 (0.78, 1.22)	0.6	0.9505017
132	Galan, 2010, 21115589	HR 1.04 (0.62, 1.75)	0.6	1.067552
133	Galan, 2010, 21115589	HR 0.93 (0.60, 1.43)	0.6	0.8860772
134	Galan, 2010, 21115589	-0.06 (nd)	0.6	-0.1

Causality Table: Comparative Studies

Row	Study	Outcome classification
128	Galan, 2010, 21115589	Secondary
129	Galan, 2010, 21115589	Secondary; Primary in registry record (ISRCTN41926726)
130	Galan, 2010, 21115589	Primary (stated); Secondary in registry record (ISRCTN41926726)
131	Galan, 2010, 21115589	Secondary
132	Galan, 2010, 21115589	Secondary
133	Galan, 2010, 21115589	Secondary
134	Galan, 2010, 21115589	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
135	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
136	Galan, 2010, 21115589	2003	France	Secondary Prevention (history of CVD event)
137	Grieger, 2014, 24454276	2011	Australia	Primary Prevention, Healthy
138	Grieger, 2014, 24454276	2011	Australia	Primary Prevention, Healthy
139	Grieger, 2014, 24454276	2011	Australia	Primary Prevention, Healthy
140	Grieger, 2014, 24454276	2011	Australia	Primary Prevention, Healthy
141	Grieger, 2014, 24454276	2011	Australia	Primary Prevention, Healthy
142	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
143	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
144	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
145	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
146	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
147	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
135	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
136	Galan, 2010, 21115589	Cardiac disease (Coronary event w/in 12 mo, including MI, ACS or suspected ACS); Cerebrovascular disease (CVA (not TIA))	2501
137	Grieger, 2014, 24454276	na	80
138	Grieger, 2014, 24454276	na	80
139	Grieger, 2014, 24454276	na	80
140	Grieger, 2014, 24454276	na	80
141	Grieger, 2014, 24454276	na	80
142	Grimsgaard, 1998, 9665096	na	147
143	Grimsgaard, 1998, 9665096	na	147
144	Grimsgaard, 1998, 9665096	na	147
145	Grimsgaard, 1998, 9665096	na	147
146	Grimsgaard, 1998, 9665096	na	147
147	Grimsgaard, 1998, 9665096	na	147

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
135	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
136	Galan, 2010, 21115589	60.9 (8.8)	79.4	nd
137	Grieger, 2014, 24454276	69.5 (5.8) [range 64, 85]	49	nd
138	Grieger, 2014, 24454276	69.5 (5.8) [range 64, 85]	49	nd
139	Grieger, 2014, 24454276	69.5 (5.8) [range 64, 85]	49	nd
140	Grieger, 2014, 24454276	69.5 (5.8) [range 64, 85]	49	nd
141	Grieger, 2014, 24454276	69.5 (5.8) [range 64, 85]	49	nd
142	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
143	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
144	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
145	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
146	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
147	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
135	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
136	Galan, 2010, 21115589	132.6 (20.0)/82.6 (12.1)
137	Grieger, 2014, 24454276	126 (SE 2)/67 (SE 1)
138	Grieger, 2014, 24454276	126 (SE 2)/67 (SE 1)
139	Grieger, 2014, 24454276	126 (SE 2)/67 (SE 1)
140	Grieger, 2014, 24454276	126 (SE 2)/67 (SE 1)
141	Grieger, 2014, 24454276	126 (SE 2)/67 (SE 1)
142	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
143	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
144	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
145	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
146	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
147	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
135	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
136	Galan, 2010, 21115589	[median 4.5 (3.9, 5.1)]/[median 2.6 (2.2, 3.2)]/[median 1.1 (1.0, 1.3)]/[median 1.1 (0.9, 1.7)]
137	Grieger, 2014, 24454276	[5.5 (SE 0.2)]/[3.3 (SE 0.1)]/[1.6 (SE 0.1)]/[1.4 (SE 0.1)]
138	Grieger, 2014, 24454276	[5.5 (SE 0.2)]/[3.3 (SE 0.1)]/[1.6 (SE 0.1)]/[1.4 (SE 0.1)]
139	Grieger, 2014, 24454276	[5.5 (SE 0.2)]/[3.3 (SE 0.1)]/[1.6 (SE 0.1)]/[1.4 (SE 0.1)]
140	Grieger, 2014, 24454276	[5.5 (SE 0.2)]/[3.3 (SE 0.1)]/[1.6 (SE 0.1)]/[1.4 (SE 0.1)]
141	Grieger, 2014, 24454276	[5.5 (SE 0.2)]/[3.3 (SE 0.1)]/[1.6 (SE 0.1)]/[1.4 (SE 0.1)]
142	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
143	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
144	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
145	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
146	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
147	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m2/Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
135	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
136	Galan, 2010, 21115589	27.5 (3.8)	EPA: median 1.26 (IQR 0.84, 1.81) % FA, DHA: median 2.70 (IQR 2.15, 3.36), EPA+DHA % FA: median 4.04 (IQR 2.99, 5.08) % FA	plasma
137	Grieger, 2014, 24454276	26.4 (SE 0.6)/73.8	ALA: 0.147 (SE 0.008)%, EPA 1.5 (SE 0.1)%, DPA: 3.0 (SE 0.1)%, DHA 5.0 (SE 2)%, Total n3 FA 9.7 (SE 0.4)%	RBC membrane
138	Grieger, 2014, 24454276	26.4 (SE 0.6)/73.8	ALA: 0.147 (SE 0.008)%, EPA 1.5 (SE 0.1)%, DPA: 3.0 (SE 0.1)%, DHA 5.0 (SE 2)%, Total n3 FA 9.7 (SE 0.4)%	RBC membrane
139	Grieger, 2014, 24454276	26.4 (SE 0.6)/73.8	ALA: 0.147 (SE 0.008)%, EPA 1.5 (SE 0.1)%, DPA: 3.0 (SE 0.1)%, DHA 5.0 (SE 2)%, Total n3 FA 9.7 (SE 0.4)%	RBC membrane
140	Grieger, 2014, 24454276	26.4 (SE 0.6)/73.8	ALA: 0.147 (SE 0.008)%, EPA 1.5 (SE 0.1)%, DPA: 3.0 (SE 0.1)%, DHA 5.0 (SE 2)%, Total n3 FA 9.7 (SE 0.4)%	RBC membrane
141	Grieger, 2014, 24454276	26.4 (SE 0.6)/73.8	ALA: 0.147 (SE 0.008)%, EPA 1.5 (SE 0.1)%, DPA: 3.0 (SE 0.1)%, DHA 5.0 (SE 2)%, Total n3 FA 9.7 (SE 0.4)%	RBC membrane
142	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
143	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
144	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
145	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
146	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
147	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
135	Galan, 2010, 21115589	EPA+DHA (+/- B vitamin) vs Placebo (+/- B vitamin)	% FA	Trial: Randomized Parallel	DBP
136	Galan, 2010, 21115589	EPA + DHA (+/- B vitamin) vs Placebo (+/- B vitamin)	g/d	Trial: Randomized Parallel	MAP
137	Grieger, 2014, 24454276	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
138	Grieger, 2014, 24454276	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
139	Grieger, 2014, 24454276	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
140	Grieger, 2014, 24454276	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
141	Grieger, 2014, 24454276	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
142	Grimsgaard, 1998, 9665096	EPA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
143	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
144	Grimsgaard, 1998, 9665096	DHA vs EPA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
145	Grimsgaard, 1998, 9665096	EPA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
146	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
147	Grimsgaard, 1998, 9665096	DHA vs EPA	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
135	Galan, 2010, 21115589	0.06 (nd)	0.6	0.1
136	Galan, 2010, 21115589	0.007 (nd)	0.6	0.0116667
137	Grieger, 2014, 24454276	0.00 (-10.70, 10.70)	0.8	0
138	Grieger, 2014, 24454276	11.58 (0.88, 22.29)	0.8	14.475
139	Grieger, 2014, 24454276	0.00 (-24.53, 24.53)	0.8	0
140	Grieger, 2014, 24454276	-2.0 (-9.3, 5.3)	0.8	-2.5
141	Grieger, 2014, 24454276	0 (-4.8, 4.8)	0.8	0
142	Grimsgaard, 1998, 9665096	-0.5 (-0.8, -0.2)	3.8	-0.131579
143	Grimsgaard, 1998, 9665096	-0.5 (-0.8, -0.2)	3.6	-0.1388889
144	Grimsgaard, 1998, 9665096	0.02 (-0.3, 0.4)	NA	
145	Grimsgaard, 1998, 9665096	0.77 (-0.64, 2.19)	3.6	0.2138889
146	Grimsgaard, 1998, 9665096	-5.41 (-6.70, -4.11)	3.8	-1.423684
147	Grimsgaard, 1998, 9665096	-1.93 (-3.49, -0.37)	NA	

Causality Table: Comparative Studies

Row	Study	Outcome classification
135	Galan, 2010, 21115589	Secondary
136	Galan, 2010, 21115589	Secondary
137	Grieger, 2014, 24454276	Secondary
138	Grieger, 2014, 24454276	Secondary
139	Grieger, 2014, 24454276	Secondary
140	Grieger, 2014, 24454276	Secondary
141	Grieger, 2014, 24454276	Secondary
142	Grimsgaard, 1998, 9665096	Primary (stated)
143	Grimsgaard, 1998, 9665096	Primary (stated)
144	Grimsgaard, 1998, 9665096	Primary (stated)
145	Grimsgaard, 1998, 9665096	Secondary
146	Grimsgaard, 1998, 9665096	Secondary
147	Grimsgaard, 1998, 9665096	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
148	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
149	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
150	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
151	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
152	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
153	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
154	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
155	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
156	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
157	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
158	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
159	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
160	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
161	Grimsgaard, 1998, 9665096	1993	Norway	Primary Prevention, Healthy
162	Harrison, 2004, 15853118	2001	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
163	Harrison, 2004, 15853118	2001	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
164	Harrison, 2004, 15853118	2001	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
165	Harrison, 2004, 15853118	2001	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
166	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
167	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
168	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
169	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
170	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
171	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
172	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
148	Grimsgaard, 1998, 9665096	na	147
149	Grimsgaard, 1998, 9665096	na	147
150	Grimsgaard, 1998, 9665096	na	147
151	Grimsgaard, 1998, 9665096	na	147
152	Grimsgaard, 1998, 9665096	na	147
153	Grimsgaard, 1998, 9665096	na	147
154	Grimsgaard, 1998, 9665096	na	147
155	Grimsgaard, 1998, 9665096	na	147
156	Grimsgaard, 1998, 9665096	na	147
157	Grimsgaard, 1998, 9665096	na	147
158	Grimsgaard, 1998, 9665096	na	147
159	Grimsgaard, 1998, 9665096	na	147
160	Grimsgaard, 1998, 9665096	na	147
161	Grimsgaard, 1998, 9665096	na	147
162	Harrison, 2004, 15853118	Hypertension (SBP \geq 130 mmHg); Dyslipidemia (Total cholesterol \geq 5.7 mmol/l)	152
163	Harrison, 2004, 15853118	Hypertension (SBP \geq 130 mmHg); Dyslipidemia (Total cholesterol \geq 5.7 mmol/l)	152
164	Harrison, 2004, 15853118	Hypertension (SBP \geq 130 mmHg); Dyslipidemia (Total cholesterol \geq 5.7 mmol/l)	152
165	Harrison, 2004, 15853118	Hypertension (SBP \geq 130 mmHg); Dyslipidemia (Total cholesterol \geq 5.7 mmol/l)	152
166	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
167	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
168	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
169	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
170	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
171	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
172	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
148	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
149	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
150	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
151	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
152	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
153	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
154	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
155	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
156	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
157	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
158	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
159	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
160	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
161	Grimsgaard, 1998, 9665096	45.1 (5.6)	nd	nd
162	Harrison, 2004, 15853118	52	54.4	nd
163	Harrison, 2004, 15853118	52	54.4	nd
164	Harrison, 2004, 15853118	52	54.4	nd
165	Harrison, 2004, 15853118	52	54.4	nd
166	Holman, 2009, 19002433	[65 (5773)]	58	88 white
167	Holman, 2009, 19002433	[65 (5773)]	58	88 white
168	Holman, 2009, 19002433	[65 (5773)]	58	88 white
169	Holman, 2009, 19002433	[65 (5773)]	58	88 white
170	Holman, 2009, 19002433	[65 (5773)]	58	88 white
171	Holman, 2009, 19002433	[65 (5773)]	58	88 white
172	Holman, 2009, 19002433	[65 (5773)]	58	88 white

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
148	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
149	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
150	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
151	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
152	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
153	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
154	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
155	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
156	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
157	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
158	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
159	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
160	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
161	Grimsgaard, 1998, 9665096	122.2 (5.7)/76.9 (8.0)
162	Harrison, 2004, 15853118	134.7/81.8
163	Harrison, 2004, 15853118	134.7/81.8
164	Harrison, 2004, 15853118	134.7/81.8
165	Harrison, 2004, 15853118	134.7/81.8
166	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
167	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
168	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
169	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
170	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
171	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
172	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
148	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
149	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
150	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
151	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
152	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
153	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
154	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
155	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
156	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
157	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
158	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
159	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
160	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
161	Grimsgaard, 1998, 9665096	[6.02 (1.08)]/[4.04 (0.98)]/[1.41 (0.28)]/[1.22 (0.55)]
162	Harrison, 2004, 15853118	[6.7]/[5.0]/[1.7]/
163	Harrison, 2004, 15853118	[6.7]/[5.0]/[1.7]/
164	Harrison, 2004, 15853118	[6.7]/[5.0]/[1.7]/
165	Harrison, 2004, 15853118	[6.7]/[5.0]/[1.7]/
166	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
167	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
168	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
169	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
170	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
171	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
172	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
148	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
149	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
150	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
151	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
152	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
153	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
154	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
155	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
156	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
157	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
158	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
159	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
160	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
161	Grimsgaard, 1998, 9665096	24.6 (2.7)	nd	nd
162	Harrison, 2004, 15853118	27.2	DHA: 1.51 (0.15) % FA	plasma
163	Harrison, 2004, 15853118	27.2	DHA: 1.51 (0.15) % FA	plasma
164	Harrison, 2004, 15853118	27.2	DHA: 1.51 (0.15) % FA	plasma
165	Harrison, 2004, 15853118	27.2	DHA: 1.51 (0.15) % FA	plasma
166	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
167	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
168	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
169	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
170	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
171	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
172	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
148	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
149	Grimsgaard, 1998, 9665096	DHA vs EPA	g/d	Trial: Randomized Parallel	LDL-c
150	Grimsgaard, 1998, 9665096	EPA vs Placebo	g/d	Trial: Randomized Parallel	Tg
151	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
152	Grimsgaard, 1998, 9665096	DHA vs EPA	g/d	Trial: Randomized Parallel	Tg
153	Grimsgaard, 1998, 9665096	EPA vs Placebo	g/d	Trial: Randomized Parallel	SBP
154	Grimsgaard, 1998, 9665096	EPA vs DHA	g/d	Trial: Randomized Parallel	SBP
155	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
156	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
157	Grimsgaard, 1998, 9665096	EPA vs Placebo	g/d	Trial: Randomized Parallel	DBP
158	Grimsgaard, 1998, 9665096	EPA vs DHA	g/d	Trial: Randomized Parallel	DBP
159	Grimsgaard, 1998, 9665096	DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP
160	Grimsgaard, 1998, 9665096	EPA vs Placebo	g/d	Trial: Randomized Parallel	MAP
161	Grimsgaard, 1998, 9665096	EPA vs DHA	g/d	Trial: Randomized Parallel	MAP
162	Harrison, 2004, 15853118	DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
163	Harrison, 2004, 15853118	DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
164	Harrison, 2004, 15853118	DHA vs Placebo	g/d	Trial: Randomized Factorial Design	SBP
165	Harrison, 2004, 15853118	DHA vs Placebo	% FA	Trial: Randomized Factorial Design	DBP
166	Holman, 2009, 19002433	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
167	Holman, 2009, 19002433	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
168	Holman, 2009, 19002433	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
169	Holman, 2009, 19002433	EPA+DHA(+/- atorvastatin) vs Placebo (+/- atorvastatin)	g/d	Trial: Randomized Factorial Design	SBP
170	Holman, 2009, 19002433	EPA+DHA (+atorvastatin) vs Placebo (+atorvastatin)	g/d	Trial: Randomized Factorial Design	SBP
171	Holman, 2009, 19002433	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	SBP
172	Holman, 2009, 19002433	EPA+DHA(+/- atorvastatin) vs Placebo (+/- atorvastatin)	g/d	Trial: Randomized Factorial Design	DBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
148	Grimsgaard, 1998, 9665096	11.97 (7.20, 16.74)	3.8	3.15
149	Grimsgaard, 1998, 9665096	-5.79 (-11.66, 0.08)	NA	
150	Grimsgaard, 1998, 9665096	-23.01 (-33.47, -12.55)	3.6	-6.391667
151	Grimsgaard, 1998, 9665096	-8.85 (-19.45, 1.75)	3.8	-2.328947
152	Grimsgaard, 1998, 9665096	6.19 (-4.02, 16.41)	NA	
153	Grimsgaard, 1998, 9665096	-5.3 (-8.1, -2.5)	3.8	-1.394737
154	Grimsgaard, 1998, 9665096	-5.9 (-8.6, 3.2)	NA	
155	Grimsgaard, 1998, 9665096	0.6 (-2.2, 3.4)	3.6	0.1666667
156	Grimsgaard, 1998, 9665096	-0.4 (-2.5, 1.7)	3.6	-0.1111111
157	Grimsgaard, 1998, 9665096	-0.6 (-2.7, 1.5)	3.8	-0.1578947
158	Grimsgaard, 1998, 9665096	-0.2 (-2.2, 1.8)	NA	
159	Grimsgaard, 1998, 9665096	0.4 (-1.9, 2.7)	3.6	0.1111111
160	Grimsgaard, 1998, 9665096	-0.4 (-2.8, 2)	3.8	-0.1052632
161	Grimsgaard, 1998, 9665096	-0.8 (-3, 1.4)	NA	
162	Harrison, 2004, 15853118	-0.17 (-0.08, 0.26)	2	-0.085
163	Harrison, 2004, 15853118	-7.45 (-45.74, 30.83)	2	-3.725
164	Harrison, 2004, 15853118	-0.94% (-4.68%, 2.79%)	2	-0.47
165	Harrison, 2004, 15853118	-2.19% (-5.57%, 1.18%)	2	-1.095
166	Holman, 2009, 19002433	0.77 (-0.10, 1.64)	2	0.385
167	Holman, 2009, 19002433	-1.16 (-11.13, 8.82)	2	-0.58
168	Holman, 2009, 19002433	-7.96 (-13.23, -2.70)	2	-3.98
169	Holman, 2009, 19002433	0.4 (nd)	1.68	0.2380952
170	Holman, 2009, 19002433	2 (-2.1, 6.1)	1.68	1.190476
171	Holman, 2009, 19002433	0 (-4, 4)	1.68	0
172	Holman, 2009, 19002433	0.6 (nd)	1.68	0.3571429

Causality Table: Comparative Studies

Row	Study	Outcome classification
148	Grimsgaard, 1998, 9665096	Secondary
149	Grimsgaard, 1998, 9665096	Secondary
150	Grimsgaard, 1998, 9665096	Secondary
151	Grimsgaard, 1998, 9665096	Secondary
152	Grimsgaard, 1998, 9665096	Secondary
153	Grimsgaard, 1998, 9665096	Secondary
154	Grimsgaard, 1998, 9665096	Secondary
155	Grimsgaard, 1998, 9665096	Secondary
156	Grimsgaard, 1998, 9665096	Secondary
157	Grimsgaard, 1998, 9665096	Secondary
158	Grimsgaard, 1998, 9665096	Secondary
159	Grimsgaard, 1998, 9665096	Secondary
160	Grimsgaard, 1998, 9665096	Secondary
161	Grimsgaard, 1998, 9665096	Secondary
162	Harrison, 2004, 15853118	Primary (stated)
163	Harrison, 2004, 15853118	Secondary
164	Harrison, 2004, 15853118	Secondary
165	Harrison, 2004, 15853118	Primary (stated)
166	Holman, 2009, 19002433	Secondary; Primary in registry record (NCT00141232)
167	Holman, 2009, 19002433	Secondary
168	Holman, 2009, 19002433	Secondary
169	Holman, 2009, 19002433	Secondary
170	Holman, 2009, 19002433	Secondary
171	Holman, 2009, 19002433	Secondary
172	Holman, 2009, 19002433	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
173	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
174	Holman, 2009, 19002433	2004	UK	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
175	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
176	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
177	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
178	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
179	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
180	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
181	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
182	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
183	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
184	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
173	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
174	Holman, 2009, 19002433	Diabetes and/or metabolic syndrome	658
175	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
176	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
177	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
178	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
179	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
180	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
181	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
182	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
183	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
184	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
173	Holman, 2009, 19002433	[65 (5773)]	58	88 white
174	Holman, 2009, 19002433	[65 (5773)]	58	88 white
175	Jones, 2014, 24829493	46.46 (14.18)	54	nd
176	Jones, 2014, 24829493	46.46 (14.18)	54	nd
177	Jones, 2014, 24829493	46.46 (14.18)	54	nd
178	Jones, 2014, 24829493	46.46 (14.18)	54	nd
179	Jones, 2014, 24829493	46.46 (14.18)	54	nd
180	Jones, 2014, 24829493	46.46 (14.18)	54	nd
181	Jones, 2014, 24829493	46.46 (14.18)	54	nd
182	Jones, 2014, 24829493	46.46 (14.18)	54	nd
183	Jones, 2014, 24829493	46.46 (14.18)	54	nd
184	Jones, 2014, 24829493	46.46 (14.18)	54	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
173	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
174	Holman, 2009, 19002433	139.8 (15.9)/78.8 (9.2)
175	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
176	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
177	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
178	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
179	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
180	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
181	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
182	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
183	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
184	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
173	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
174	Holman, 2009, 19002433	[5.0 (1)]/[3.1 (0.8)]/[1.1 (0.9)]/[median 1.5 (1.2, 2.2)]
175	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
176	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
177	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
178	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
179	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
180	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
181	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
182	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
183	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
184	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
173	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
174	Holman, 2009, 19002433	30.6 (5.8)/87.3 (18.5)	nd	nd
175	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
176	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
177	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
178	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
179	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
180	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
181	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
182	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
183	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
184	Jones, 2014, 24829493	29.8 (4.37)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
173	Holman, 2009, 19002433	EPA+DHA(+/- atorvastatin) vs Placebo(+ atorvastatin)	g/d	Trial: Randomized Factorial Design	DBP
174	Holman, 2009, 19002433	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	DBP
175	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	Total:HDL-c ratio
176	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	Total:HDL-c ratio
177	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	Total:HDL-c ratio
178	Jones, 2014, 24829493	ALA+EPA+DHA vs ALA	g/d	Trial: Randomized Cross-over	Total:HDL-c ratio
179	Jones, 2014, 24829493	ALA+EPA+DHA vs ALA	g/d	Trial: Randomized Cross-over	Total:HDL-c ratio
180	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
181	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	HDL-c
182	Jones, 2014, 24829493	ALA vs ALA+DHA+EPA	g/d	Trial: Randomized Cross-over	HDL-c
183	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
184	Jones, 2014, 24829493	ALA+DHA+EPA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
173	Holman, 2009, 19002433	-1 (-3.3, 1.3)	1.68	-0.5952381
174	Holman, 2009, 19002433	-1 (-3.1, 1.1)	1.68	-0.5952381
175	Jones, 2014, 24829493	0.15 (-0.18, 0.48)	5.7	0.0263158
176	Jones, 2014, 24829493	0.16 (-0.17, 0.49)	1.2	0.1333333
177	Jones, 2014, 24829493	-0.01 (-0.34, 0.32)	4.5	-0.0022222
178	Jones, 2014, 24829493	-0.16 (-0.49, 0.17)	NA	
179	Jones, 2014, 24829493	-0.31 (-0.64, 0.02)	NA	
180	Jones, 2014, 24829493	0.00 (-30.04, 30.04)	5.7	0
181	Jones, 2014, 24829493	0.77 (-29.27, 30.81)	4.5	0.1711111
182	Jones, 2014, 24829493	4.63 (-25.39, 34.66)	NA	
183	Jones, 2014, 24829493	-0.77 (-30.81, 29.27)	1.2	-0.6416667
184	Jones, 2014, 24829493	3.86 (-26.18, 33.90)	6	0.6433333

Causality Table: Comparative Studies

Row	Study	Outcome classification
173	Holman, 2009, 19002433	Secondary
174	Holman, 2009, 19002433	Secondary
175	Jones, 2014, 24829493	Secondary
176	Jones, 2014, 24829493	Secondary
177	Jones, 2014, 24829493	Secondary
178	Jones, 2014, 24829493	Secondary
179	Jones, 2014, 24829493	Secondary
180	Jones, 2014, 24829493	Secondary
181	Jones, 2014, 24829493	Secondary
182	Jones, 2014, 24829493	Secondary
183	Jones, 2014, 24829493	Secondary
184	Jones, 2014, 24829493	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
185	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
186	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
187	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
188	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
189	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
190	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
191	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
192	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
193	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
194	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
195	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
196	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
185	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
186	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
187	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
188	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
189	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
190	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
191	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
192	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
193	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
194	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
195	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
196	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
185	Jones, 2014, 24829493	46.46 (14.18)	54	nd
186	Jones, 2014, 24829493	46.46 (14.18)	54	nd
187	Jones, 2014, 24829493	46.46 (14.18)	54	nd
188	Jones, 2014, 24829493	46.46 (14.18)	54	nd
189	Jones, 2014, 24829493	46.46 (14.18)	54	nd
190	Jones, 2014, 24829493	46.46 (14.18)	54	nd
191	Jones, 2014, 24829493	46.46 (14.18)	54	nd
192	Jones, 2014, 24829493	46.46 (14.18)	54	nd
193	Jones, 2014, 24829493	46.46 (14.18)	54	nd
194	Jones, 2014, 24829493	46.46 (14.18)	54	nd
195	Jones, 2014, 24829493	46.46 (14.18)	54	nd
196	Jones, 2014, 24829493	46.46 (14.18)	54	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
185	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
186	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
187	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
188	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
189	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
190	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
191	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
192	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
193	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
194	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
195	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
196	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
185	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
186	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
187	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
188	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
189	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
190	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
191	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
192	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
193	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
194	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
195	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
196	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
185	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
186	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
187	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
188	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
189	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
190	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
191	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
192	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
193	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
194	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
195	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
196	Jones, 2014, 24829493	29.8 (4.37)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
185	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
186	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	LDL-c
187	Jones, 2014, 24829493	ALA vs ALA+DHA+EPA	g/d	Trial: Randomized Cross-over	LDL-c
188	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
189	Jones, 2014, 24829493	ALA+DHA+EPA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
190	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
191	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	Tg
192	Jones, 2014, 24829493	ALA vs ALA+DHA+EPA	g/d	Trial: Randomized Cross-over	Tg
193	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
194	Jones, 2014, 24829493	ALA + DHA + EPA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
195	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	SBP
196	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	SBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
185	Jones, 2014, 24829493	2.32 (-93.22, 97.86)	5.7	0.4070175
186	Jones, 2014, 24829493	1.94 (-93.60, 97.48)	4.5	0.4311111
187	Jones, 2014, 24829493	6.18 (-89.35, 101.72)	NA	
188	Jones, 2014, 24829493	0.38 (-95.16, 95.92)	1.2	0.3166667
189	Jones, 2014, 24829493	6.56 (-88.98, 102.10)	6	1.093333
190	Jones, 2014, 24829493	3.54 (-18.72, 25.80)	5.7	0.6210526
191	Jones, 2014, 24829493	-3.54 (-208.25, 201.17)	4.5	-0.7866667
192	Jones, 2014, 24829493	-34.51 (-239.22, 170.19)	0.3	-115.0333
193	Jones, 2014, 24829493	7.08 (-197.63, 211.79)	1.2	5.9
194	Jones, 2014, 24829493	-27.43 (-232.14, 177.28)	6	-4.571667
195	Jones, 2014, 24829493	-1.1 (-43.9, 41.8)	5.9	-0.1864407
196	Jones, 2014, 24829493	0.1 (-42.8, 42.9)	1.38	0.0724638

Causality Table: Comparative Studies

Row	Study	Outcome classification
185	Jones, 2014, 24829493	Secondary
186	Jones, 2014, 24829493	Secondary
187	Jones, 2014, 24829493	Secondary
188	Jones, 2014, 24829493	Secondary
189	Jones, 2014, 24829493	Secondary
190	Jones, 2014, 24829493	Secondary
191	Jones, 2014, 24829493	Secondary
192	Jones, 2014, 24829493	Secondary
193	Jones, 2014, 24829493	Secondary
194	Jones, 2014, 24829493	Secondary
195	Jones, 2014, 24829493	Secondary
196	Jones, 2014, 24829493	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
197	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
198	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
199	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
200	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
201	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
202	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
203	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
204	Jones, 2014, 24829493	2010	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
205	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
206	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
197	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
198	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
199	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
200	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
201	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
202	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
203	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
204	Jones, 2014, 24829493	Hypertension (blood pressure \geq 130 mmHg (systolic) and/or \geq 85 mmHg (diastolic)); Dyslipidemia (TG \geq 1.7 mmol/L, HDL $<$ 1 mmol/L (males) or $<$ 1.3 mmol/L (females)); Obesity/Overweight (waist circumference \geq 94 cm for men and \geq 80 cm for women); Other (glucose level \geq 5.5 mmol/L)	130
205	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index \geq 20)	393
206	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index \geq 20)	393

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
197	Jones, 2014, 24829493	46.46 (14.18)	54	nd
198	Jones, 2014, 24829493	46.46 (14.18)	54	nd
199	Jones, 2014, 24829493	46.46 (14.18)	54	nd
200	Jones, 2014, 24829493	46.46 (14.18)	54	nd
201	Jones, 2014, 24829493	46.46 (14.18)	54	nd
202	Jones, 2014, 24829493	46.46 (14.18)	54	nd
203	Jones, 2014, 24829493	46.46 (14.18)	54	nd
204	Jones, 2014, 24829493	46.46 (14.18)	54	nd
205	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
206	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
197	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
198	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
199	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
200	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
201	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
202	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
203	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
204	Jones, 2014, 24829493	120.62 (16.70)/77.04 (11.80)
205	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
206	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
197	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
198	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
199	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
200	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
201	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
202	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
203	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
204	Jones, 2014, 24829493	[5.32 (1.05)]/[3.35 (0.93)]/[1.22 (0.29)]/[1.67 (0.88)]
205	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
206	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
197	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
198	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
199	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
200	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
201	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
202	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
203	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
204	Jones, 2014, 24829493	29.8 (4.37)	nd	nd
205	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
206	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
197	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	SBP
198	Jones, 2014, 24829493	ALA + DHA + EPA vs Placebo	g/d	Trial: Randomized Cross-over	SBP
199	Jones, 2014, 24829493	ALA + DHA + EPA vs ALA	g/d	Trial: Randomized Cross-over	SBP
200	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	DBP
201	Jones, 2014, 24829493	ALA vs Placebo	g/d	Trial: Randomized Cross-over	DBP
202	Jones, 2014, 24829493	ALA vs ALA	g/d	Trial: Randomized Cross-over	DBP
203	Jones, 2014, 24829493	ALA+DHA+EPA (Canola DHA) vs Placebo	g/d	Trial: Randomized Cross-over	DBP
204	Jones, 2014, 24829493	ALA+DHA+EPA (Canola DHA) vs ALA	g/d	Trial: Randomized Cross-over	DBP
205	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
206	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
197	Jones, 2014, 24829493	-1.2 (-44, 41.7)	4.52	-0.2654867
198	Jones, 2014, 24829493	-1.1 (-43.9, 41.8)	6.24	-0.176282
199	Jones, 2014, 24829493	-1.2 (-44, 41.7)	NA	
200	Jones, 2014, 24829493	0 (-28.8, 28.8)	5.9	0
201	Jones, 2014, 24829493	-0.3 (-36.2, 35.6)	1.38	-0.2173913
202	Jones, 2014, 24829493	0.3 (-35.6, 36.2)	4.52	0.0663717
203	Jones, 2014, 24829493	-2.5 (-31.3, 26.3)	6.24	-0.400641
204	Jones, 2014, 24829493	-2.2 (-38.1, 33.8)	NA	
205	Kastelein, 2014, 24528690	-1.2 (-1.6, -0.3)	3	-0.4
206	Kastelein, 2014, 24528690	-0.8 (-1.3, -0.2)	2.25	-0.3555556

Causality Table: Comparative Studies

Row	Study	Outcome classification
197	Jones, 2014, 24829493	Secondary
198	Jones, 2014, 24829493	Secondary
199	Jones, 2014, 24829493	Secondary
200	Jones, 2014, 24829493	Secondary
201	Jones, 2014, 24829493	Secondary
202	Jones, 2014, 24829493	Secondary
203	Jones, 2014, 24829493	Secondary
204	Jones, 2014, 24829493	Secondary
205	Kastelein, 2014, 24528690	Secondary
206	Kastelein, 2014, 24528690	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
207	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
208	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
209	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
210	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
211	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
212	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
213	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
207	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
208	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
209	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
210	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
211	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
212	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
213	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
207	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
208	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
209	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
210	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
211	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
212	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
213	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
207	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
208	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
209	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
210	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
211	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
212	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
213	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
207	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
208	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
209	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
210	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
211	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
212	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
213	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
207	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
208	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
209	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
210	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
211	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
212	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
213	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
207	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
208	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
209	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
210	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
211	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	µg/mL	Trial: Randomized Parallel	HDL-c
212	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
213	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
207	Kastelein, 2014, 24528690	-1.0 (-1.5, -0.5)	1.5	-0.666667
208	Kastelein, 2014, 24528690	-1.2 (-1.7, -0.6)	0.75	-1.6
209	Kastelein, 2014, 24528690	-1.2 (-1.6, -0.6)	1.5	-0.8
210	Kastelein, 2014, 24528690	-0.8 (-1.3, -0.2)	0.75	-1.066667
211	Kastelein, 2014, 24528690	0.40 (nd)	1.5	0.266667
212	Kastelein, 2014, 24528690	-0.80 (nd)	2.25	-0.355556
213	Kastelein, 2014, 24528690	-1.00 (nd)	3	-0.333333

Causality Table: Comparative Studies

Row	Study	Outcome classification
207	Kastelein, 2014, 24528690	Secondary
208	Kastelein, 2014, 24528690	Secondary
209	Kastelein, 2014, 24528690	Secondary
210	Kastelein, 2014, 24528690	Secondary
211	Kastelein, 2014, 24528690	Secondary
212	Kastelein, 2014, 24528690	Secondary
213	Kastelein, 2014, 24528690	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
214	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
215	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
216	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
217	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
218	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
219	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
220	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
214	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
215	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
216	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
217	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
218	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
219	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
220	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
214	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
215	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
216	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
217	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
218	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
219	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
220	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
214	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
215	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
216	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
217	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
218	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
219	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
220	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
214	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
215	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
216	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
217	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
218	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
219	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
220	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
214	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
215	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
216	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
217	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
218	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
219	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
220	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
214	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
215	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
216	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
217	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
218	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
219	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
220	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
214	Kastelein, 2014, 24528690	-1.40 (nd)	1.5	-0.9333333
215	Kastelein, 2014, 24528690	-1.20 (nd)	0.75	-1.6
216	Kastelein, 2014, 24528690	-0.20 (nd)	0.75	-0.2666667
217	Kastelein, 2014, 24528690	7.90 (nd)	1.5	5.266667
218	Kastelein, 2014, 24528690	5.90 (nd)	2.25	2.622222
219	Kastelein, 2014, 24528690	11.60 (nd)	3	3.866667
220	Kastelein, 2014, 24528690	3.70 (nd)	1.5	2.466667

Causality Table: Comparative Studies

Row	Study	Outcome classification
214	Kastelein, 2014, 24528690	Secondary
215	Kastelein, 2014, 24528690	Secondary
216	Kastelein, 2014, 24528690	Secondary
217	Kastelein, 2014, 24528690	Secondary
218	Kastelein, 2014, 24528690	Secondary
219	Kastelein, 2014, 24528690	Secondary
220	Kastelein, 2014, 24528690	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
221	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
222	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
223	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
224	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
225	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
226	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
227	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
221	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
222	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
223	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
224	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
225	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
226	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
227	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
221	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
222	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
223	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
224	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
225	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
226	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
227	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
221	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
222	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
223	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
224	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
225	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
226	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
227	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
221	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
222	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
223	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
224	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
225	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
226	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
227	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
221	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
222	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
223	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
224	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
225	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
226	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
227	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
221	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
222	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
223	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
224	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
225	Kastelein, 2014, 24528690	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
226	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
227	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
221	Kastelein, 2014, 24528690	-2.00 (nd)	0.75	-2.666667
222	Kastelein, 2014, 24528690	2.00 (nd)	0.75	2.666667
223	Kastelein, 2014, 24528690	-123.00 (nd)	1.5	-82
224	Kastelein, 2014, 24528690	-144.00 (nd)	2.25	-64
225	Kastelein, 2014, 24528690	-102.00 (nd)	3	-34
226	Kastelein, 2014, 24528690	-21.00 (nd)	1.5	-14
227	Kastelein, 2014, 24528690	-32.00 (nd)	0.75	-42.666667

Causality Table: Comparative Studies

Row	Study	Outcome classification
221	Kastelein, 2014, 24528690	Secondary
222	Kastelein, 2014, 24528690	Secondary
223	Kastelein, 2014, 24528690	Primary (stated)
224	Kastelein, 2014, 24528690	Primary (stated)
225	Kastelein, 2014, 24528690	Primary (stated)
226	Kastelein, 2014, 24528690	Primary (stated)
227	Kastelein, 2014, 24528690	Primary (stated)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
228	Kastelein, 2014, 24528690	2011	US, Denmark, Netherlands, India, Hungary, Ukraine, Russia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
229	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
230	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
231	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
232	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
233	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
234	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
235	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
236	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
237	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
238	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
239	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
240	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
241	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
242	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
243	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
244	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
245	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
246	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
247	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
248	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
249	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
250	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
228	Kastelein, 2014, 24528690	Dyslipidemia (average serum TG concentrations 500-2000 mg/dL); Obesity/Overweight (body mass index >=20)	393
229	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
230	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
231	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
232	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
233	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
234	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
235	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
236	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
237	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
238	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
239	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
240	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
241	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
242	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
243	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
244	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
245	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
246	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
247	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
248	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
249	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
250	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
228	Kastelein, 2014, 24528690	50.8 (10.6)	77.8	96 white, 4 Asian, 6.1 Hispanic
229	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
230	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
231	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
232	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
233	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
234	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
235	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
236	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
237	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
238	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
239	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
240	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
241	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
242	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
243	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
244	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
245	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
246	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
247	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
248	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
249	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
250	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
228	Kastelein, 2014, 24528690	130.4 (12.1)/80.5 (6.2)
229	Kromhout, 2010, 20929341	141.9 (21.6)/nd
230	Kromhout, 2010, 20929341	141.9 (21.6)/nd
231	Kromhout, 2010, 20929341	141.9 (21.6)/nd
232	Kromhout, 2010, 20929341	141.9 (21.6)/nd
233	Kromhout, 2010, 20929341	141.9 (21.6)/nd
234	Kromhout, 2010, 20929341	141.9 (21.6)/nd
235	Kromhout, 2010, 20929341	141.9 (21.6)/nd
236	Kromhout, 2010, 20929341	141.9 (21.6)/nd
237	Kromhout, 2010, 20929341	141.9 (21.6)/nd
238	Kromhout, 2010, 20929341	141.9 (21.6)/nd
239	Kromhout, 2010, 20929341	141.9 (21.6)/nd
240	Kromhout, 2010, 20929341	141.9 (21.6)/nd
241	Kromhout, 2010, 20929341	141.9 (21.6)/nd
242	Kromhout, 2010, 20929341	141.9 (21.6)/nd
243	Kromhout, 2010, 20929341	141.9 (21.6)/nd
244	Kromhout, 2010, 20929341	141.9 (21.6)/nd
245	Kromhout, 2010, 20929341	141.9 (21.6)/nd
246	Kromhout, 2010, 20929341	141.9 (21.6)/nd
247	Kromhout, 2010, 20929341	141.9 (21.6)/nd
248	Kromhout, 2010, 20929341	141.9 (21.6)/nd
249	Kromhout, 2010, 20929341	141.9 (21.6)/nd
250	Kromhout, 2010, 20929341	141.9 (21.6)/nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
228	Kastelein, 2014, 24528690	Median 241 (range 131, 542)/median 77.3 (range 19.7, 182)/median 27.3 (range 13.3, 47.3)/median 717 (range 415, 1578)
229	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
230	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
231	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
232	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
233	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
234	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
235	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
236	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
237	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
238	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
239	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
240	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
241	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
242	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
243	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
244	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
245	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
246	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
247	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
248	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
249	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
250	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
228	Kastelein, 2014, 24528690	30.4 (4.3)	ALA: median 375 (range 105, 1182) µg/mL, EPA: median 19.5 (range 6.3, 207) µg/mL, DHA: median 85.1 (range 29.7, 411) µg/mL	plasma
229	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
230	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
231	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
232	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
233	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
234	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
235	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
236	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
237	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
238	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
239	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
240	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
241	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
242	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
243	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
244	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
245	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
246	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
247	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
248	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
249	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
250	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
228	Kastelein, 2014, 24528690	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
229	Kromhout, 2010, 20929341	EPA+DHA+ALA vs ALA	g/d	Trial: Randomized Factorial Design	CVD total
230	Kromhout, 2010, 20929341	EPA+DHA+ALA vs EPA+DHA	g/d	Trial: Randomized Factorial Design	CVD total
231	Kromhout, 2010, 20929341	EPA+DHA+ALA vs ALA	g/d	Trial: Randomized Factorial Design	Death, all cause
232	Kromhout, 2010, 20929341	EPA+DHA+ALA vs EPA+DHA	g/d	Trial: Randomized Factorial Design	Death, all cause
233	Kromhout, 2010, 20929341	EPA+DHA+ALA vs ALA	g/d	Trial: Randomized Factorial Design	Death, cardiac
234	Kromhout, 2010, 20929341	EPA+DHA+ALA vs EPA+DHA	g/d	Trial: Randomized Factorial Design	Death, cardiac
235	Kromhout, 2010, 20929341	EPA+DHA+ALA vs ALA	g/d	Trial: Randomized Factorial Design	Death, CVD (total)
236	Kromhout, 2010, 20929341	EPA+DHA+ALA vs EPA+DHA	g/d	Trial: Randomized Factorial Design	Death, CVD (total)
237	Kromhout, 2010, 20929341	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	Revascularization
238	Kromhout, 2010, 20929341	ALA+Statin vs Placebo + Statin	g/d	Trial: Randomized Factorial Design	Revascularization
239	Kromhout, 2010, 20929341	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Revascularization
240	Kromhout, 2010, 20929341	EPA+DHA+Statin vs Placebo + Statin	g/d	Trial: Randomized Factorial Design	Revascularization
241	Kromhout, 2010, 20929341	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Revascularization
242	Kromhout, 2010, 20929341	ALA+EPA+DHA + Statin vs Placebo + Statin	g/d	Trial: Randomized Factorial Design	Revascularization
243	Kromhout, 2010, 20929341	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
244	Kromhout, 2010, 20929341	ALA + Statin vs Placebo + Statin	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
245	Kromhout, 2010, 20929341	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
246	Kromhout, 2010, 20929341	EPA+DHA + Statin vs Placebo + Statin	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
247	Kromhout, 2010, 20929341	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
248	Kromhout, 2010, 20929341	ALA+EPA+DHA + Statin vs Placebo + Statin	g/d	Trial: Randomized Factorial Design	Total:HDL-c ratio
249	Kromhout, 2010, 20929341	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
250	Kromhout, 2010, 20929341	ALA (+EPA+DHA) vs (EPA+DHA)	g/d	Trial: Randomized Factorial Design	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
228	Kastelein, 2014, 24528690	-21.00 (nd)	0.75	-28
229	Kromhout, 2010, 20929341	HR 0.92 (0.75, 1.13)	NA	
230	Kromhout, 2010, 20929341	HR 0.92 (0.73, 1.11)	NA	
231	Kromhout, 2010, 20929341	HR 1.01 (0.82, 1.24)	NA	
232	Kromhout, 2010, 20929341	HR 0.97 (0.79, 1.19)	NA	
233	Kromhout, 2010, 20929341	HR 0.95 (0.68, 1.32)	NA	
234	Kromhout, 2010, 20929341	HR 0.92 (0.66, 1.29)	NA	
235	Kromhout, 2010, 20929341	HR 0.98 (0.72, 1.33)	NA	
236	Kromhout, 2010, 20929341	HR 0.94 (0.69, 1.27)	NA	
237	Kromhout, 2010, 20929341	HR 0.94 (0.49, 1.80)	2	0.9695359
238	Kromhout, 2010, 20929341	HR 0.98 (0.76, 1.27)	2	0.9899495
239	Kromhout, 2010, 20929341	HR 0.84 (0.44, 1.62)	0.4	0.6466931
240	Kromhout, 2010, 20929341	HR 1.06 (0.83, 1.36)	0.4	1.156817
241	Kromhout, 2010, 20929341	HR 0.48 (0.22, 1.06)	2.4	0.7365188
242	Kromhout, 2010, 20929341	HR 1.02 (0.79, 1.31)	2.4	1.008285
243	Kromhout, 2010, 20929341	0.057 (-0.19, 0.30)	2	0.0285
244	Kromhout, 2010, 20929341	0.063 (-0.012, 0.14)	2	0.0315
245	Kromhout, 2010, 20929341	0.89 (-0.15, 0.32)	0.4	2.225
246	Kromhout, 2010, 20929341	-0.062 (-0.14, 0.013)	0.4	-0.155
247	Kromhout, 2010, 20929341	0.12 (-0.13, 0.37)	2.4	0.05
248	Kromhout, 2010, 20929341	-0.036 (-0.11, 0.039)	2.4	-0.015
249	Kromhout, 2010, 20929341	-0.77 (-1.84, 0.30)	2	-0.385
250	Kromhout, 2010, 20929341	-1.54 (-2.61, -0.47)	2	-0.77

Causality Table: Comparative Studies

Row	Study	Outcome classification
228	Kastelein, 2014, 24528690	Primary (stated)
229	Kromhout, 2010, 20929341	Secondary
230	Kromhout, 2010, 20929341	Secondary
231	Kromhout, 2010, 20929341	Primary (stated)
232	Kromhout, 2010, 20929341	Primary (stated)
233	Kromhout, 2010, 20929341	Secondary
234	Kromhout, 2010, 20929341	Secondary
235	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
236	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
237	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
238	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
239	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
240	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
241	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
242	Kromhout, 2010, 20929341	Secondary; Primary in registry record (NCT00127452)
243	Kromhout, 2010, 20929341	Secondary
244	Kromhout, 2010, 20929341	Secondary
245	Kromhout, 2010, 20929341	Secondary
246	Kromhout, 2010, 20929341	Secondary
247	Kromhout, 2010, 20929341	Secondary
248	Kromhout, 2010, 20929341	Secondary
249	Kromhout, 2010, 20929341	Secondary
250	Kromhout, 2010, 20929341	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
251	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
252	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
253	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
254	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
255	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
256	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
257	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
258	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
259	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
260	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
261	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
262	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
263	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
264	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
265	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
266	Kromhout, 2010, 20929341	2002	Netherlands	Secondary Prevention (history of CVD event)
267	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthYoung adults 20-35 y; EOI vs FOI
268	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthOlder adults 49-69 y; EOII vs FOII
269	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthYoung adults 20-35 y; EOI vs FOI
270	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthOlder adults 49-69 y; EOII vs FOII
271	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthYoung adults 20-35 y; EOI vs FOI
272	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthOlder adults 49-69 y; EOII vs FOII
273	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthYoung adults 20-35 y; EOI vs FOI
274	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthOlder adults 49-69 y; EOII vs FOII
275	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthYoung adults 20-35 y; EOI vs FOI
276	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthOlder adults 49-69 y; EOII vs FOII
277	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthYoung adults 20-35 y; EOI vs FOI

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
251	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
252	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
253	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
254	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
255	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
256	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
257	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
258	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
259	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
260	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
261	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
262	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
263	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
264	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
265	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
266	Kromhout, 2010, 20929341	Cardiac disease (myocardial infarction)	4837
267	Kuhnt, 2014, 24553695	nd	30
268	Kuhnt, 2014, 24553695	nd	29
269	Kuhnt, 2014, 24553695	nd	30
270	Kuhnt, 2014, 24553695	nd	29
271	Kuhnt, 2014, 24553695	nd	30
272	Kuhnt, 2014, 24553695	nd	29
273	Kuhnt, 2014, 24553695	nd	30
274	Kuhnt, 2014, 24553695	nd	29
275	Kuhnt, 2014, 24553695	nd	30
276	Kuhnt, 2014, 24553695	nd	29
277	Kuhnt, 2014, 24553695	nd	30

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
251	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
252	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
253	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
254	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
255	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
256	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
257	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
258	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
259	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
260	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
261	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
262	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
263	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
264	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
265	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
266	Kromhout, 2010, 20929341	68.9 (5.6)	78.7	nd
267	Kuhnt, 2014, 24553695	27.7 (2.8)	50	nd
268	Kuhnt, 2014, 24553695	59.3 (5.3)	48	nd
269	Kuhnt, 2014, 24553695	27.7 (2.8)	50	nd
270	Kuhnt, 2014, 24553695	59.3 (5.3)	48	nd
271	Kuhnt, 2014, 24553695	27.7 (2.8)	50	nd
272	Kuhnt, 2014, 24553695	59.3 (5.3)	48	nd
273	Kuhnt, 2014, 24553695	27.7 (2.8)	50	nd
274	Kuhnt, 2014, 24553695	59.3 (5.3)	48	nd
275	Kuhnt, 2014, 24553695	27.7 (2.8)	50	nd
276	Kuhnt, 2014, 24553695	59.3 (5.3)	48	nd
277	Kuhnt, 2014, 24553695	27.7 (2.8)	50	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
251	Kromhout, 2010, 20929341	141.9 (21.6)/nd
252	Kromhout, 2010, 20929341	141.9 (21.6)/nd
253	Kromhout, 2010, 20929341	141.9 (21.6)/nd
254	Kromhout, 2010, 20929341	141.9 (21.6)/nd
255	Kromhout, 2010, 20929341	141.9 (21.6)/nd
256	Kromhout, 2010, 20929341	141.9 (21.6)/nd
257	Kromhout, 2010, 20929341	141.9 (21.6)/nd
258	Kromhout, 2010, 20929341	141.9 (21.6)/nd
259	Kromhout, 2010, 20929341	141.9 (21.6)/nd
260	Kromhout, 2010, 20929341	141.9 (21.6)/nd
261	Kromhout, 2010, 20929341	141.9 (21.6)/nd
262	Kromhout, 2010, 20929341	141.9 (21.6)/nd
263	Kromhout, 2010, 20929341	141.9 (21.6)/nd
264	Kromhout, 2010, 20929341	141.9 (21.6)/nd
265	Kromhout, 2010, 20929341	141.9 (21.6)/nd
266	Kromhout, 2010, 20929341	141.9 (21.6)/nd
267	Kuhnt, 2014, 24553695	128.7 (12.7)/84.0 (9.0)
268	Kuhnt, 2014, 24553695	135.3 (19.5)/89.4 (10.9)
269	Kuhnt, 2014, 24553695	128.7 (12.7)/84.0 (9.0)
270	Kuhnt, 2014, 24553695	135.3 (19.5)/89.4 (10.9)
271	Kuhnt, 2014, 24553695	128.7 (12.7)/84.0 (9.0)
272	Kuhnt, 2014, 24553695	135.3 (19.5)/89.4 (10.9)
273	Kuhnt, 2014, 24553695	128.7 (12.7)/84.0 (9.0)
274	Kuhnt, 2014, 24553695	135.3 (19.5)/89.4 (10.9)
275	Kuhnt, 2014, 24553695	128.7 (12.7)/84.0 (9.0)
276	Kuhnt, 2014, 24553695	135.3 (19.5)/89.4 (10.9)
277	Kuhnt, 2014, 24553695	128.7 (12.7)/84.0 (9.0)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
251	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
252	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
253	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
254	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
255	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
256	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
257	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
258	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
259	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
260	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
261	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
262	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
263	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
264	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
265	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
266	Kromhout, 2010, 20929341	[4.75 (0.99)]/[2.60 (0.87)]/[1.28 (0.34)]/[1.69 (1.22, 2.38)]
267	Kuhnt, 2014, 24553695	[4.4 (0.7)/1.8 (0.8)/1.5 (0.3)/0.9 (0.3)]
268	Kuhnt, 2014, 24553695	[5.7 (1.1)/2.0 (1.0)/1.7 (0.5)/1.1 (0.4)]
269	Kuhnt, 2014, 24553695	[4.4 (0.7)/1.8 (0.8)/1.5 (0.3)/0.9 (0.3)]
270	Kuhnt, 2014, 24553695	[5.7 (1.1)/2.0 (1.0)/1.7 (0.5)/1.1 (0.4)]
271	Kuhnt, 2014, 24553695	[4.4 (0.7)/1.8 (0.8)/1.5 (0.3)/0.9 (0.3)]
272	Kuhnt, 2014, 24553695	[5.7 (1.1)/2.0 (1.0)/1.7 (0.5)/1.1 (0.4)]
273	Kuhnt, 2014, 24553695	[4.4 (0.7)/1.8 (0.8)/1.5 (0.3)/0.9 (0.3)]
274	Kuhnt, 2014, 24553695	[5.7 (1.1)/2.0 (1.0)/1.7 (0.5)/1.1 (0.4)]
275	Kuhnt, 2014, 24553695	[4.4 (0.7)/1.8 (0.8)/1.5 (0.3)/0.9 (0.3)]
276	Kuhnt, 2014, 24553695	[5.7 (1.1)/2.0 (1.0)/1.7 (0.5)/1.1 (0.4)]
277	Kuhnt, 2014, 24553695	[4.4 (0.7)/1.8 (0.8)/1.5 (0.3)/0.9 (0.3)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
251	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
252	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
253	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
254	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
255	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
256	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
257	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
258	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
259	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
260	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
261	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
262	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
263	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
264	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
265	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
266	Kromhout, 2010, 20929341	27.8 (3.9)	nd	nd
267	Kuhnt, 2014, 24553695	21.8 (2.4)	nd	nd
268	Kuhnt, 2014, 24553695	23.9 (2.7)	nd	nd
269	Kuhnt, 2014, 24553695	21.8 (2.4)	nd	nd
270	Kuhnt, 2014, 24553695	23.9 (2.7)	nd	nd
271	Kuhnt, 2014, 24553695	21.8 (2.4)	nd	nd
272	Kuhnt, 2014, 24553695	23.9 (2.7)	nd	nd
273	Kuhnt, 2014, 24553695	21.8 (2.4)	nd	nd
274	Kuhnt, 2014, 24553695	23.9 (2.7)	nd	nd
275	Kuhnt, 2014, 24553695	21.8 (2.4)	nd	nd
276	Kuhnt, 2014, 24553695	23.9 (2.7)	nd	nd
277	Kuhnt, 2014, 24553695	21.8 (2.4)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
251	Kromhout, 2010, 20929341	ALA + EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
252	Kromhout, 2010, 20929341	EPA+DHA vs ALA	g/d	Trial: Randomized Factorial Design	HDL-c
253	Kromhout, 2010, 20929341	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
254	Kromhout, 2010, 20929341	EPA+DHA (+ALA) vs (ALA)	g/d	Trial: Randomized Factorial Design	HDL-c
255	Kromhout, 2010, 20929341	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
256	Kromhout, 2010, 20929341	EPA+DHA (+ALA) vs (ALA)	g/d	Trial: Randomized Factorial Design	LDL-c
257	Kromhout, 2010, 20929341	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
258	Kromhout, 2010, 20929341	ALA (+EPA+DHA) vs (EPA+DHA)	g/d	Trial: Randomized Factorial Design	LDL-c
259	Kromhout, 2010, 20929341	ALA + EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
260	Kromhout, 2010, 20929341	EPA+DHA vs ALA	g/d	Trial: Randomized Factorial Design	LDL-c
261	Kromhout, 2010, 20929341	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
262	Kromhout, 2010, 20929341	ALA (+EPA+DHA) vs (EPA+DHA)	g/d	Trial: Randomized Factorial Design	Tg
263	Kromhout, 2010, 20929341	ALA + EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
264	Kromhout, 2010, 20929341	EPA+DHA vs ALA	g/d	Trial: Randomized Factorial Design	Tg
265	Kromhout, 2010, 20929341	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
266	Kromhout, 2010, 20929341	EPA+DHA (+ALA) vs (ALA)	g/d	Trial: Randomized Factorial Design	Tg
267	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
268	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
269	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
270	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
271	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
272	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
273	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
274	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
275	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	SBP
276	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	SBP
277	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	DBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
251	Kromhout, 2010, 20929341	-0.39 (-1.46, 0.68)	2.4	-0.1625
252	Kromhout, 2010, 20929341	1.93 (0.86, 3.00)	NA	
253	Kromhout, 2010, 20929341	1.16 (0.09, 2.23)	0.4	2.9
254	Kromhout, 2010, 20929341	0.39 (-0.68, 1.46)	0.4	0.975
255	Kromhout, 2010, 20929341	-0.77 (-3.98, 2.44)	0.4	-1.925
256	Kromhout, 2010, 20929341	0.39 (-2.82, 3.60)	0.4	0.975
257	Kromhout, 2010, 20929341	0.39 (-2.82, 3.60)	2	0.195
258	Kromhout, 2010, 20929341	1.54 (-1.67, 4.76)	2	0.77
259	Kromhout, 2010, 20929341	0.77 (-2.44, 3.98)	2.4	0.3208333
260	Kromhout, 2010, 20929341	-1.16 (-4.37, 2.05)	NA	
261	Kromhout, 2010, 20929341	-5.31 (-15.12, 4.50)	2	-2.655
262	Kromhout, 2010, 20929341	-5.31 (-15.42, 4.80)	2	-2.655
263	Kromhout, 2010, 20929341	-7.96 (-16.64, 0.71)	2.4	-3.316667
264	Kromhout, 2010, 20929341	2.65 (-8.45, 13.76)	NA	
265	Kromhout, 2010, 20929341	-2.65 (-13.76, 8.45)	0.4	-6.625
266	Kromhout, 2010, 20929341	-2.65 (-11.33, 6.02)	0.4	-6.625
267	Kuhnt, 2014, 24553695	0.02 (-0.45, 0.49)	NA	
268	Kuhnt, 2014, 24553695	0.03 (-0.59, 0.65)	NA	
269	Kuhnt, 2014, 24553695	-4.25 (-15.69, 7.19)	NA	
270	Kuhnt, 2014, 24553695	-2.71 (-19, 13.58)	NA	
271	Kuhnt, 2014, 24553695	-3.87 (-22.48, 14.74)	NA	
272	Kuhnt, 2014, 24553695	-10.4 (-34.13, 13.33)	NA	
273	Kuhnt, 2014, 24553695	-1.75 (-17.58, 14.08)	NA	
274	Kuhnt, 2014, 24553695	13.16 (-10.1, 36.42)	NA	
275	Kuhnt, 2014, 24553695	6 (-3.12, 15.12)	NA	
276	Kuhnt, 2014, 24553695	2 (-12.7, 16.7)	NA	
277	Kuhnt, 2014, 24553695	3 (-3.1, 9.1)	NA	

Causality Table: Comparative Studies

Row	Study	Outcome classification
251	Kromhout, 2010, 20929341	Secondary
252	Kromhout, 2010, 20929341	Secondary
253	Kromhout, 2010, 20929341	Secondary
254	Kromhout, 2010, 20929341	Secondary
255	Kromhout, 2010, 20929341	Secondary
256	Kromhout, 2010, 20929341	Secondary
257	Kromhout, 2010, 20929341	Secondary
258	Kromhout, 2010, 20929341	Secondary
259	Kromhout, 2010, 20929341	Secondary
260	Kromhout, 2010, 20929341	Secondary
261	Kromhout, 2010, 20929341	Secondary
262	Kromhout, 2010, 20929341	Secondary
263	Kromhout, 2010, 20929341	Secondary
264	Kromhout, 2010, 20929341	Secondary
265	Kromhout, 2010, 20929341	Secondary
266	Kromhout, 2010, 20929341	Secondary
267	Kuhnt, 2014, 24553695	Secondary
268	Kuhnt, 2014, 24553695	Secondary
269	Kuhnt, 2014, 24553695	Secondary
270	Kuhnt, 2014, 24553695	Secondary
271	Kuhnt, 2014, 24553695	Secondary
272	Kuhnt, 2014, 24553695	Secondary
273	Kuhnt, 2014, 24553695	Secondary
274	Kuhnt, 2014, 24553695	Secondary
275	Kuhnt, 2014, 24553695	Secondary
276	Kuhnt, 2014, 24553695	Secondary
277	Kuhnt, 2014, 24553695	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
278	Kuhnt, 2014, 24553695	2011	Germany	Primary Prevention, HealthOlder adults 49-69 y; EOII vs FOII
279	Leaf, 2005, 16267249	1999	US	Secondary Prevention (history of CVD event)
280	Leaf, 2005, 16267249	1999	US	Secondary Prevention (history of CVD event)
281	Leaf, 2005, 16267249	1999	US	Secondary Prevention (history of CVD event)
282	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
283	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
284	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
285	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
286	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
287	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
288	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
289	Liu, 2003, no PMID	2001 (approx)	Sweden	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
290	Lungershausen, 1994	1992 (approx)	Australia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
291	Lungershausen, 1994	1992 (approx)	Australia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
292	Lungershausen, 1994	1992 (approx)	Australia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
293	Lungershausen, 1994	1992 (approx)	Australia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
294	Lungershausen, 1994	1992 (approx)	Australia	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
295	Macchia, 2013, 23265344	2008	Italy, Argentina	Secondary Prevention (history of CVD event)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
278	Kuhnt, 2014, 24553695	nd	29
279	Leaf, 2005, 16267249	Arrhythmia (ICD implanted)	402
280	Leaf, 2005, 16267249	Arrhythmia (ICD implanted)	402
281	Leaf, 2005, 16267249	Arrhythmia (ICD implanted)	402
282	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
283	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
284	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
285	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
286	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
287	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
288	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
289	Liu, 2003, no PMID	Dyslipidemia (fasting TC>6.2 mmol/L and/or fasting TG>1.8 mmol/L)	59
290	Lungershausen, 1994	Hypertension (Treated for hypertension, on medication)	42
291	Lungershausen, 1994	Hypertension (Treated for hypertension, on medication)	42
292	Lungershausen, 1994	Hypertension (Treated for hypertension, on medication)	42
293	Lungershausen, 1994	Hypertension (Treated for hypertension, on medication)	42
294	Lungershausen, 1994	Hypertension (Treated for hypertension, on medication)	42
295	Macchia, 2013, 23265344	Arrhythmia	586

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
278	Kuhnt, 2014, 24553695	59.3 (5.3)	48	nd
279	Leaf, 2005, 16267249	65.3 (0.82)	81.7	95.5 white
280	Leaf, 2005, 16267249	65.3 (0.82)	81.7	95.5 white
281	Leaf, 2005, 16267249	65.3 (0.82)	81.7	95.5 white
282	Liu, 2003, no PMID	57 (10)	30.7	nd
283	Liu, 2003, no PMID	57 (10)	30.7	nd
284	Liu, 2003, no PMID	57 (10)	30.7	nd
285	Liu, 2003, no PMID	57 (10)	30.7	nd
286	Liu, 2003, no PMID	57 (10)	30.7	nd
287	Liu, 2003, no PMID	57 (10)	30.7	nd
288	Liu, 2003, no PMID	57 (10)	30.7	nd
289	Liu, 2003, no PMID	57 (10)	30.7	nd
290	Lungershausen, 1994	61 (11.34)	30.95	nd
291	Lungershausen, 1994	61 (11.34)	30.95	nd
292	Lungershausen, 1994	61 (11.34)	30.95	nd
293	Lungershausen, 1994	61 (11.34)	30.95	nd
294	Lungershausen, 1994	61 (11.34)	30.95	nd
295	Macchia, 2013, 23265344	65.9 (10.5)	51.9	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
278	Kuhnt, 2014, 24553695	135.3 (19.5)/89.4 (10.9)
279	Leaf, 2005, 16267249	nd
280	Leaf, 2005, 16267249	nd
281	Leaf, 2005, 16267249	nd
282	Liu, 2003, no PMID	nd
283	Liu, 2003, no PMID	nd
284	Liu, 2003, no PMID	nd
285	Liu, 2003, no PMID	nd
286	Liu, 2003, no PMID	nd
287	Liu, 2003, no PMID	nd
288	Liu, 2003, no PMID	nd
289	Liu, 2003, no PMID	nd
290	Lungershausen, 1994	132.57 (11.43)/76.52 (7.23)
291	Lungershausen, 1994	132.57 (11.43)/76.52 (7.23)
292	Lungershausen, 1994	132.57 (11.43)/76.52 (7.23)
293	Lungershausen, 1994	132.57 (11.43)/76.52 (7.23)
294	Lungershausen, 1994	132.57 (11.43)/76.52 (7.23)
295	Macchia, 2013, 23265344	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
278	Kuhnt, 2014, 24553695	[5.7 (1.1)/2.0 (1.0)/1.7 (0.5)/1.1 (0.4)]
279	Leaf, 2005, 16267249	nd
280	Leaf, 2005, 16267249	nd
281	Leaf, 2005, 16267249	nd
282	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
283	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
284	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
285	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
286	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
287	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
288	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
289	Liu, 2003, no PMID	[6.77 (0.75)]/[4.50 (0.72)]/[1.53 (0.43)]/[1.61 (0.83)]
290	Lungershausen, 1994	[5.74 (SE 0.21)]/[4.04 (SE 0.19)]/[1.03 (SE 0.04)]/
291	Lungershausen, 1994	[5.74 (SE 0.21)]/[4.04 (SE 0.19)]/[1.03 (SE 0.04)]/
292	Lungershausen, 1994	[5.74 (SE 0.21)]/[4.04 (SE 0.19)]/[1.03 (SE 0.04)]/
293	Lungershausen, 1994	[5.74 (SE 0.21)]/[4.04 (SE 0.19)]/[1.03 (SE 0.04)]/
294	Lungershausen, 1994	[5.74 (SE 0.21)]/[4.04 (SE 0.19)]/[1.03 (SE 0.04)]/
295	Macchia, 2013, 23265344	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
278	Kuhnt, 2014, 24553695	23.9 (2.7)	nd	nd
279	Leaf, 2005, 16267249	nd	EPA+DHA: 3.5 (SEM 1.2) % FA	phospholipids of red blood cells
280	Leaf, 2005, 16267249	nd	EPA+DHA: 3.5 (SEM 1.2) % FA	phospholipids of red blood cells
281	Leaf, 2005, 16267249	nd	EPA+DHA: 3.5 (SEM 1.2) % FA	phospholipids of red blood cells
282	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
283	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
284	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
285	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
286	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
287	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
288	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
289	Liu, 2003, no PMID	nd	EPA: 2.1 (0.3)% FA/DHA: 5.0 (0.5)% FA	erythrocyte
290	Lungershausen, 1994	27.33 (3.93)	nd	nd
291	Lungershausen, 1994	27.33 (3.93)	nd	nd
292	Lungershausen, 1994	27.33 (3.93)	nd	nd
293	Lungershausen, 1994	27.33 (3.93)	nd	nd
294	Lungershausen, 1994	27.33 (3.93)	nd	nd
295	Macchia, 2013, 23265344	weight 83 (19)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
278	Kuhnt, 2014, 24553695	SDA vs EPA+DHA	g/d	Trial: Randomized Parallel	DBP
279	Leaf, 2005, 16267249	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
280	Leaf, 2005, 16267249	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, cardiac
281	Leaf, 2005, 16267249	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Sudden cardiac death
282	Liu, 2003, no PMID	EPA+DHA+ simvastatin vs Placebo + simvastatin	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
283	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
284	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
285	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
286	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
287	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
288	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
289	Liu, 2003, no PMID	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
290	Lungershausen, 1994	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
291	Lungershausen, 1994	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
292	Lungershausen, 1994	DHA+EPA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
293	Lungershausen, 1994	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	SBP
294	Lungershausen, 1994	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	DBP
295	Macchia, 2013, 23265344	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Atrial fibrillation

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
278	Kuhnt, 2014, 24553695	1 (-7.05, 9.05)	NA	
279	Leaf, 2005, 16267249	OR 1.10 (0.49, 2.47)	2.6	1.037338
280	Leaf, 2005, 16267249	OR 1.01 (0.39, 2.60)	2.6	1.003834
281	Leaf, 2005, 16267249	3.06 (0.32, 29.68)	0.6	6.449644
282	Liu, 2003, no PMID	-0.02 (-0.45, 0.41)	2.8	-0.0071429
283	Liu, 2003, no PMID	-0.1 (-0.7, 0.5)	2.8	-0.0357143
284	Liu, 2003, no PMID	2.32 (-7.32, 11.95)	2.8	0.8285714
285	Liu, 2003, no PMID	2.32 (-9.32, 13.95)	2.8	0.8285714
286	Liu, 2003, no PMID	5.41 (-13.28, 24.09)	2.8	1.932143
287	Liu, 2003, no PMID	5.02 (-17.04, 27.07)	2.8	1.792857
288	Liu, 2003, no PMID	-39.82 (-76.39, -3.26)	2.8	-14.22143
289	Liu, 2003, no PMID	-35.40 (-79.60, 8.80)	2.8	-12.64286
290	Lungershausen, 1994	0.77 (-2.71, 4.25)	3.4	0.2264706
291	Lungershausen, 1994	6.56 (-7.50, 20.56)	3.4	1.929412
292	Lungershausen, 1994	28.32 (19.65, 36.99)	3.4	8.329412
293	Lungershausen, 1994	-3.1 (-8.3, 2.1)	3.4	-0.9117647
294	Lungershausen, 1994	-1.8 (-4.8, 1.2)	3.4	-0.5294118
295	Macchia, 2013, 23265344	HR 1.28 (0.90, 1.83)	0.866	1.329839

Causality Table: Comparative Studies

Row	Study	Outcome classification
278	Kuhnt, 2014, 24553695	Secondary
279	Leaf, 2005, 16267249	Secondary
280	Leaf, 2005, 16267249	Secondary
281	Leaf, 2005, 16267249	Secondary
282	Liu, 2003, no PMID	No data; unclear
283	Liu, 2003, no PMID	No data; unclear
284	Liu, 2003, no PMID	No data; unclear
285	Liu, 2003, no PMID	No data; unclear
286	Liu, 2003, no PMID	No data; unclear
287	Liu, 2003, no PMID	No data; unclear
288	Liu, 2003, no PMID	No data; unclear
289	Liu, 2003, no PMID	No data; unclear
290	Lungershausen, 1994	Primary (implied)
291	Lungershausen, 1994	Primary (implied)
292	Lungershausen, 1994	Primary (implied)
293	Lungershausen, 1994	Primary (implied)
294	Lungershausen, 1994	Primary (implied)
295	Macchia, 2013, 23265344	Secondary; Primary in registry record (NCT00597220)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
296	Macchia, 2013, 23265344	2008	Italy, Argentina	Secondary Prevention (history of CVD event)
297	Macchia, 2013, 23265344	2008	Italy, Argentina	Secondary Prevention (history of CVD event)
298	Macchia, 2013, 23265344	2008	Italy, Argentina	Secondary Prevention (history of CVD event)
299	Macchia, 2013, 23265344	2008	Italy, Argentina	Secondary Prevention (history of CVD event)
300	Maki, 2010, 20451686	2005	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
301	Maki, 2010, 20451686	2005	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
302	Maki, 2010, 20451686	2005	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
303	Maki, 2010, 20451686	2005	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
304	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
305	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
306	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
307	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
296	Macchia, 2013, 23265344	Arrhythmia	586
297	Macchia, 2013, 23265344	Arrhythmia	586
298	Macchia, 2013, 23265344	Arrhythmia	586
299	Macchia, 2013, 23265344	Arrhythmia	586
300	Maki, 2010, 20451686	Dyslipidemia (mean fasting TG level >200 and <500 mg/dL, and a mean LDL-C level below 254 or within 10% of the patient's NCEP ATP III goal)	254
301	Maki, 2010, 20451686	Dyslipidemia (mean fasting TG level >200 and <500 mg/dL, and a mean LDL-C level below 254 or within 10% of the patient's NCEP ATP III goal)	254
302	Maki, 2010, 20451686	Dyslipidemia (mean fasting TG level >200 and <500 mg/dL, and a mean LDL-C level below 254 or within 10% of the patient's NCEP ATP III goal)	254
303	Maki, 2010, 20451686	Dyslipidemia (mean fasting TG level >200 and <500 mg/dL, and a mean LDL-C level below 254 or within 10% of the patient's NCEP ATP III goal)	254
304	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
305	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
306	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
307	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
296	Macchia, 2013, 23265344	65.9 (10.5)	51.9	nd
297	Macchia, 2013, 23265344	65.9 (10.5)	51.9	nd
298	Macchia, 2013, 23265344	65.9 (10.5)	51.9	nd
299	Macchia, 2013, 23265344	65.9 (10.5)	51.9	nd
300	Maki, 2010, 20451686	59.3 (10.8)	60.6	96.2 white, 2.3 black, 2.3 Hispanic
301	Maki, 2010, 20451686	59.3 (10.8)	60.6	96.2 white, 2.3 black, 2.3 Hispanic
302	Maki, 2010, 20451686	59.3 (10.8)	60.6	96.2 white, 2.3 black, 2.3 Hispanic
303	Maki, 2010, 20451686	59.3 (10.8)	60.6	96.2 white, 2.3 black, 2.3 Hispanic
304	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
305	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
306	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
307	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
296	Macchia, 2013, 23265344	nd
297	Macchia, 2013, 23265344	nd
298	Macchia, 2013, 23265344	nd
299	Macchia, 2013, 23265344	nd
300	Maki, 2010, 20451686	nd
301	Maki, 2010, 20451686	nd
302	Maki, 2010, 20451686	nd
303	Maki, 2010, 20451686	nd
304	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
305	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
306	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
307	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
296	Macchia, 2013, 23265344	nd
297	Macchia, 2013, 23265344	nd
298	Macchia, 2013, 23265344	nd
299	Macchia, 2013, 23265344	nd
300	Maki, 2010, 20451686	186.0 (32.1) median 183.5 /92.3 (23.2) median 88.2 /44.7 (9.3) median 43.3 /286.7 (77.5) median 270.7
301	Maki, 2010, 20451686	186.0 (32.1) median 183.5 /92.3 (23.2) median 88.2 /44.7 (9.3) median 43.3 /286.7 (77.5) median 270.7
302	Maki, 2010, 20451686	186.0 (32.1) median 183.5 /92.3 (23.2) median 88.2 /44.7 (9.3) median 43.3 /286.7 (77.5) median 270.7
303	Maki, 2010, 20451686	186.0 (32.1) median 183.5 /92.3 (23.2) median 88.2 /44.7 (9.3) median 43.3 /286.7 (77.5) median 270.7
304	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
305	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
306	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
307	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
296	Macchia, 2013, 23265344	weight 83 (19)	nd	nd
297	Macchia, 2013, 23265344	weight 83 (19)	nd	nd
298	Macchia, 2013, 23265344	weight 83 (19)	nd	nd
299	Macchia, 2013, 23265344	weight 83 (19)	nd	nd
300	Maki, 2010, 20451686	31.5 (5.5)	nd	nd
301	Maki, 2010, 20451686	31.5 (5.5)	nd	nd
302	Maki, 2010, 20451686	31.5 (5.5)	nd	nd
303	Maki, 2010, 20451686	31.5 (5.5)	nd	nd
304	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
305	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
306	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
307	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
296	Macchia, 2013, 23265344	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Congestive heart failure
297	Macchia, 2013, 23265344	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
298	Macchia, 2013, 23265344	ALA+DHA+EPA vs Placebo	g/d	Trial: Randomized Parallel	MACE
299	Macchia, 2013, 23265344	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Stroke
300	Maki, 2010, 20451686	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
301	Maki, 2010, 20451686	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
302	Maki, 2010, 20451686	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
303	Maki, 2010, 20451686	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
304	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
305	Maki, 2013, 23998969	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
306	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
307	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
296	Macchia, 2013, 23265344	HR 0.86 (0.26, 2.81)	0.866	0.8401622
297	Macchia, 2013, 23265344	HR 0.80 (0.21, 3.00)	0.866	0.772849
298	Macchia, 2013, 23265344	HR 0.88 (0.44, 1.66)	0.866	0.8627644
299	Macchia, 2013, 23265344	HR 1.16 (0.23, 5.78)	1	1.16
300	Maki, 2010, 20451686	-0.3 (-0.52, 0.08)	3.36	-0.0892857
301	Maki, 2010, 20451686	2.50 (-0.18, 5.18)	3.36	0.7440476
302	Maki, 2010, 20451686	3.40 (-2.07, 8.87)	3.36	1.011905
303	Maki, 2010, 20451686	-68.80 (-89.32, -48.28)	3.36	-20.47619
304	Maki, 2013, 23998969	-0.2 (-0.3, -0.1)	4	-0.05
305	Maki, 2013, 23998969	-0.1 (-0.2, 0.05)	2	-0.05
306	Maki, 2013, 23998969	-0.1 (-0.2, 0.05)	2	-0.05
307	Maki, 2013, 23998969	0.5 (-1.5, 2.5)	4	

Causality Table: Comparative Studies

Row	Study	Outcome classification
296	Macchia, 2013, 23265344	Secondary
297	Macchia, 2013, 23265344	Secondary
298	Macchia, 2013, 23265344	Secondary
299	Macchia, 2013, 23265344	Secondary
300	Maki, 2010, 20451686	Secondary; Primary in registry record (NCT00246701)
301	Maki, 2010, 20451686	Secondary; Primary in registry record (NCT00246701)
302	Maki, 2010, 20451686	Secondary; Primary in registry record (NCT00246701)
303	Maki, 2010, 20451686	Secondary; Primary in registry record (NCT00246701)
304	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
305	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
306	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
307	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
308	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
309	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
310	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
311	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
312	Maki, 2013, 23998969	2011	US	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
313	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
314	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
315	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
316	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
317	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
318	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
319	Marchioli, 2002, 11997274	1993	Italy	Secondary Prevention (history of CVD event)
320	Natvig, 1968, 5756076	1965	Norway	Primary Prevention, Healthy
321	Natvig, 1968, 5756076	1965	Norway	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
308	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
309	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
310	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
311	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
312	Maki, 2013, 23998969	Dyslipidemia ((TG) levels 200 mg/dL and <500 mg/dL)	627
313	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
314	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
315	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
316	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
317	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
318	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
319	Marchioli, 2002, 11997274	Other (myocardial infarction)	11334
320	Natvig, 1968, 5756076	na	13406
321	Natvig, 1968, 5756076	na	13406

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
308	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
309	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
310	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
311	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
312	Maki, 2013, 23998969	61.5 (9.6)	56.7	91.6 white, 4.7 black, 1.4 Asian, 2.3 American lian or Alaska native, native Hawaiian, or Pacific Islaer, multiple, a other
313	Marchioli, 2002, 11997274	59.4	85.1	nd
314	Marchioli, 2002, 11997274	59.4	85.1	nd
315	Marchioli, 2002, 11997274	59.4	85.1	nd
316	Marchioli, 2002, 11997274	59.4	85.1	nd
317	Marchioli, 2002, 11997274	59.4	85.1	nd
318	Marchioli, 2002, 11997274	59.4	85.1	nd
319	Marchioli, 2002, 11997274	59.4	85.1	nd
320	Natvig, 1968, 5756076	range 49, 61	100	nd
321	Natvig, 1968, 5756076	range 49, 61	100	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
308	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
309	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
310	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
311	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
312	Maki, 2013, 23998969	128.9 (14.3)/76.1 (7.7)
313	Marchioli, 2002, 11997274	nd
314	Marchioli, 2002, 11997274	nd
315	Marchioli, 2002, 11997274	nd
316	Marchioli, 2002, 11997274	nd
317	Marchioli, 2002, 11997274	nd
318	Marchioli, 2002, 11997274	nd
319	Marchioli, 2002, 11997274	nd
320	Natvig, 1968, 5756076	nd
321	Natvig, 1968, 5756076	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
308	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
309	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
310	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
311	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
312	Maki, 2013, 23998969	174 (29.5)/91.7 (27.3)/38.3 (9.0)/280 (70.7)
313	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
314	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
315	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
316	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
317	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
318	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
319	Marchioli, 2002, 11997274	211.6/138.5/41.7/161.9
320	Natvig, 1968, 5756076	nd
321	Natvig, 1968, 5756076	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m2/Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
308	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
309	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
310	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
311	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
312	Maki, 2013, 23998969	32.7 (5.3)	EPA: 20.8 (10.7) mcg/mL, DPA: 21.8 (8.0) mcg/mL, DHA: 58.9 (18.9) mcg/mL	plasma
313	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
314	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
315	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
316	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
317	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
318	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
319	Marchioli, 2002, 11997274	>30 (13.8%)	nd	nd
320	Natvig, 1968, 5756076	weight range 60, >90	nd	nd
321	Natvig, 1968, 5756076	weight range 60, >90	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
308	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
309	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
310	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
311	Maki, 2013, 23998969	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
312	Maki, 2013, 23998969	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
313	Marchioli, 2002, 11997274	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Death, all cause
314	Marchioli, 2002, 11997274	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, cardiac
315	Marchioli, 2002, 11997274	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Death, CVD (total)
316	Marchioli, 2002, 11997274	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Stroke
317	Marchioli, 2002, 11997274	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
318	Marchioli, 2002, 11997274	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
319	Marchioli, 2002, 11997274	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
320	Natvig, 1968, 5756076	ALA vs Placebo	g/d	Trial: Randomized Factorial Design	Angina, stable
321	Natvig, 1968, 5756076	ALA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
308	Maki, 2013, 23998969	0.1 (-1.75, 1.95)	2	
309	Maki, 2013, 23998969	-0.50 (-5.69, 4.69)	4	-0.25
310	Maki, 2013, 23998969	-3.70 (-8.88, 1.48)	2	-1.85
311	Maki, 2013, 23998969	-42 (-59.3, -24.7)	4	-0.05
312	Maki, 2013, 23998969	-28 (-44.0, -12.0)	2	-0.05
313	Marchioli, 2002, 11997274	RR 0.79 (0.66, 0.93)	0.866	0.7617044
314	Marchioli, 2002, 11997274	RR 0.65 (0.51, 0.82)	0.866	0.6080855
315	Marchioli, 2002, 11997274	RR 0.70 (0.56, 0.86)	0.866	0.6624138
316	Marchioli, 2002, 11997274	RR 1.22 (0.75, 1.97)	0.866	1.258122
317	Marchioli, 2002, 11997274	0.00 (nd)	0.866	0
318	Marchioli, 2002, 11997274	2.00 (nd)	0.866	2.309469
319	Marchioli, 2002, 11997274	-10.00 (nd)	0.866	-11.54734
320	Natvig, 1968, 5756076	OR 1.58 (0.77, 3.26)	5.2	1.091951
321	Natvig, 1968, 5756076	OR 0.93 (0.61, 1.44)	5.2	0.986141

Causality Table: Comparative Studies

Row	Study	Outcome classification
308	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
309	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
310	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
311	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
312	Maki, 2013, 23998969	Secondary; Primary in registry record (NCT01408303)
313	Marchioli, 2002, 11997274	Primary (stated)
314	Marchioli, 2002, 11997274	Primary (stated)
315	Marchioli, 2002, 11997274	Secondary
316	Marchioli, 2002, 11997274	Secondary
317	Marchioli, 2002, 11997274	Secondary
318	Marchioli, 2002, 11997274	Secondary
319	Marchioli, 2002, 11997274	Secondary
320	Natvig, 1968, 5756076	No data; unclear
321	Natvig, 1968, 5756076	No data; unclear

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
322	Natvig, 1968, 5756076	1965	Norway	Primary Prevention, Healthy
323	Natvig, 1968, 5756076	1965	Norway	Primary Prevention, Healthy
324	Natvig, 1968, 5756076	1965	Norway	Primary Prevention, Healthy
325	Natvig, 1968, 5756076	1965	Norway	Primary Prevention, Healthy
326	Nilsen, 2001, 11451717	1995	Norway	Secondary Prevention (history of CVD event)
327	Nilsen, 2001, 11451717	1995	Norway	Secondary Prevention (history of CVD event)
328	Nilsen, 2001, 11451717	1995	Norway	Secondary Prevention (history of CVD event)
329	Nilsen, 2001, 11451717	1995	Norway	Secondary Prevention (history of CVD event)
330	Nilsen, 2001, 11451717	1995	Norway	Secondary Prevention (history of CVD event)
331	Nilsen, 2001, 11451717	1995	Norway	Secondary Prevention (history of CVD event)
332	Nodari, 2011, 21215550	2007	Italy	Secondary Prevention (history of CVD event)
333	Nodari, 2011, 21215550	2007	Italy	Secondary Prevention (history of CVD event)
334	Nodari, 2011, 21215550	2007	Italy	Secondary Prevention (history of CVD event)
335	Nodari, 2011, 21844082	2006	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
336	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
337	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
338	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
339	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
340	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
341	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
342	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
322	Natvig, 1968, 5756076	na	13406
323	Natvig, 1968, 5756076	na	13406
324	Natvig, 1968, 5756076	na	13406
325	Natvig, 1968, 5756076	na	13406
326	Nilsen, 2001, 11451717	Other (MI)	300
327	Nilsen, 2001, 11451717	Other (MI)	300
328	Nilsen, 2001, 11451717	Other (MI)	300
329	Nilsen, 2001, 11451717	Other (MI)	300
330	Nilsen, 2001, 11451717	Other (MI)	300
331	Nilsen, 2001, 11451717	Other (MI)	300
332	Nodari, 2011, 21215550	Other (mild and moderate heart failure (HF) due to nonischemic dilated cardiomyopathy (NICM))	133
333	Nodari, 2011, 21215550	Other (mild and moderate heart failure (HF) due to nonischemic dilated cardiomyopathy (NICM))	133
334	Nodari, 2011, 21215550	Other (mild and moderate heart failure (HF) due to nonischemic dilated cardiomyopathy (NICM))	133
335	Nodari, 2011, 21844082	Arrhythmia	199
336	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
337	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
338	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
339	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
340	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
341	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
342	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
322	Natvig, 1968, 5756076	range 49, 61	100	nd
323	Natvig, 1968, 5756076	range 49, 61	100	nd
324	Natvig, 1968, 5756076	range 49, 61	100	nd
325	Natvig, 1968, 5756076	range 49, 61	100	nd
326	Nilsen, 2001, 11451717		82	nd
327	Nilsen, 2001, 11451717		82	nd
328	Nilsen, 2001, 11451717		82	nd
329	Nilsen, 2001, 11451717		82	nd
330	Nilsen, 2001, 11451717		82	nd
331	Nilsen, 2001, 11451717		82	nd
332	Nodari, 2011, 21215550	64 (9)	84.9	nd
333	Nodari, 2011, 21215550	64 (9)	84.9	nd
334	Nodari, 2011, 21215550	64 (9)	84.9	nd
335	Nodari, 2011, 21844082	69 (9)	63.6	nd
336	Oh, 2014, 25147070	54 (9)	54.8	nd
337	Oh, 2014, 25147070	54 (9)	54.8	nd
338	Oh, 2014, 25147070	54 (9)	54.8	nd
339	Oh, 2014, 25147070	54 (9)	54.8	nd
340	Oh, 2014, 25147070	54 (9)	54.8	nd
341	Oh, 2014, 25147070	54 (9)	54.8	nd
342	Oh, 2014, 25147070	54 (9)	54.8	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
322	Natvig, 1968, 5756076	nd
323	Natvig, 1968, 5756076	nd
324	Natvig, 1968, 5756076	nd
325	Natvig, 1968, 5756076	nd
326	Nilsen, 2001, 11451717	122.1 (range 80, 190)/nd
327	Nilsen, 2001, 11451717	122.1 (range 80, 190)/nd
328	Nilsen, 2001, 11451717	122.1 (range 80, 190)/nd
329	Nilsen, 2001, 11451717	122.1 (range 80, 190)/nd
330	Nilsen, 2001, 11451717	122.1 (range 80, 190)/nd
331	Nilsen, 2001, 11451717	122.1 (range 80, 190)/nd
332	Nodari, 2011, 21215550	119.5 (9.2)/76 (5.2)
333	Nodari, 2011, 21215550	119.5 (9.2)/76 (5.2)
334	Nodari, 2011, 21215550	119.5 (9.2)/76 (5.2)
335	Nodari, 2011, 21844082	136 (16)/82 (9)
336	Oh, 2014, 25147070	nd
337	Oh, 2014, 25147070	nd
338	Oh, 2014, 25147070	nd
339	Oh, 2014, 25147070	nd
340	Oh, 2014, 25147070	nd
341	Oh, 2014, 25147070	nd
342	Oh, 2014, 25147070	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
322	Natvig, 1968, 5756076	nd
323	Natvig, 1968, 5756076	nd
324	Natvig, 1968, 5756076	nd
325	Natvig, 1968, 5756076	nd
326	Nilsen, 2001, 11451717	nd
327	Nilsen, 2001, 11451717	nd
328	Nilsen, 2001, 11451717	nd
329	Nilsen, 2001, 11451717	nd
330	Nilsen, 2001, 11451717	nd
331	Nilsen, 2001, 11451717	nd
332	Nodari, 2011, 21215550	187 (28)nd154 (76)
333	Nodari, 2011, 21215550	187 (28)nd154 (76)
334	Nodari, 2011, 21215550	187 (28)nd154 (76)
335	Nodari, 2011, 21844082	nd
336	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
337	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
338	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
339	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
340	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
341	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
342	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
322	Natvig, 1968, 5756076	weight range 60, >90	nd	nd
323	Natvig, 1968, 5756076	weight range 60, >90	nd	nd
324	Natvig, 1968, 5756076	weight range 60, >90	nd	nd
325	Natvig, 1968, 5756076	weight range 60, >90	nd	nd
326	Nilsen, 2001, 11451717	26.0 (range 19.4, 33.6)	nd	nd
327	Nilsen, 2001, 11451717	26.0 (range 19.4, 33.6)	nd	nd
328	Nilsen, 2001, 11451717	26.0 (range 19.4, 33.6)	nd	nd
329	Nilsen, 2001, 11451717	26.0 (range 19.4, 33.6)	nd	nd
330	Nilsen, 2001, 11451717	26.0 (range 19.4, 33.6)	nd	nd
331	Nilsen, 2001, 11451717	26.0 (range 19.4, 33.6)	nd	nd
332	Nodari, 2011, 21215550	25.7 (2.22)/76.0 (7.5)	EPA+DHA: 1.68 (0.43) % FA	circulating free FA
333	Nodari, 2011, 21215550	25.7 (2.22)/76.0 (7.5)	EPA+DHA: 1.68 (0.43) % FA	circulating free FA
334	Nodari, 2011, 21215550	25.7 (2.22)/76.0 (7.5)	EPA+DHA: 1.68 (0.43) % FA	circulating free FA
335	Nodari, 2011, 21844082	23.6 (5.3)/76.5 (10.1)	nd	nd
336	Oh, 2014, 25147070	nd	nd	nd
337	Oh, 2014, 25147070	nd	nd	nd
338	Oh, 2014, 25147070	nd	nd	nd
339	Oh, 2014, 25147070	nd	nd	nd
340	Oh, 2014, 25147070	nd	nd	nd
341	Oh, 2014, 25147070	nd	nd	nd
342	Oh, 2014, 25147070	nd	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
322	Natvig, 1968, 5756076	ALA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
323	Natvig, 1968, 5756076	ALA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
324	Natvig, 1968, 5756076	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
325	Natvig, 1968, 5756076	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Stroke
326	Nilsen, 2001, 11451717	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Angina, unstable
327	Nilsen, 2001, 11451717	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
328	Nilsen, 2001, 11451717	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, CVD (total)
329	Nilsen, 2001, 11451717	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Revascularization
330	Nilsen, 2001, 11451717	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
331	Nilsen, 2001, 11451717	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
332	Nodari, 2011, 21215550	EPA+DHA vs Placebo	% FA	Trial: Randomized Parallel	Tg
333	Nodari, 2011, 21215550	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
334	Nodari, 2011, 21215550	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
335	Nodari, 2011, 21844082	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Atrial fibrillation
336	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
337	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
338	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
339	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
340	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
341	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
342	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
322	Natvig, 1968, 5756076	OR 0.99 (0.67, 1.45)	5.2	0.9980691
323	Natvig, 1968, 5756076	OR 0.17 (0.04, 0.79)	5.2	0.7112289
324	Natvig, 1968, 5756076	OR 0.84 (0.33, 2.16)	5.2	0.9670264
325	Natvig, 1968, 5756076	OR 1.33 (0.56, 3.16)	5.2	1.056374
326	Nilsen, 2001, 11451717	OR 1.18 (0.67, 2.08)	3.52	1.048144
327	Nilsen, 2001, 11451717	OR 1.19 (0.61, 2.34)	3.464	1.0515
328	Nilsen, 2001, 11451717	1.37 (0.63, 3.01)		
329	Nilsen, 2001, 11451717	OR 0.92 (0.57, 1.47)	1.732	0.9529986
330	Nilsen, 2001, 11451717	4.73 (1.79, 7.67)	4	1.1825
331	Nilsen, 2001, 11451717	-36.90 (-55.37, -18.43)	4	-9.225
332	Nodari, 2011, 21215550	-7.00 (-29.01, 15.01)	2	-3.5
333	Nodari, 2011, 21215550	3 (-0.4, 6.4)	4.25	0.7058824
334	Nodari, 2011, 21215550	-1.0 (-2.6, 0.6)	4.25	-0.2352941
335	Nodari, 2011, 21844082	OR 0.52 (0.26, 1.06)	1.76	0.6896651
336	Oh, 2014, 25147070	-1.00 (-4.19, 2.19)	4	-0.25
337	Oh, 2014, 25147070	-2.00 (-5.21, 1.21)	2	-1
338	Oh, 2014, 25147070	1.00 (-2.40, 4.40)	1	1
339	Oh, 2014, 25147070	1.00 (-2.17, 4.17)	2	0.5
340	Oh, 2014, 25147070	-2.00 (-5.37, 1.37)	3	-0.6666667
341	Oh, 2014, 25147070	-3.00 (-6.39, 0.39)	1	-3
342	Oh, 2014, 25147070	1.00 (-13.17, 15.17)	4	0.25

Causality Table: Comparative Studies

Row	Study	Outcome classification
322	Natvig, 1968, 5756076	No data; unclear
323	Natvig, 1968, 5756076	No data; unclear
324	Natvig, 1968, 5756076	No data; unclear
325	Natvig, 1968, 5756076	No data; unclear
326	Nilsen, 2001, 11451717	No data; unclear
327	Nilsen, 2001, 11451717	No data; unclear
328	Nilsen, 2001, 11451717	No data; unclear
329	Nilsen, 2001, 11451717	No data; unclear
330	Nilsen, 2001, 11451717	No data; unclear
331	Nilsen, 2001, 11451717	No data; unclear
332	Nodari, 2011, 21215550	Secondary
333	Nodari, 2011, 21215550	Secondary
334	Nodari, 2011, 21215550	Secondary
335	Nodari, 2011, 21844082	Secondary; Primary in registry record (NCT01198275)
336	Oh, 2014, 25147070	Secondary
337	Oh, 2014, 25147070	Secondary
338	Oh, 2014, 25147070	Secondary
339	Oh, 2014, 25147070	Secondary
340	Oh, 2014, 25147070	Secondary
341	Oh, 2014, 25147070	Secondary
342	Oh, 2014, 25147070	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
343	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
344	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
345	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
346	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
347	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
348	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
349	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
350	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
351	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
352	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
353	Oh, 2014, 25147070	nd	Korea	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
354	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
355	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
356	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
357	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
343	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
344	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
345	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
346	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
347	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
348	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
349	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
350	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
351	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
352	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
353	Oh, 2014, 25147070	Dyslipidemia (hypertriglyceridemia)	173
354	Olano-Martin, 2010, 19748619	na	38
355	Olano-Martin, 2010, 19748619	na	38
356	Olano-Martin, 2010, 19748619	na	38
357	Olano-Martin, 2010, 19748619	na	38

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
343	Oh, 2014, 25147070	54 (9)	54.8	nd
344	Oh, 2014, 25147070	54 (9)	54.8	nd
345	Oh, 2014, 25147070	54 (9)	54.8	nd
346	Oh, 2014, 25147070	54 (9)	54.8	nd
347	Oh, 2014, 25147070	54 (9)	54.8	nd
348	Oh, 2014, 25147070	54 (9)	54.8	nd
349	Oh, 2014, 25147070	54 (9)	54.8	nd
350	Oh, 2014, 25147070	54 (9)	54.8	nd
351	Oh, 2014, 25147070	54 (9)	54.8	nd
352	Oh, 2014, 25147070	54 (9)	54.8	nd
353	Oh, 2014, 25147070	54 (9)	54.8	nd
354	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
355	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
356	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
357	Olano-Martin, 2010, 19748619	range 18, 70	100	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
343	Oh, 2014, 25147070	nd
344	Oh, 2014, 25147070	nd
345	Oh, 2014, 25147070	nd
346	Oh, 2014, 25147070	nd
347	Oh, 2014, 25147070	nd
348	Oh, 2014, 25147070	nd
349	Oh, 2014, 25147070	nd
350	Oh, 2014, 25147070	nd
351	Oh, 2014, 25147070	nd
352	Oh, 2014, 25147070	nd
353	Oh, 2014, 25147070	nd
354	Olano-Martin, 2010, 19748619	nd
355	Olano-Martin, 2010, 19748619	nd
356	Olano-Martin, 2010, 19748619	nd
357	Olano-Martin, 2010, 19748619	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
343	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
344	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
345	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
346	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
347	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
348	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
349	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
350	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
351	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
352	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
353	Oh, 2014, 25147070	201 (29)/111 (34)/42 (8)/281 (63)
354	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
355	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
356	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
357	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m2/Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
343	Oh, 2014, 25147070	nd	nd	nd
344	Oh, 2014, 25147070	nd	nd	nd
345	Oh, 2014, 25147070	nd	nd	nd
346	Oh, 2014, 25147070	nd	nd	nd
347	Oh, 2014, 25147070	nd	nd	nd
348	Oh, 2014, 25147070	nd	nd	nd
349	Oh, 2014, 25147070	nd	nd	nd
350	Oh, 2014, 25147070	nd	nd	nd
351	Oh, 2014, 25147070	nd	nd	nd
352	Oh, 2014, 25147070	nd	nd	nd
353	Oh, 2014, 25147070	nd	nd	nd
354	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
355	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
356	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
357	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
343	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
344	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
345	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
346	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
347	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
348	Oh, 2014, 25147070	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
349	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
350	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
351	Oh, 2014, 25147070	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
352	Oh, 2014, 25147070	EPA vs Placebo	g/d	Trial: Randomized Parallel	Tg
353	Oh, 2014, 25147070	EPA vs DHA	% FA	Trial: Randomized Parallel	Tg
354	Olano-Martin, 2010, 19748619	DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
355	Olano-Martin, 2010, 19748619	EPA vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
356	Olano-Martin, 2010, 19748619	EPA vs DHA	g/d	Trial: Randomized Cross-over	HDL-c
357	Olano-Martin, 2010, 19748619	DHA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
343	Oh, 2014, 25147070	6.00 (-8.15, 20.15)	2	3
344	Oh, 2014, 25147070	3.00 (-11.07, 17.07)	1	3
345	Oh, 2014, 25147070	-5.00 (-18.77, 8.77)	2	-2.5
346	Oh, 2014, 25147070	-2.00 (-15.69, 11.69)	3	-0.6666667
347	Oh, 2014, 25147070	3.00 (-10.66, 16.66)	1	3
348	Oh, 2014, 25147070	-62.00 (-102.52, -21.48)	4	-15.5
349	Oh, 2014, 25147070	-30.00 (-73.10, 13.10)	2	-15
350	Oh, 2014, 25147070	-23.00 (-60.64, 14.64)	1	-23
351	Oh, 2014, 25147070	-32.00 (-77.22, 13.22)	2	-16
352	Oh, 2014, 25147070	-39.00 (-79.06, 1.06)	3	-13
353	Oh, 2014, 25147070	-7.00 (-49.67, 35.67)	1	-7
354	Olano-Martin, 2010, 19748619	-0.77 (-6.43, 4.89)	3.3	-0.2333333
355	Olano-Martin, 2010, 19748619	-1.16 (-6.51, 4.19)	NA	
356	Olano-Martin, 2010, 19748619	0.39 (-5.27, 6.05)	3.7	0.1054054
357	Olano-Martin, 2010, 19748619	2.70 (-12.17, 17.57)	3.3	0.8181818

Causality Table: Comparative Studies

Row	Study	Outcome classification
343	Oh, 2014, 25147070	Secondary
344	Oh, 2014, 25147070	Secondary
345	Oh, 2014, 25147070	Secondary
346	Oh, 2014, 25147070	Secondary
347	Oh, 2014, 25147070	Secondary
348	Oh, 2014, 25147070	Secondary
349	Oh, 2014, 25147070	Secondary
350	Oh, 2014, 25147070	Secondary
351	Oh, 2014, 25147070	Secondary
352	Oh, 2014, 25147070	Secondary
353	Oh, 2014, 25147070	Secondary
354	Olano-Martin, 2010, 19748619	Secondary
355	Olano-Martin, 2010, 19748619	Secondary
356	Olano-Martin, 2010, 19748619	Secondary
357	Olano-Martin, 2010, 19748619	Primary (stated)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
358	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
359	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
360	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
361	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
362	Olano-Martin, 2010, 19748619	2007 (approx)	UK	Primary Prevention, Healthy
363	Pase, 2015, 25565485	2015	Australia	Primary Prevention, Healthy
364	Pase, 2015, 25565485	2015	Australia	Primary Prevention, Healthy
365	Pase, 2015, 25565485	2015	Australia	Primary Prevention, Healthy
366	Pase, 2015, 25565485	2015	Australia	Primary Prevention, Healthy
367	Pieters_2015_25226826	2011	Netherlands	Primary Prevention, Increased CVD Risk
368	Pieters_2015_25226826	2011	Netherlands	Primary Prevention, Increased CVD Risk
369	Pieters_2015_25226826	2011	Netherlands	Primary Prevention, Increased CVD Risk
370	Pieters_2015_25226826	2011	Netherlands	Primary Prevention, Increased CVD Risk
371	Pieters_2015_25226826	2011	Netherlands	Primary Prevention, Increased CVD Risk
372	Pieters_2015_25226826	2011	Netherlands	Primary Prevention, Increased CVD Risk
373	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk
374	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk
375	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk
376	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk
377	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
358	Olano-Martin, 2010, 19748619	na	38
359	Olano-Martin, 2010, 19748619	na	38
360	Olano-Martin, 2010, 19748619	na	38
361	Olano-Martin, 2010, 19748619	na	38
362	Olano-Martin, 2010, 19748619	na	38
363	Pase, 2015, 25565485	na	160
364	Pase, 2015, 25565485	na	160
365	Pase, 2015, 25565485	na	160
366	Pase, 2015, 25565485	na	160
367	Pieters_2015_25226826	Overweight hypertiglyceridemic	32
368	Pieters_2015_25226826	Overweight hypertiglyceridemic	32
369	Pieters_2015_25226826	Overweight hypertiglyceridemic	32
370	Pieters_2015_25226826	Overweight hypertiglyceridemic	32
371	Pieters_2015_25226826	Overweight hypertiglyceridemic	32
372	Pieters_2015_25226826	Overweight hypertiglyceridemic	32
373	Raitt_2005_15956633,	Arrhythmia	200
374	Raitt_2005_15956633,	Arrhythmia	200
375	Raitt_2005_15956633,	Arrhythmia	200
376	Raitt_2005_15956633,	Arrhythmia	200
377	Raitt_2005_15956633,	Arrhythmia	200

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
358	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
359	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
360	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
361	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
362	Olano-Martin, 2010, 19748619	range 18, 70	100	nd
363	Pase, 2015, 25565485	59.3 (5.7)	46.9	nd
364	Pase, 2015, 25565485	59.3 (5.7)	46.9	nd
365	Pase, 2015, 25565485	59.3 (5.7)	46.9	nd
366	Pase, 2015, 25565485	59.3 (5.7)	46.9	nd
367	Pieters_2015_25226826	51 (15)	47.2	nd
368	Pieters_2015_25226826	51 (15)	47.2	nd
369	Pieters_2015_25226826	51 (15)	47.2	nd
370	Pieters_2015_25226826	51 (15)	47.2	nd
371	Pieters_2015_25226826	51 (15)	47.2	nd
372	Pieters_2015_25226826	51 (15)	47.2	nd
373	Raitt_2005_15956633,	63.5 (13)	86	95.5% white
374	Raitt_2005_15956633,	63.5 (13)	86	95.5% white
375	Raitt_2005_15956633,	63.5 (13)	86	95.5% white
376	Raitt_2005_15956633,	63.5 (13)	86	95.5% white
377	Raitt_2005_15956633,	63.5 (13)	86	95.5% white

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
358	Olano-Martin, 2010, 19748619	nd
359	Olano-Martin, 2010, 19748619	nd
360	Olano-Martin, 2010, 19748619	nd
361	Olano-Martin, 2010, 19748619	nd
362	Olano-Martin, 2010, 19748619	nd
363	Pase, 2015, 25565485	124.1 (19.1)/76.3 (11.6)
364	Pase, 2015, 25565485	124.1 (19.1)/76.3 (11.6)
365	Pase, 2015, 25565485	124.1 (19.1)/76.3 (11.6)
366	Pase, 2015, 25565485	124.1 (19.1)/76.3 (11.6)
367	Pieters_2015_25226826	nd
368	Pieters_2015_25226826	nd
369	Pieters_2015_25226826	nd
370	Pieters_2015_25226826	nd
371	Pieters_2015_25226826	nd
372	Pieters_2015_25226826	nd
373	Raitt_2005_15956633,	nd
374	Raitt_2005_15956633,	nd
375	Raitt_2005_15956633,	nd
376	Raitt_2005_15956633,	nd
377	Raitt_2005_15956633,	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
358	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
359	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
360	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
361	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
362	Olano-Martin, 2010, 19748619	[5.44 (SE 0.14)]/[3.54 (SE 0.13)]/[1.33 (SE 0.05)]/[1.39 (SE 0.08)]
363	Pase, 2015, 25565485	[nd/3.36 (0.75)/1.56 (0.40)/1.20 (0.62)]
364	Pase, 2015, 25565485	[nd/3.36 (0.75)/1.56 (0.40)/1.20 (0.62)]
365	Pase, 2015, 25565485	[nd/3.36 (0.75)/1.56 (0.40)/1.20 (0.62)]
366	Pase, 2015, 25565485	[nd/3.36 (0.75)/1.56 (0.40)/1.20 (0.62)]
367	Pieters_2015_25226826	[5.94 (0.93)/3.69 (0.73)/1.66 (0.37)/1.30 (0.61)]
368	Pieters_2015_25226826	[5.94 (0.93)/3.69 (0.73)/1.66 (0.37)/1.30 (0.61)]
369	Pieters_2015_25226826	[5.94 (0.93)/3.69 (0.73)/1.66 (0.37)/1.30 (0.61)]
370	Pieters_2015_25226826	[5.94 (0.93)/3.69 (0.73)/1.66 (0.37)/1.30 (0.61)]
371	Pieters_2015_25226826	[5.94 (0.93)/3.69 (0.73)/1.66 (0.37)/1.30 (0.61)]
372	Pieters_2015_25226826	[5.94 (0.93)/3.69 (0.73)/1.66 (0.37)/1.30 (0.61)]
373	Raitt_2005_15956633,	nd
374	Raitt_2005_15956633,	nd
375	Raitt_2005_15956633,	nd
376	Raitt_2005_15956633,	nd
377	Raitt_2005_15956633,	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
358	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
359	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
360	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
361	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
362	Olano-Martin, 2010, 19748619	range 18.5, 32	EPA: 1.7 (SEM 0.2)% FA, DPA: 1.2 (0.0)% FA, DHA: 4.8 (0.2)% FA	plasma phospholipids fatty acid
363	Pase, 2015, 25565485	24.9 (3.4)	nd	nd
364	Pase, 2015, 25565485	24.9 (3.4)	nd	nd
365	Pase, 2015, 25565485	24.9 (3.4)	nd	nd
366	Pase, 2015, 25565485	24.9 (3.4)	nd	nd
367	Pieters_2015_25226826	28.9 (3)	nd	nd
368	Pieters_2015_25226826	28.9 (3)	nd	nd
369	Pieters_2015_25226826	28.9 (3)	nd	nd
370	Pieters_2015_25226826	28.9 (3)	nd	nd
371	Pieters_2015_25226826	28.9 (3)	nd	nd
372	Pieters_2015_25226826	28.9 (3)	nd	nd
373	Raitt_2005_15956633,	nd	nd	nd
374	Raitt_2005_15956633,	nd	nd	nd
375	Raitt_2005_15956633,	nd	nd	nd
376	Raitt_2005_15956633,	nd	nd	nd
377	Raitt_2005_15956633,	nd	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
358	Olano-Martin, 2010, 19748619	EPA vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
359	Olano-Martin, 2010, 19748619	EPA vs DHA	g/d	Trial: Randomized Cross-over	LDL-c
360	Olano-Martin, 2010, 19748619	DHA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
361	Olano-Martin, 2010, 19748619	EPH + DHA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
362	Olano-Martin, 2010, 19748619	EPA+DHA vs Placebo	g/d	Trial: Randomized Cross-over	Tg
363	Pase, 2015, 25565485	EPA+DHA (0.48) vs Placebo	g/d	Trial: Randomized Cross-over	SBP
364	Pase, 2015, 25565485	EPA+DHA (0.48) vs EPA+DHA (0.28)	g/d	Trial: Randomized Parallel	SBP
365	Pase, 2015, 25565485	EPA+DHA (0.48) vs Placebo	g/d	Trial: Randomized Parallel	DBP
366	Pase, 2015, 25565485	EPA+DHA (0.48) vs EPA+DHA (0.28)	g/d	Trial: Randomized Parallel	DBP
367	Pieters_2015_25226826	SDA 1.2; ALA 3.03 vs Placebo	g/d	Trial: Randomized Cross-over	Total:HDL-c ratio
368	Pieters_2015_25226826	SDA 1.2; ALA 3.03 vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
369	Pieters_2015_25226826	SDA 1.2; ALA 3.03 vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
370	Pieters_2015_25226826	SDA 1.2; ALA 3.03 vs Placebo	g/d	Trial: Randomized Cross-over	Tg
371	Pieters_2015_25226826	SDA 1.2; ALA 3.03 vs Placebo	g/d	Trial: Randomized Cross-over	SBP
372	Pieters_2015_25226826	SDA 1.2; ALA 3.03 vs Placebo	g/d	Trial: Randomized Cross-over	DBP
373	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Death, cardiac
374	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Death, all cause
375	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
376	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Revascularization
377	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Sudden Cardiac Death

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
358	Olano-Martin, 2010, 19748619	-6.18 (-21.77, 9.41)	NA	
359	Olano-Martin, 2010, 19748619	8.88 (-5.32, 23.08)	3.7	2.4
360	Olano-Martin, 2010, 19748619	-41.64 (-69.92, -13.36)	3.3	-12.61818
361	Olano-Martin, 2010, 19748619	-3.54 (-27.69, 20.61)	NA	
362	Olano-Martin, 2010, 19748619	-27.43 (-51.59, -3.27)	3.7	-7.413514
363	Pase, 2015, 25565485	-6.9 (-13.96, 0.16)	0.48	-14.38
364	Pase, 2015, 25565485	-1 (-9.04, 7.04)	0.2	-5
365	Pase, 2015, 25565485	-3.5 (-8.2, 1.2)	0.48	-7.29
366	Pase, 2015, 25565485	-1.5 (-6.99, 3.99)	0.2	-7.5
367	Pieters_2015_25226826	-0.06 (-0.22, 0.1)	1.2	-0.05
368	Pieters_2015_25226826	1.16 (-0.39, 2.71)	1.2	0.97
369	Pieters_2015_25226826	-1.55 (-6.2, 3.1)	1.2	-1.29
370	Pieters_2015_25226826	9.73 (-4.73, 24.19)	1.2	8.11
371	Pieters_2015_25226826	2.00 (-3.73, 7.73)	1.2	1.67
372	Pieters_2015_25226826	1.00 (-1.84, 3.84)	1.2	0.83
373	Raitt_2005_15956633,	0.39 (0.07, 2.05)	1.8	0.22
374	Raitt_2005_15956633,	0.38 (0.11, 1.24)	1.8	0.21
375	Raitt_2005_15956633,	0.33 (0.03, 3.19)	1.8	0.18
376	Raitt_2005_15956633,	0.49 (0.09, 2.74)	1.8	0.27
377	Raitt_2005_15956633,	5.1 (0.24, 107.64)	1.8	2.83

Causality Table: Comparative Studies

Row	Study	Outcome classification
358	Olano-Martin, 2010, 19748619	Primary (stated)
359	Olano-Martin, 2010, 19748619	Primary (stated)
360	Olano-Martin, 2010, 19748619	Secondary
361	Olano-Martin, 2010, 19748619	Secondary
362	Olano-Martin, 2010, 19748619	Secondary
363	Pase, 2015, 25565485	Secondary
364	Pase, 2015, 25565485	Secondary
365	Pase, 2015, 25565485	Secondary
366	Pase, 2015, 25565485	Secondary
367	Pieters_2015_25226826	Secondary
368	Pieters_2015_25226826	Secondary
369	Pieters_2015_25226826	Secondary
370	Pieters_2015_25226826	Primary (stated)
371	Pieters_2015_25226826	Secondary
372	Pieters_2015_25226826	Secondary
373	Raitt_2005_15956633,	Secondary
374	Raitt_2005_15956633,	Secondary
375	Raitt_2005_15956633,	Secondary
376	Raitt_2005_15956633,	Secondary
377	Raitt_2005_15956633,	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
378	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk
379	Raitt_2005_15956633,	2001	US	Primary Prevention, Increased CVD Risk
380	Ras 2014 25122648	2011	Sweden	Primary Prevention, Healthy
381	Ras 2014 25122649	2011	Sweden	Primary Prevention, Healthy
382	Ras 2014 25122650	2011	Sweden	Primary Prevention, Healthy
383	Ras 2014 25122651	2011	Sweden	Primary Prevention, Healthy
384	Ras 2014 25122651	2011	Sweden	Primary Prevention, Healthy
385	Ras 2014 25122651	2011	Sweden	Primary Prevention, Healthy
386	Ras 2014 25122652	2011	Sweden	Primary Prevention, Healthy
387	Ras 2014 25122653	2011	Sweden	Primary Prevention, Healthy
388	Ras 2014 25122654	2011	Sweden	Primary Prevention, Healthy
389	Ras 2014 25122655	2011	Sweden	Primary Prevention, Healthy
390	Ras 2014 25122655	2011	Sweden	Primary Prevention, Healthy
391	Ras 2014 25122655	2011	Sweden	Primary Prevention, Healthy
392	Ras 2014 25122656	2011	Sweden	Primary Prevention, Healthy
393	Ras 2014 25122657	2011	Sweden	Primary Prevention, Healthy
394	Ras 2014 25122658	2011	Sweden	Primary Prevention, Healthy
395	Ras 2014 25122659	2011	Sweden	Primary Prevention, Healthy
396	Ras 2014 25122659	2011	Sweden	Primary Prevention, Healthy
397	Ras 2014 25122659	2011	Sweden	Primary Prevention, Healthy
398	Rasmussen, 2006, 16469978	2009 (Approx)	Denmark, Finland, Italy, Sweden, Australia	Primary Prevention, Healthy
399	Rasmussen, 2006, 16469978	2009 (Approx)	Denmark, Finland, Italy, Sweden, Australia	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
378	Raitt_2005_15956633,	Arrhythmia	200
379	Raitt_2005_15956633,	Arrhythmia	200
380	Ras 2014 25122648	na	314
381	Ras 2014 25122649	na	314
382	Ras 2014 25122650	na	314
383	Ras 2014 25122651	na	314
384	Ras 2014 25122651	na	314
385	Ras 2014 25122651	na	314
386	Ras 2014 25122652	na	314
387	Ras 2014 25122653	na	314
388	Ras 2014 25122654	na	314
389	Ras 2014 25122655	na	314
390	Ras 2014 25122655	na	314
391	Ras 2014 25122655	na	314
392	Ras 2014 25122656	na	314
393	Ras 2014 25122657	na	314
394	Ras 2014 25122658	na	314
395	Ras 2014 25122659	na	314
396	Ras 2014 25122659	na	314
397	Ras 2014 25122659	na	314
398	Rasmussen, 2006, 16469978	na	97
399	Rasmussen, 2006, 16469978	na	97

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
378	Raitt_2005_15956633,	63.5 (13)	86	95.5% white
379	Raitt_2005_15956633,	63.5 (13)	86	95.5% white
380	Ras 2014 25122648	57.9 (0.6)	26.8	nd
381	Ras 2014 25122649	57.9 (0.6)	26.8	nd
382	Ras 2014 25122650	57.9 (0.6)	26.8	nd
383	Ras 2014 25122651	57.9 (0.6)	26.8	nd
384	Ras 2014 25122651	57.9 (0.6)	26.8	nd
385	Ras 2014 25122651	57.9 (0.6)	26.8	nd
386	Ras 2014 25122652	57.9 (0.6)	26.8	nd
387	Ras 2014 25122653	57.9 (0.6)	26.8	nd
388	Ras 2014 25122654	57.9 (0.6)	26.8	nd
389	Ras 2014 25122655	57.9 (0.6)	26.8	nd
390	Ras 2014 25122655	57.9 (0.6)	26.8	nd
391	Ras 2014 25122655	57.9 (0.6)	26.8	nd
392	Ras 2014 25122656	57.9 (0.6)	26.8	nd
393	Ras 2014 25122657	57.9 (0.6)	26.8	nd
394	Ras 2014 25122658	57.9 (0.6)	26.8	nd
395	Ras 2014 25122659	57.9 (0.6)	26.8	nd
396	Ras 2014 25122659	57.9 (0.6)	26.8	nd
397	Ras 2014 25122659	57.9 (0.6)	26.8	nd
398	Rasmussen, 2006, 16469978	48.5	nd	nd
399	Rasmussen, 2006, 16469978	48.5	nd	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
378	Raitt_2005_15956633,	nd
379	Raitt_2005_15956633,	nd
380	Ras 2014 25122648	128.2 (0.8)/77.7 (0.4)
381	Ras 2014 25122649	128.2 (0.8)/77.7 (0.4)
382	Ras 2014 25122650	128.2 (0.8)/77.7 (0.4)
383	Ras 2014 25122651	128.2 (0.8)/77.7 (0.4)
384	Ras 2014 25122651	128.2 (0.8)/77.7 (0.4)
385	Ras 2014 25122651	128.2 (0.8)/77.7 (0.4)
386	Ras 2014 25122652	128.2 (0.8)/77.7 (0.4)
387	Ras 2014 25122653	128.2 (0.8)/77.7 (0.4)
388	Ras 2014 25122654	128.2 (0.8)/77.7 (0.4)
389	Ras 2014 25122655	128.2 (0.8)/77.7 (0.4)
390	Ras 2014 25122655	128.2 (0.8)/77.7 (0.4)
391	Ras 2014 25122655	128.2 (0.8)/77.7 (0.4)
392	Ras 2014 25122656	128.2 (0.8)/77.7 (0.4)
393	Ras 2014 25122657	128.2 (0.8)/77.7 (0.4)
394	Ras 2014 25122658	128.2 (0.8)/77.7 (0.4)
395	Ras 2014 25122659	128.2 (0.8)/77.7 (0.4)
396	Ras 2014 25122659	128.2 (0.8)/77.7 (0.4)
397	Ras 2014 25122659	128.2 (0.8)/77.7 (0.4)
398	Rasmussen, 2006, 16469978	122.7 (11.4)/77.1 (9.0)
399	Rasmussen, 2006, 16469978	122.7 (11.4)/77.1 (9.0)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
378	Raitt_2005_15956633,	nd
379	Raitt_2005_15956633,	nd
380	Ras 2014 25122648	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
381	Ras 2014 25122649	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
382	Ras 2014 25122650	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
383	Ras 2014 25122651	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
384	Ras 2014 25122651	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
385	Ras 2014 25122651	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
386	Ras 2014 25122652	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
387	Ras 2014 25122653	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
388	Ras 2014 25122654	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
389	Ras 2014 25122655	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
390	Ras 2014 25122655	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
391	Ras 2014 25122655	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
392	Ras 2014 25122656	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
393	Ras 2014 25122657	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
394	Ras 2014 25122658	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
395	Ras 2014 25122659	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
396	Ras 2014 25122659	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
397	Ras 2014 25122659	[6.45 (0.05)/4.00 (0.04)/1.63 (0.02)/1.09 (0.03)]
398	Rasmussen, 2006, 16469978	nd
399	Rasmussen, 2006, 16469978	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
378	Raitt_2005_15956633,	nd	nd	nd
379	Raitt_2005_15956633,	nd	nd	nd
380	Ras 2014 25122648	25.0 (0.1)	nd	nd
381	Ras 2014 25122649	25.0 (0.1)	nd	nd
382	Ras 2014 25122650	25.0 (0.1)	nd	nd
383	Ras 2014 25122651	25.0 (0.1)	nd	nd
384	Ras 2014 25122651	25.0 (0.1)	nd	nd
385	Ras 2014 25122651	25.0 (0.1)	nd	nd
386	Ras 2014 25122652	25.0 (0.1)	nd	nd
387	Ras 2014 25122653	25.0 (0.1)	nd	nd
388	Ras 2014 25122654	25.0 (0.1)	nd	nd
389	Ras 2014 25122655	25.0 (0.1)	nd	nd
390	Ras 2014 25122655	25.0 (0.1)	nd	nd
391	Ras 2014 25122655	25.0 (0.1)	nd	nd
392	Ras 2014 25122656	25.0 (0.1)	nd	nd
393	Ras 2014 25122657	25.0 (0.1)	nd	nd
394	Ras 2014 25122658	25.0 (0.1)	nd	nd
395	Ras 2014 25122659	25.0 (0.1)	nd	nd
396	Ras 2014 25122659	25.0 (0.1)	nd	nd
397	Ras 2014 25122659	25.0 (0.1)	nd	nd
398	Rasmussen, 2006, 16469978	26.9 (3.0)	ALA: 0.31% FA, EPA: 1.5% FA, DPA: 1.07% FA, DHA 4.67 % FA	serum
399	Rasmussen, 2006, 16469978	26.9 (3.0)	ALA: 0.31% FA, EPA: 1.5% FA, DPA: 1.07% FA, DHA 4.67 % FA	serum

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
378	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Congestive Heart Failure
379	Raitt_2005_15956633,	EPA 0.756 + DHA 0.54 vs. Placebo	g/d	Trial: Randomized Parallel	Angina pectoris
380	Ras 2014 25122648	EPA+DHA 0.9 vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
381	Ras 2014 25122649	EPA+DHA 1.3 vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
382	Ras 2014 25122650	EPA+DHA 1.8 vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
383	Ras 2014 25122651	EPA+DHA 1.8 vs EPA+DHA 0.9	g/d	Trial: Randomized Parallel	LDL-c
384	Ras 2014 25122651	EPA+DHA 1.8 vs EPA+DHA 1.3	g/d	Trial: Randomized Parallel	LDL-c
385	Ras 2014 25122651	EPA+DHA 1.3 vs EPA+DHA 0.9	g/d	Trial: Randomized Parallel	LDL-c
386	Ras 2014 25122652	EPA+DHA 0.9 vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
387	Ras 2014 25122653	EPA+DHA 1.3 vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
388	Ras 2014 25122654	EPA+DHA 1.8 vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
389	Ras 2014 25122655	EPA+DHA 1.8 vs EPA+DHA 0.9	g/d	Trial: Randomized Parallel	HDL-c
390	Ras 2014 25122655	EPA+DHA 1.8 vs EPA+DHA 1.3	g/d	Trial: Randomized Parallel	HDL-c
391	Ras 2014 25122655	EPA+DHA 1.3 vs EPA+DHA 0.9	g/d	Trial: Randomized Parallel	HDL-c
392	Ras 2014 25122656	EPA+DHA 0.9 vs Placebo	g/d	Trial: Randomized Parallel	Tg
393	Ras 2014 25122657	EPA+DHA 1.3 vs Placebo	g/d	Trial: Randomized Parallel	Tg
394	Ras 2014 25122658	EPA+DHA 1.8 vs Placebo	g/d	Trial: Randomized Parallel	Tg
395	Ras 2014 25122659	EPA+DHA 1.8 vs EPA+DHA 0.9	g/d	Trial: Randomized Parallel	Tg
396	Ras 2014 25122659	EPA+DHA 1.8 vs EPA+DHA 1.3	g/d	Trial: Randomized Parallel	Tg
397	Ras 2014 25122659	EPA+DHA 1.3 vs EPA+DHA 0.9	g/d	Trial: Randomized Parallel	Tg
398	Rasmussen, 2006, 16469978	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
399	Rasmussen, 2006, 16469978	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
378	Raitt_2005_15956633,	1.19 (0.52, 2.73)	1.8	0.66
379	Raitt_2005_15956633,	1.48 (0.54, 4.05)	1.8	0.82
380	Ras 2014 25122648	-1.9 (nd)	0.9	-2.11
381	Ras 2014 25122649	-1.5 (nd)	1.3	-1.15
382	Ras 2014 25122650	-3.1 (nd)	1.8	-1.72
383	Ras 2014 25122651	-1.2 (nd)	0.9	-1.33
384	Ras 2014 25122651	-1.5 (nd)	0.5	-3
385	Ras 2014 25122651	0.39 (nd)	0.4	0.98
386	Ras 2014 25122652	0.7 (nd)	0.9	0.78
387	Ras 2014 25122653	3.5 (nd)	1.3	2.69
388	Ras 2014 25122654	3.9 (nd)	1.8	2.17
389	Ras 2014 25122655	3.1 (nd)	0.9	3.44
390	Ras 2014 25122655	0.39 (nd)	0.5	0.78
391	Ras 2014 25122655	2.7 (nd)	0.4	6.75
392	Ras 2014 25122656	-2.5 (nd)	0.9	-2.78
393	Ras 2014 25122657	-4.8 (nd)	1.3	-3.69
394	Ras 2014 25122658	-10.7 (nd)	1.8	-5.94
395	Ras 2014 25122659	-8.3 (nd)	0.9	-9.22
396	Ras 2014 25122659	-5.9 (nd)	0.5	-11.8
397	Ras 2014 25122659	-2.3 (nd)	0.4	-5.75
398	Rasmussen, 2006, 16469978	1.13 (-9.48, 11.74)	2.4	0.4708333
399	Rasmussen, 2006, 16469978	7.07 (-0.16, 14.30)	2.4	2.945833

Causality Table: Comparative Studies

Row	Study	Outcome classification
378	Raitt_2005_15956633,	Secondary
379	Raitt_2005_15956633,	Secondary
380	Ras 2014 25122648	Secondary; Primary in registry record (NCT01313988)
381	Ras 2014 25122649	Secondary; Primary in registry record (NCT01313988)
382	Ras 2014 25122650	Secondary; Primary in registry record (NCT01313988)
383	Ras 2014 25122651	Secondary; Primary in registry record (NCT01313988)
384	Ras 2014 25122651	Secondary; Primary in registry record (NCT01313988)
385	Ras 2014 25122651	Secondary; Primary in registry record (NCT01313988)
386	Ras 2014 25122652	Secondary; Primary in registry record (NCT01313988)
387	Ras 2014 25122653	Secondary; Primary in registry record (NCT01313988)
388	Ras 2014 25122654	Secondary; Primary in registry record (NCT01313988)
389	Ras 2014 25122655	Secondary; Primary in registry record (NCT01313988)
390	Ras 2014 25122655	Secondary; Primary in registry record (NCT01313988)
391	Ras 2014 25122655	Secondary; Primary in registry record (NCT01313988)
392	Ras 2014 25122656	Primary (power analysis)
393	Ras 2014 25122657	Primary (power analysis)
394	Ras 2014 25122658	Primary (power analysis)
395	Ras 2014 25122659	Primary (power analysis)
396	Ras 2014 25122659	Primary (power analysis)
397	Ras 2014 25122659	Primary (power analysis)
398	Rasmussen, 2006, 16469978	Primary (stated)
399	Rasmussen, 2006, 16469978	Primary (stated)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
400	Rasmussen, 2006, 16469978	2009 (Approx)	Denmark, Finland, Italy, Sweden, Australia	Primary Prevention, Healthy
401	Rasmussen, 2006, 16469978	2009 (Approx)	Denmark, Finland, Italy, Sweden, Australia	Primary Prevention, Healthy
402	Rauch, 2010, 21060071	2003	Germany	Secondary Prevention (history of CVD event)
403	Rauch, 2010, 21060071	2003	Germany	Secondary Prevention (history of CVD event)
404	Rauch, 2010, 21060071	2003	Germany	Secondary Prevention (history of CVD event)
405	Rauch, 2010, 21060071	2003	Germany	Secondary Prevention (history of CVD event)
406	Rauch, 2010, 21060071	2003	Germany	Secondary Prevention (history of CVD event)
407	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
408	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
409	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
410	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
411	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
412	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
413	Rodriguez-Leyva, 2013, 24126178	2008	Canada	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
414	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
415	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
416	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
400	Rasmussen, 2006, 16469978	na	97
401	Rasmussen, 2006, 16469978	na	97
402	Rauch, 2010, 21060071	Cardiac disease (Myocardial infarction)	3804
403	Rauch, 2010, 21060071	Cardiac disease (Myocardial infarction)	3804
404	Rauch, 2010, 21060071	Cardiac disease (Myocardial infarction)	3804
405	Rauch, 2010, 21060071	Cardiac disease (Myocardial infarction)	3804
406	Rauch, 2010, 21060071	Cardiac disease (Myocardial infarction)	3804
407	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
408	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
409	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
410	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
411	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
412	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
413	Rodriguez-Leyva, 2013, 24126178	Peripheral vascular disease	87
414	Roncaglioni, 2013, 23656645	nd	12513
415	Roncaglioni, 2013, 23656645	nd	12513
416	Roncaglioni, 2013, 23656645	nd	12513

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
400	Rasmussen, 2006, 16469978	48.5	nd	nd
401	Rasmussen, 2006, 16469978	48.5	nd	nd
402	Rauch, 2010, 21060071	[64 (54, 72)]	73.7	nd
403	Rauch, 2010, 21060071	[64 (54, 72)]	73.7	nd
404	Rauch, 2010, 21060071	[64 (54, 72)]	73.7	nd
405	Rauch, 2010, 21060071	[64 (54, 72)]	73.7	nd
406	Rauch, 2010, 21060071	[64 (54, 72)]	73.7	nd
407	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
408	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
409	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
410	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
411	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
412	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
413	Rodriguez-Leyva, 2013, 24126178	67.3 (8.5)	nd	nd
414	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
415	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
416	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
400	Rasmussen, 2006, 16469978	122.7 (11.4)/77.1 (9.0)
401	Rasmussen, 2006, 16469978	122.7 (11.4)/77.1 (9.0)
402	Rauch, 2010, 21060071	median 140 (IQR 120, 160)]/nd
403	Rauch, 2010, 21060071	median 140 (IQR 120, 160)]/nd
404	Rauch, 2010, 21060071	median 140 (IQR 120, 160)]/nd
405	Rauch, 2010, 21060071	median 140 (IQR 120, 160)]/nd
406	Rauch, 2010, 21060071	median 140 (IQR 120, 160)]/nd
407	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
408	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
409	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
410	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
411	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
412	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
413	Rodriguez-Leyva, 2013, 24126178	142.9 (20.1)/77.5 (12.8)
414	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
415	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
416	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
400	Rasmussen, 2006, 16469978	nd
401	Rasmussen, 2006, 16469978	nd
402	Rauch, 2010, 21060071	nd
403	Rauch, 2010, 21060071	nd
404	Rauch, 2010, 21060071	nd
405	Rauch, 2010, 21060071	nd
406	Rauch, 2010, 21060071	nd
407	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
408	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
409	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
410	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
411	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
412	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
413	Rodriguez-Leyva, 2013, 24126178	[4.5 (1.2)]/[2.5 (1.0)]/[1.2 (0.3)]/[1.6 (0.7)]
414	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
415	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
416	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
400	Rasmussen, 2006, 16469978	26.9 (3.0)	ALA: 0.31% FA, EPA: 1.5% FA, DPA: 1.07% FA, DHA 4.67 % FA	serum
401	Rasmussen, 2006, 16469978	26.9 (3.0)	ALA: 0.31% FA, EPA: 1.5% FA, DPA: 1.07% FA, DHA 4.67 % FA	serum
402	Rauch, 2010, 21060071	median 27.3 (24.9, 30.1)	nd	nd
403	Rauch, 2010, 21060071	median 27.3 (24.9, 30.1)	nd	nd
404	Rauch, 2010, 21060071	median 27.3 (24.9, 30.1)	nd	nd
405	Rauch, 2010, 21060071	median 27.3 (24.9, 30.1)	nd	nd
406	Rauch, 2010, 21060071	median 27.3 (24.9, 30.1)	nd	nd
407	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
408	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
409	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
410	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
411	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
412	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
413	Rodriguez-Leyva, 2013, 24126178	27.8 (4.5)	nd	nd
414	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
415	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
416	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
400	Rasmussen, 2006, 16469978	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
401	Rasmussen, 2006, 16469978	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
402	Rauch, 2010, 21060071	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
403	Rauch, 2010, 21060071	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Revascularization
404	Rauch, 2010, 21060071	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Sudden cardiac death
405	Rauch, 2010, 21060071	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
406	Rauch, 2010, 21060071	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
407	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
408	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
409	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
410	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
411	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
412	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
413	Rodriguez-Leyva, 2013, 24126178	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
414	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Congestive heart failure
415	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Congestive heart failure
416	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
400	Rasmussen, 2006, 16469978	-0.4 (-2.6, 1.8)	2.4	-0.1666667
401	Rasmussen, 2006, 16469978	-0.6 (-2.8, 0.8)	2.4	-0.1666667
402	Rauch, 2010, 21060071	OR 1.25 (0.90, 1.72)	0.84	1.304275
403	Rauch, 2010, 21060071	OR 0.93 (0.80, 1.08)	0.84	0.917233
404	Rauch, 2010, 21060071	0.95 (0.56, 1.6)	1	0.95
405	Rauch, 2010, 21060071	0.00 (nd)	1	0
406	Rauch, 2010, 21060071	-5.00 (nd)	1	-5
407	Rodriguez-Leyva, 2013, 24126178	0.1 (-0.3, 0.5)	5.9	
408	Rodriguez-Leyva, 2013, 24126178	0.2 (-0.3, 0.7)	5.9	
409	Rodriguez-Leyva, 2013, 24126178	-3.5 (-8.2, 1.2)	5.9	
410	Rodriguez-Leyva, 2013, 24126178	0 (-16.6, 16.6)	5.9	
411	Rodriguez-Leyva, 2013, 24126178	26.5 (-4.4, 57.5)	5.9	
412	Rodriguez-Leyva, 2013, 24126178	-7.3 (-15.4, 0.8)	5.9	-1.237288
413	Rodriguez-Leyva, 2013, 24126178	-2.1 (-7.2, 3.0)	5.9	-1.237288
414	Roncaglioni, 2013, 23656645	HR 1.00 (0.53, 1.88)	0.85	1
415	Roncaglioni, 2013, 23656645	HR 0.67 (0.52, 0.87)	0.85	0.6242839
416	Roncaglioni, 2013, 23656645	HR 1.03 (0.88, 1.19)	0.85	1.035387

Causality Table: Comparative Studies

Row	Study	Outcome classification
400	Rasmussen, 2006, 16469978	Secondary
401	Rasmussen, 2006, 16469978	Secondary
402	Rauch, 2010, 21060071	Secondary
403	Rauch, 2010, 21060071	Secondary
404	Rauch, 2010, 21060071	Secondary; Primary in registry record (NCT00251134)
405	Rauch, 2010, 21060071	Secondary
406	Rauch, 2010, 21060071	Primary (stated); Secondary in registry record (NCT00317707)
407	Rodriguez-Leyva, 2013, 24126178	Primary (stated)
408	Rodriguez-Leyva, 2013, 24126178	Primary (stated)
409	Rodriguez-Leyva, 2013, 24126178	Secondary
410	Rodriguez-Leyva, 2013, 24126178	Secondary
411	Rodriguez-Leyva, 2013, 24126178	Secondary
412	Rodriguez-Leyva, 2013, 24126178	Secondary
413	Rodriguez-Leyva, 2013, 24126178	Secondary
414	Roncaglioni, 2013, 23656645	Secondary
415	Roncaglioni, 2013, 23656645	Secondary
416	Roncaglioni, 2013, 23656645	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
417	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
418	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
419	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
420	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
421	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
422	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
423	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
424	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
425	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
426	Roncaglioni, 2013, 23656645	2004	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
427	Sacks, 1994, 8021472	1987	US	Primary Prevention, Healthy
428	Sacks, 1994, 8021472	1987	US	Primary Prevention, Healthy
429	Sacks, 1994, 8021472	1987	US	Primary Prevention, Healthy
430	Sacks, 1994, 8021472	1987	US	Primary Prevention, Healthy
431	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
432	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
433	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
434	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
417	Roncaglioni, 2013, 23656645	nd	12513
418	Roncaglioni, 2013, 23656645	nd	12513
419	Roncaglioni, 2013, 23656645	nd	12513
420	Roncaglioni, 2013, 23656645	nd	12513
421	Roncaglioni, 2013, 23656645	nd	12513
422	Roncaglioni, 2013, 23656645	nd	12513
423	Roncaglioni, 2013, 23656645	nd	12513
424	Roncaglioni, 2013, 23656645	nd	12513
425	Roncaglioni, 2013, 23656645	nd	12513
426	Roncaglioni, 2013, 23656645	nd	12513
427	Sacks, 1994, 8021472	na	350
428	Sacks, 1994, 8021472	na	350
429	Sacks, 1994, 8021472	na	350
430	Sacks, 1994, 8021472	na	350
431	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
432	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
433	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
434	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
417	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
418	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
419	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
420	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
421	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
422	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
423	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
424	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
425	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
426	Roncaglioni, 2013, 23656645	64.0 (9.6)	60.6	nd
427	Sacks, 1994, 8021472	43 (6.7)	70	range 84, 88 white
428	Sacks, 1994, 8021472	43 (6.7)	70	range 84, 88 white
429	Sacks, 1994, 8021472	43 (6.7)	70	range 84, 88 white
430	Sacks, 1994, 8021472	43 (6.7)	70	range 84, 88 white
431	Sacks, 1995, 7759696	62 (7)	92.9	nd
432	Sacks, 1995, 7759696	62 (7)	92.9	nd
433	Sacks, 1995, 7759696	62 (7)	92.9	nd
434	Sacks, 1995, 7759696	62 (7)	92.9	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
417	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
418	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
419	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
420	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
421	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
422	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
423	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
424	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
425	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
426	Roncaglioni, 2013, 23656645	140.1 (15.1)/82.5 (8.2)
427	Sacks, 1994, 8021472	122.6 (8.3)/81.1 (4.9)
428	Sacks, 1994, 8021472	122.6 (8.3)/81.1 (4.9)
429	Sacks, 1994, 8021472	122.6 (8.3)/81.1 (4.9)
430	Sacks, 1994, 8021472	122.6 (8.3)/81.1 (4.9)
431	Sacks, 1995, 7759696	133 (19)/77 (7.6)
432	Sacks, 1995, 7759696	133 (19)/77 (7.6)
433	Sacks, 1995, 7759696	133 (19)/77 (7.6)
434	Sacks, 1995, 7759696	133 (19)/77 (7.6)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
417	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
418	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
419	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
420	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
421	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
422	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
423	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
424	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
425	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
426	Roncaglioni, 2013, 23656645	216.5 (42.2)/132.5 (36.1)/51.2 (13.4)/median 150
427	Sacks, 1994, 8021472	189 (32)/ /45 (12)/
428	Sacks, 1994, 8021472	189 (32)/ /45 (12)/
429	Sacks, 1994, 8021472	189 (32)/ /45 (12)/
430	Sacks, 1994, 8021472	189 (32)/ /45 (12)/
431	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
432	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
433	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
434	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
417	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
418	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
419	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
420	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
421	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
422	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
423	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
424	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
425	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
426	Roncaglioni, 2013, 23656645	29.4 (5.0)	nd	nd
427	Sacks, 1994, 8021472	nd	nd	nd
428	Sacks, 1994, 8021472	nd	nd	nd
429	Sacks, 1994, 8021472	nd	nd	nd
430	Sacks, 1994, 8021472	nd	nd	nd
431	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
432	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
433	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
434	Sacks, 1995, 7759696	weight 79 (15)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
417	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, CVD (total)
418	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, stroke
419	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MACE
420	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
421	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Sudden cardiac death
422	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
423	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
424	Roncaglioni, 2013, 23656645	EPA+DHA +DPA vs Placebo	g/d	Trial: Randomized Parallel	Tg
425	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
426	Roncaglioni, 2013, 23656645	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
427	Sacks, 1994, 8021472	DHA vs Placebo	g/d	Trial: Randomized Parallel	Angina, unstable
428	Sacks, 1994, 8021472	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
429	Sacks, 1994, 8021472	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
430	Sacks, 1994, 8021472	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
431	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Congestive heart failure
432	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, cardiac
433	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
434	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Stroke

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
417	Roncaglioni, 2013, 23656645	HR 1.03 (0.82, 1.30)	0.85	1.035387
418	Roncaglioni, 2013, 23656645	HR 1.05 (0.55, 2.00)	0.85	1.05908
419	Roncaglioni, 2013, 23656645	HR 0.98 (0.88, 1.08)	0.85	0.9765123
420	Roncaglioni, 2013, 23656645	HR 0.76 (0.34, 1.74)	0.85	0.7240703
421	Roncaglioni, 2013, 23656645	OR 1.28 (0.88, 1.89)	0.85	1.336994
422	Roncaglioni, 2013, 23656645	0.55 (0.03, 1.07)	0.85	0.6470588
423	Roncaglioni, 2013, 23656645	-0.35 (-1.79, 1.09)	0.85	-0.4117647
424	Roncaglioni, 2013, 23656645	-8.08 (-11.43, -4.74)	0.85	-9.505882
425	Roncaglioni, 2013, 23656645	0.2 (-0.4, 0.7)	0.85	0.2352941
426	Roncaglioni, 2013, 23656645	-0.2 (-25, 24.6)	0.85	-0.2352941
427	Sacks, 1994, 8021472	OR 0.64 (0.13, 3.16)	2.4	0.8303127
428	Sacks, 1994, 8021472	1.8 (-1.0, 4.5)	2.4	0.75
429	Sacks, 1994, 8021472	1.2 (-0.3, 2.8)	2.4	0.5
430	Sacks, 1994, 8021472	-0.5 (-1.5, 0.5)	2.4	-0.2083333
431	Sacks, 1995, 7759696	nd	6	
432	Sacks, 1995, 7759696	RD -3.6% (-10.4%, 3.3%)	6	
433	Sacks, 1995, 7759696	OR 0.43 (0.04, 5.06)	6	0.8687832
434	Sacks, 1995, 7759696	OR 2.8 (0.11, 71.63)	4.8	1.239247

Causality Table: Comparative Studies

Row	Study	Outcome classification
417	Roncaglioni, 2013, 23656645	Primary (stated, a priori)
418	Roncaglioni, 2013, 23656645	Secondary
419	Roncaglioni, 2013, 23656645	Primary (stated, added at 1 year)
420	Roncaglioni, 2013, 23656645	Secondary
421	Roncaglioni, 2013, 23656645	Secondary
422	Roncaglioni, 2013, 23656645	Secondary
423	Roncaglioni, 2013, 23656645	Secondary
424	Roncaglioni, 2013, 23656645	Secondary
425	Roncaglioni, 2013, 23656645	Secondary
426	Roncaglioni, 2013, 23656645	Secondary
427	Sacks, 1994, 8021472	Primary (stated)
428	Sacks, 1994, 8021472	Secondary
429	Sacks, 1994, 8021472	Secondary
430	Sacks, 1994, 8021472	Secondary
431	Sacks, 1995, 7759696	Secondary
432	Sacks, 1995, 7759696	Secondary
433	Sacks, 1995, 7759696	Secondary
434	Sacks, 1995, 7759696	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
435	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
436	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
437	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
438	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
439	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
440	Sacks, 1995, 7759696	1993 (approx)	US	Secondary Prevention (history of CVD event)
441	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
442	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
443	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
444	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
445	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
446	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
447	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
448	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
449	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
450	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
435	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
436	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
437	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
438	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
439	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
440	Sacks, 1995, 7759696	Dyslipidemia (total cholesterol concentration <250 mg/dl (6.43 mmol/liter) and triglyceride level <350 mg/dl (4.0 mmol/liter)); Cardiac disease (narrowing of =>30% lumen diameter of a major coronary artery)	59
441	Sanders, 2011, 21865334	na	310
442	Sanders, 2011, 21865334	na	310
443	Sanders, 2011, 21865334	na	310
444	Sanders, 2011, 21865334	na	310
445	Sanders, 2011, 21865334	na	310
446	Sanders, 2011, 21865334	na	310
447	Sanders, 2011, 21865334	na	310
448	Sanders, 2011, 21865334	na	310
449	Sanders, 2011, 21865334	na	310
450	Sanders, 2011, 21865334	na	310

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
435	Sacks, 1995, 7759696	62 (7)	92.9	nd
436	Sacks, 1995, 7759696	62 (7)	92.9	nd
437	Sacks, 1995, 7759696	62 (7)	92.9	nd
438	Sacks, 1995, 7759696	62 (7)	92.9	nd
439	Sacks, 1995, 7759696	62 (7)	92.9	nd
440	Sacks, 1995, 7759696	62 (7)	92.9	nd
441	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
442	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
443	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
444	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
445	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
446	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
447	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
448	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
449	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
450	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
435	Sacks, 1995, 7759696	133 (19)/77 (7.6)
436	Sacks, 1995, 7759696	133 (19)/77 (7.6)
437	Sacks, 1995, 7759696	133 (19)/77 (7.6)
438	Sacks, 1995, 7759696	133 (19)/77 (7.6)
439	Sacks, 1995, 7759696	133 (19)/77 (7.6)
440	Sacks, 1995, 7759696	133 (19)/77 (7.6)
441	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
442	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
443	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
444	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
445	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
446	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
447	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
448	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
449	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
450	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
435	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
436	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
437	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
438	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
439	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
440	Sacks, 1995, 7759696	184 (28)/117 (27)/40 (12)/137 (73)
441	Sanders, 2011, 21865334	nd
442	Sanders, 2011, 21865334	nd
443	Sanders, 2011, 21865334	nd
444	Sanders, 2011, 21865334	nd
445	Sanders, 2011, 21865334	nd
446	Sanders, 2011, 21865334	nd
447	Sanders, 2011, 21865334	nd
448	Sanders, 2011, 21865334	nd
449	Sanders, 2011, 21865334	nd
450	Sanders, 2011, 21865334	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
435	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
436	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
437	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
438	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
439	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
440	Sacks, 1995, 7759696	weight 79 (15)	nd	nd
441	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
442	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
443	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
444	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
445	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
446	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
447	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
448	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
449	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
450	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
435	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
436	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
437	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
438	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
439	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
440	Sacks, 1995, 7759696	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
441	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
442	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
443	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
444	Sanders, 2011, 21865334	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
445	Sanders, 2011, 21865334	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
446	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
447	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
448	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
449	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c
450	Sanders, 2011, 21865334	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
435	Sacks, 1995, 7759696	1.80 (-0.92, 4.52)	2	0.9
436	Sacks, 1995, 7759696	-1.00 (-6.86, 4.86)	6	-0.1666667
437	Sacks, 1995, 7759696	5.00 (-9.07, 19.07)	6	0.8333333
438	Sacks, 1995, 7759696	-33.00 (-66.57, 0.57)	6	-5.5
439	Sacks, 1995, 7759696	-1.0 (-14.0, 12.0)	6	-0.1666667
440	Sacks, 1995, 7759696	1.0 (-4.6, 6.6)	6	0.1666667
441	Sanders, 2011, 21865334	-0.07 (-0.35, 0.21)	1.8	
442	Sanders, 2011, 21865334	-0.03 (-0.31, 0.25)	0.9	
443	Sanders, 2011, 21865334	-0.01 (-0.29, 0.27)	0.45	
444	Sanders, 2011, 21865334	-0.04 (-0.30, 0.22)	1.8	
445	Sanders, 2011, 21865334	-0.06 (-0.33, 0.21)	1.8	
446	Sanders, 2011, 21865334	-0.02 (-0.28, 0.24)	0.9	
447	Sanders, 2011, 21865334	3.9 (-1.6, 9.3)	1.8	
448	Sanders, 2011, 21865334	0 (-5.5, 5.5)	0.9	
449	Sanders, 2011, 21865334	3.9 (-1.6, 9.3)	0.45	
450	Sanders, 2011, 21865334	3.9 (-1.6, 9.3)	1.8	

Causality Table: Comparative Studies

Row	Study	Outcome classification
435	Sacks, 1995, 7759696	Secondary
436	Sacks, 1995, 7759696	Secondary
437	Sacks, 1995, 7759696	Secondary
438	Sacks, 1995, 7759696	Secondary
439	Sacks, 1995, 7759696	Secondary
440	Sacks, 1995, 7759696	Secondary
441	Sanders, 2011, 21865334	Secondary
442	Sanders, 2011, 21865334	Secondary
443	Sanders, 2011, 21865334	Secondary
444	Sanders, 2011, 21865334	Secondary
445	Sanders, 2011, 21865334	Secondary
446	Sanders, 2011, 21865334	Secondary
447	Sanders, 2011, 21865334	Secondary
448	Sanders, 2011, 21865334	Secondary
449	Sanders, 2011, 21865334	Secondary
450	Sanders, 2011, 21865334	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
451	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
452	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
453	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
454	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
455	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
456	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
457	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
458	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
459	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
460	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
461	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
462	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
463	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
464	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
465	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
466	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
451	Sanders, 2011, 21865334	na	310
452	Sanders, 2011, 21865334	na	310
453	Sanders, 2011, 21865334	na	310
454	Sanders, 2011, 21865334	na	310
455	Sanders, 2011, 21865334	na	310
456	Sanders, 2011, 21865334	na	310
457	Sanders, 2011, 21865334	na	310
458	Sanders, 2011, 21865334	na	310
459	Sanders, 2011, 21865334	na	310
460	Sanders, 2011, 21865334	na	310
461	Sanders, 2011, 21865334	na	310
462	Sanders, 2011, 21865334	na	310
463	Sanders, 2011, 21865334	na	310
464	Sanders, 2011, 21865334	na	310
465	Sanders, 2011, 21865334	na	310
466	Sanders, 2011, 21865334	na	310

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
451	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
452	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
453	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
454	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
455	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
456	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
457	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
458	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
459	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
460	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
461	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
462	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
463	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
464	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
465	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
466	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
451	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
452	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
453	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
454	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
455	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
456	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
457	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
458	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
459	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
460	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
461	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
462	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
463	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
464	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
465	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
466	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
451	Sanders, 2011, 21865334	nd
452	Sanders, 2011, 21865334	nd
453	Sanders, 2011, 21865334	nd
454	Sanders, 2011, 21865334	nd
455	Sanders, 2011, 21865334	nd
456	Sanders, 2011, 21865334	nd
457	Sanders, 2011, 21865334	nd
458	Sanders, 2011, 21865334	nd
459	Sanders, 2011, 21865334	nd
460	Sanders, 2011, 21865334	nd
461	Sanders, 2011, 21865334	nd
462	Sanders, 2011, 21865334	nd
463	Sanders, 2011, 21865334	nd
464	Sanders, 2011, 21865334	nd
465	Sanders, 2011, 21865334	nd
466	Sanders, 2011, 21865334	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
451	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
452	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
453	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
454	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
455	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
456	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
457	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
458	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
459	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
460	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
461	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
462	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
463	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
464	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
465	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
466	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
451	Sanders, 2011, 21865334	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Parallel	HDL-c
452	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
453	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
454	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
455	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
456	Sanders, 2011, 21865334	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
457	Sanders, 2011, 21865334	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Parallel	LDL-c
458	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
459	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
460	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
461	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
462	Sanders, 2011, 21865334	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
463	Sanders, 2011, 21865334	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Parallel	Tg
464	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
465	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
466	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	SBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
451	Sanders, 2011, 21865334	0 (-5.5, 5.5)	1.8	
452	Sanders, 2011, 21865334	-3.9 (-9.3, 1.6)	0.9	
453	Sanders, 2011, 21865334	3.9 (-5.6, 13.6)	1.8	
454	Sanders, 2011, 21865334	0 (-10.2, 10.2)	0.9	
455	Sanders, 2011, 21865334	7.7 (-2.5, 17.9)	0.45	
456	Sanders, 2011, 21865334	3.9 (-6.4, 14.1)	1.8	
457	Sanders, 2011, 21865334	-11.6 (-22.5, -0.66) -3.9 (-13.5, 5.8)	1.8	
458	Sanders, 2011, 21865334	-7.7 (-18.6, 3.2)	0.9	
459	Sanders, 2011, 21865334	-15.0 (-27.4, -2.7)	1.8	
460	Sanders, 2011, 21865334	-3.5 (-16.5, 9.4)	0.9	
461	Sanders, 2011, 21865334	-2.7 (-15.8, 10.5)	0.45	
462	Sanders, 2011, 21865334	-11.5 (-24.2, 1.2)	1.8	
463	Sanders, 2011, 21865334	-12.4 (-88.4, 63.7)	1.8	
464	Sanders, 2011, 21865334	-0.9 (-77.0, 75.3)	0.9	
465	Sanders, 2011, 21865334	-0.3 (-4.3, 3.7)	1.8	
466	Sanders, 2011, 21865334	-0.8 (-4.8, 3.2)	0.9	

Causality Table: Comparative Studies

Row	Study	Outcome classification
451	Sanders, 2011, 21865334	Secondary
452	Sanders, 2011, 21865334	Secondary
453	Sanders, 2011, 21865334	Secondary
454	Sanders, 2011, 21865334	Secondary
455	Sanders, 2011, 21865334	Secondary
456	Sanders, 2011, 21865334	Secondary
457	Sanders, 2011, 21865334	Secondary
458	Sanders, 2011, 21865334	Secondary
459	Sanders, 2011, 21865334	Secondary
460	Sanders, 2011, 21865334	Secondary
461	Sanders, 2011, 21865334	Secondary
462	Sanders, 2011, 21865334	Secondary
463	Sanders, 2011, 21865334	Secondary
464	Sanders, 2011, 21865334	Secondary
465	Sanders, 2011, 21865334	Secondary
466	Sanders, 2011, 21865334	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
467	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
468	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
469	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
470	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
471	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
472	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
473	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
474	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
475	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
476	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
477	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
478	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
479	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
480	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
481	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
482	Sanders, 2011, 21865334	2008	UK	Primary Prevention, Healthy
483	Shaikh 2014 25185754	nd	Canada	Primary Prevention, Healthy

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
467	Sanders, 2011, 21865334	na	310
468	Sanders, 2011, 21865334	na	310
469	Sanders, 2011, 21865334	na	310
470	Sanders, 2011, 21865334	na	310
471	Sanders, 2011, 21865334	na	310
472	Sanders, 2011, 21865334	na	310
473	Sanders, 2011, 21865334	na	310
474	Sanders, 2011, 21865334	na	310
475	Sanders, 2011, 21865334	na	310
476	Sanders, 2011, 21865334	na	310
477	Sanders, 2011, 21865334	na	310
478	Sanders, 2011, 21865334	na	310
479	Sanders, 2011, 21865334	na	310
480	Sanders, 2011, 21865334	na	310
481	Sanders, 2011, 21865334	na	310
482	Sanders, 2011, 21865334	na	310
483	Shaikh 2014 25185754	na	110

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
467	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
468	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
469	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
470	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
471	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
472	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
473	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
474	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
475	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
476	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
477	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
478	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
479	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
480	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
481	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
482	Sanders, 2011, 21865334	55 (95% CI 54, 57)	38.6	77.3 white, 10.2 black, 6.8 Asian, 2.3 far eastern, 3.4 other
483	Shaikh 2014 25185754	53.6 (14.2)	53.5	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
467	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
468	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
469	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
470	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
471	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
472	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
473	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
474	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
475	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
476	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
477	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
478	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
479	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
480	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
481	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
482	Sanders, 2011, 21865334	120 (95% CI 117, 124)/77 (95% CI 75, 79)
483	Shaikh 2014 25185754	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
467	Sanders, 2011, 21865334	nd
468	Sanders, 2011, 21865334	nd
469	Sanders, 2011, 21865334	nd
470	Sanders, 2011, 21865334	nd
471	Sanders, 2011, 21865334	nd
472	Sanders, 2011, 21865334	nd
473	Sanders, 2011, 21865334	nd
474	Sanders, 2011, 21865334	nd
475	Sanders, 2011, 21865334	nd
476	Sanders, 2011, 21865334	nd
477	Sanders, 2011, 21865334	nd
478	Sanders, 2011, 21865334	nd
479	Sanders, 2011, 21865334	nd
480	Sanders, 2011, 21865334	nd
481	Sanders, 2011, 21865334	nd
482	Sanders, 2011, 21865334	nd
483	Shaikh 2014 25185754	[4.83 (1.02)/2.92 (0.84)/1.09 (0.27)/2.25 (1.03)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
467	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
468	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
469	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
470	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
471	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
472	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
473	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
474	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
475	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
476	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
477	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
478	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
479	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
480	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
481	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
482	Sanders, 2011, 21865334	26 (95% CI 25, 27) (women); 27 (95% CI 26, 28) (men)	nd	nd
483	Shaikh 2014 25185754	31.9 (6.6)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
467	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	SBP
468	Sanders, 2011, 21865334	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
469	Sanders, 2011, 21865334	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Parallel	SBP
470	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
471	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
472	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	DBP
473	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	DBP
474	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
475	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
476	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
477	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP
478	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	MAP
479	Sanders, 2011, 21865334	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	MAP
480	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP
481	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP
482	Sanders, 2011, 21865334	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MAP
483	Shaikh 2014 25185754	EPA+DHA 3.6 vs Placebo	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
467	Sanders, 2011, 21865334	0 (-4, 4)	0.45	
468	Sanders, 2011, 21865334	0.5 (-3.5, 4.5)	1.8	
469	Sanders, 2011, 21865334	-0.3 (-4.3, 3.7)	1.8	
470	Sanders, 2011, 21865334	-0.8 (-4.8, 3.2)	0.9	
471	Sanders, 2011, 21865334	0.6 (-1.4, 2.6)	1.8	
472	Sanders, 2011, 21865334	0.6 (-1.5, 2.7)	0.9	
473	Sanders, 2011, 21865334	1.2 (-0.9, 3.3)	0.45	
474	Sanders, 2011, 21865334	0 (-2.0, 2.0)	1.8	
475	Sanders, 2011, 21865334	-0.6 (-2.5, 1.3)	1.8	
476	Sanders, 2011, 21865334	-0.6 (-2.7, 1.5)	0.9	
477	Sanders, 2011, 21865334	2 (-1.4, 5.4)	1.8	
478	Sanders, 2011, 21865334	1 (-2.4, 4.4)	0.9	
479	Sanders, 2011, 21865334	-1 (-4.5, 2.5)	0.45	
480	Sanders, 2011, 21865334	1 (-2.2, 4.2)	1.8	
481	Sanders, 2011, 21865334	3 (-0.4, 6.4)	1.8	
482	Sanders, 2011, 21865334	1.0 (-2.7, 4.7)	0.9	
483	Shaikh 2014 25185754	2.32 (-3.31, 7.95)	3.6	0.64

Causality Table: Comparative Studies

Row	Study	Outcome classification
467	Sanders, 2011, 21865334	Secondary
468	Sanders, 2011, 21865334	Secondary
469	Sanders, 2011, 21865334	Secondary
470	Sanders, 2011, 21865334	Secondary
471	Sanders, 2011, 21865334	Secondary
472	Sanders, 2011, 21865334	Secondary
473	Sanders, 2011, 21865334	Secondary
474	Sanders, 2011, 21865334	Secondary
475	Sanders, 2011, 21865334	Secondary
476	Sanders, 2011, 21865334	Secondary
477	Sanders, 2011, 21865334	Secondary
478	Sanders, 2011, 21865334	Secondary
479	Sanders, 2011, 21865334	Secondary
480	Sanders, 2011, 21865334	Secondary
481	Sanders, 2011, 21865334	Secondary
482	Sanders, 2011, 21865334	Secondary
483	Shaikh 2014 25185754	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
484	Shaikh 2014 25185754	nd	Canada	Primary Prevention, Increased CVD Risk
485	Shaikh 2014 25185754	nd	Canada	Primary Prevention, Healthy
486	Shaikh 2014 25185754	nd	Canada	Primary Prevention, Increased CVD Risk
487	Shaikh 2014 25185754	nd	Canada	Primary Prevention, Healthy
488	Shaikh 2014 25185754	nd	Canada	Primary Prevention, Increased CVD Risk
489	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
490	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
491	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
492	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
493	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
494	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
495	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
496	Shidfar, 2003, 12847992	2001 (approx)	Iran	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
497	Sirtori, 1997, 9174486	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
484	Shaikh 2014 25185754	TG: 2.26-5.65 mmol/L	110
485	Shaikh 2014 25185754	na	110
486	Shaikh 2014 25185754	TG: 2.26-5.65 mmol/L	110
487	Shaikh 2014 25185754	na	110
488	Shaikh 2014 25185754	TG: 2.26-5.65 mmol/L	110
489	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
490	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
491	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
492	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
493	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
494	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
495	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
496	Shidfar, 2003, 12847992	Dyslipidemia (serum total cholesterol and triglyceride > 200 mg/dl)	68
497	Sirtori, 1997, 9174486	Diabetes and/or metabolic syndrome ; Hypertension (Patients treated with antihypertensive drugs or who on more than one occasion in the past year had had a systolic blood pressure (SBP) >= 160 mm Hg, a diastolic blood pressure (DBP) >= 95 mm Hg, or both, independent of drug treatment, were considered to have arterial hypertension.); Dyslipidemia (Patients with significant and stable triacylglycerol elevations (> 2.26 mmol/L, or 200 mg/dL) were selected. These were defined as type IIB if serum total cholesterol was > 7.21 mmol/L (270 mg/dL) and type IV if cholesterol was >= 7.21 mmol/L (270 mg/dL). Patients with total cholesterol concentrations > 7.76 mmol/L (300 mg/dL) with triacylglycerol concentrations >= 4.52 mmol/L (400 mg/dL) were excluded for ethical reasons.); Other (Impaired glucose tolerance)	935

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
484	Shaikh 2014 25185754	53.6 (14.2)	53.5	nd
485	Shaikh 2014 25185754	53.6 (14.2)	53.5	nd
486	Shaikh 2014 25185754	53.6 (14.2)	53.5	nd
487	Shaikh 2014 25185754	53.6 (14.2)	53.5	nd
488	Shaikh 2014 25185754	53.6 (14.2)	53.5	nd
489	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
490	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
491	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
492	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
493	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
494	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
495	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
496	Shidfar, 2003, 12847992	54.4 (12.2)	36.8	nd
497	Sirtori, 1997, 9174486	58.8 (8.99)	62.2	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
484	Shaikh 2014 25185754	nd
485	Shaikh 2014 25185754	nd
486	Shaikh 2014 25185754	nd
487	Shaikh 2014 25185754	nd
488	Shaikh 2014 25185754	nd
489	Shidfar, 2003, 12847992	nd
490	Shidfar, 2003, 12847992	nd
491	Shidfar, 2003, 12847992	nd
492	Shidfar, 2003, 12847992	nd
493	Shidfar, 2003, 12847992	nd
494	Shidfar, 2003, 12847992	nd
495	Shidfar, 2003, 12847992	nd
496	Shidfar, 2003, 12847992	nd
497	Sirtori, 1997, 9174486	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
484	Shaikh 2014 25185754	[4.83 (1.02)/2.92 (0.84)/1.09 (0.27)/2.25 (1.03)]
485	Shaikh 2014 25185754	[4.83 (1.02)/2.92 (0.84)/1.09 (0.27)/2.25 (1.03)]
486	Shaikh 2014 25185754	[4.83 (1.02)/2.92 (0.84)/1.09 (0.27)/2.25 (1.03)]
487	Shaikh 2014 25185754	[4.83 (1.02)/2.92 (0.84)/1.09 (0.27)/2.25 (1.03)]
488	Shaikh 2014 25185754	[4.83 (1.02)/2.92 (0.84)/1.09 (0.27)/2.25 (1.03)]
489	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
490	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
491	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
492	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
493	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
494	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
495	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
496	Shidfar, 2003, 12847992	250.7 (46.3)/167.4 (38.2)/39.2 (9.3)/311.5 (100.2)
497	Sirtori, 1997, 9174486	nd

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
484	Shaikh 2014 25185754	31.9 (6.6)	nd	nd
485	Shaikh 2014 25185754	31.9 (6.6)	nd	nd
486	Shaikh 2014 25185754	31.9 (6.6)	nd	nd
487	Shaikh 2014 25185754	31.9 (6.6)	nd	nd
488	Shaikh 2014 25185754	31.9 (6.6)	nd	nd
489	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
490	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
491	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
492	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
493	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
494	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
495	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
496	Shidfar, 2003, 12847992	27.6 (3)/72 (10.8)	nd	nd
497	Sirtori, 1997, 9174486	weight 73.7 (10.08)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
484	Shaikh 2014 25185754	EPA+DHA 3.6 vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
485	Shaikh 2014 25185754	EPA+DHA 3.6 vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
486	Shaikh 2014 25185754	EPA+DHA 3.6 vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
487	Shaikh 2014 25185754	EPA+DHA 3.6 vs Placebo	g/d	Trial: Randomized Parallel	Tg
488	Shaikh 2014 25185754	EPA+DHA 3.6 vs Placebo	g/d	Trial: Randomized Parallel	Tg
489	Shidfar, 2003, 12847992	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL:HDL-c ratio
490	Shidfar, 2003, 12847992	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Factorial Design	LDL:HDL-c ratio
491	Shidfar, 2003, 12847992	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
492	Shidfar, 2003, 12847992	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Factorial Design	HDL-c
493	Shidfar, 2003, 12847992	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	LDL-c
494	Shidfar, 2003, 12847992	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Factorial Design	LDL-c
495	Shidfar, 2003, 12847992	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	Tg
496	Shidfar, 2003, 12847992	ALA+EPA+DHA+ vitamin C vs Placebo + vitamin C	g/d	Trial: Randomized Factorial Design	Tg
497	Sirtori, 1997, 9174486	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
484	Shaikh 2014 25185754	1.93 (0.53, 3.33)	3.6	0.54
485	Shaikh 2014 25185754	12.74 (-3.32, 28.8)	3.6	3.54
486	Shaikh 2014 25185754	13.9 (-2.16, 29.96)	3.6	3.86
487	Shaikh 2014 25185754	-28.32 (-63.05, 6.41)	3.6	-7.87
488	Shaikh 2014 25185754	-95.58 (-149.39, -41.76)	3.6	-26.55
489	Shidfar, 2003, 12847992	-0.3 (-1.5, 0.9)	1	-0.3
490	Shidfar, 2003, 12847992	0.2 (-1.1, 1.5)	1	0.2
491	Shidfar, 2003, 12847992	-0.3 (-6.8, 6.2)	1	-4
492	Shidfar, 2003, 12847992	-14.9 (-20.2, -9.6)	1	10.3
493	Shidfar, 2003, 12847992	-4.00 (-34.70, 26.70)	1	-4
494	Shidfar, 2003, 12847992	10.30 (-18.79, 39.39)	1	10.3
495	Shidfar, 2003, 12847992	-109.10 (-176.85, -41.35)	1	-109.1
496	Shidfar, 2003, 12847992	15.20 (-43.85, 74.25)	1	15.2
497	Sirtori, 1997, 9174486	0.39 (0.30, 0.47)	2.57	0.151751

Causality Table: Comparative Studies

Row	Study	Outcome classification
484	Shaikh 2014 25185754	Secondary
485	Shaikh 2014 25185754	Secondary
486	Shaikh 2014 25185754	Secondary
487	Shaikh 2014 25185754	Secondary
488	Shaikh 2014 25185754	Secondary
489	Shidfar, 2003, 12847992	Primary (stated)
490	Shidfar, 2003, 12847992	Primary (stated)
491	Shidfar, 2003, 12847992	Secondary
492	Shidfar, 2003, 12847992	Secondary
493	Shidfar, 2003, 12847992	Secondary
494	Shidfar, 2003, 12847992	Secondary
495	Shidfar, 2003, 12847992	Primary (stated)
496	Shidfar, 2003, 12847992	Primary (stated)
497	Sirtori, 1997, 9174486	Primary (power analysis)

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
498	Sirtori, 1997, 9174486	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
499	Sirtori, 1997, 9174486	nd	Italy	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
500	Soares, 2014, 24652053	2011	Brazil	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
501	Soares, 2014, 24652053	2011	Brazil	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
502	Soares, 2014, 24652053	2011	Brazil	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
503	Soares, 2014, 24652053	2011	Brazil	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
504	Soares, 2014, 24652053	2011	Brazil	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
498	Sirtori, 1997, 9174486	Diabetes and/or metabolic syndrome* ; Hypertension (Patients treated with antihypertensive drugs or who on more than one occasion in the past year had had a systolic blood pressure (SBP) 160 mm Hg, a diastolic blood pressure (DBP) 95 mm Hg, or both, independent of drug treatment, were considered to have arterial hypertension.); Dyslipidemia (Patients with significant and stable triacylglycerol elevations (> 2.26 mmol/L, or 200 mg/dL) were selected. These were defined as type IIB if serum total cholesterol was > 7.21 mmol/L (270 mg/dL) and type IV if cholesterol was > 7.21 mmol/L (270 mg/dL). Patients with total cholesterol concentrations > 7.76 mmol/L (300 mg/dL) with triacylglycerol concentrations > 4.52 mmol/L (400 mg/dL) were excluded for ethical reasons.); Other (Impaired glucose tolerance)	935
499	Sirtori, 1997, 9174486	Diabetes and/or metabolic syndrome ; Hypertension (Patients treated with antihypertensive drugs or who on more than one occasion in the past year had had a systolic blood pressure (SBP) >= 160 mm Hg, a diastolic blood pressure (DBP) >= 95 mm Hg, or both, independent of drug treatment, were considered to have arterial hypertension.); Dyslipidemia (Patients with significant and stable triacylglycerol elevations (> 2.26 mmol/L, or 200 mg/dL) were selected. These were defined as type IIB if serum total cholesterol was > 7.21 mmol/L (270 mg/dL) and type IV if cholesterol was >= 7.21 mmol/L (270 mg/dL). Patients with total cholesterol concentrations > 7.76 mmol/L (300 mg/dL) with triacylglycerol concentrations >= 4.52 mmol/L (400 mg/dL) were excluded for ethical reasons.); Other (Impaired glucose tolerance)	935
500	Soares, 2014, 24652053	Diabetes and/or metabolic syndrome* ; Hypertension (systolic arterial pressure (SAP) of 130 mmHg and a diastolic arterial pressure of 85 mmHg); Dyslipidemia (a triglyceride level of 150 mg/dL, and a high-density lipoprotein cholesterol (HDL-C) level of < 40 mg/dL for men and < 50 mg/dL for women); Obesity/Overweight (abdominal circumference (AC) of > 88 cm for women and > 102 cm for men)	70
501	Soares, 2014, 24652053	Diabetes and/or metabolic syndrome* ; Hypertension (systolic arterial pressure (SAP) of 130 mmHg and a diastolic arterial pressure of 85 mmHg); Dyslipidemia (a triglyceride level of 150 mg/dL, and a high-density lipoprotein cholesterol (HDL-C) level of < 40 mg/dL for men and < 50 mg/dL for women); Obesity/Overweight (abdominal circumference (AC) of > 88 cm for women and > 102 cm for men)	70
502	Soares, 2014, 24652053	Diabetes and/or metabolic syndrome ; Hypertension (systolic arterial pressure (SAP) of >= 130 mmHg and a diastolic arterial pressure of >= 85 mmHg); Dyslipidemia (a triglyceride level of >= 150 mg/dL, and a high-density lipoprotein cholesterol (HDL-C) level of < 40 mg/dL for men and < 50 mg/dL for women); Obesity/Overweight (abdominal circumference (AC) of > 88 cm for women and > 102 cm for men)	70
503	Soares, 2014, 24652053	Diabetes and/or metabolic syndrome ; Hypertension (systolic arterial pressure (SAP) of >= 130 mmHg and a diastolic arterial pressure of >= 85 mmHg); Dyslipidemia (a triglyceride level of >= 150 mg/dL, and a high-density lipoprotein cholesterol (HDL-C) level of < 40 mg/dL for men and < 50 mg/dL for women); Obesity/Overweight (abdominal circumference (AC) of > 88 cm for women and > 102 cm for men)	70
504	Soares, 2014, 24652053	Diabetes and/or metabolic syndrome ; Hypertension (systolic arterial pressure (SAP) of >= 130 mmHg and a diastolic arterial pressure of >= 85 mmHg); Dyslipidemia (a triglyceride level of >= 150 mg/dL, and a high-density lipoprotein cholesterol (HDL-C) level of < 40 mg/dL for men and < 50 mg/dL for women); Obesity/Overweight (abdominal circumference (AC) of > 88 cm for women and > 102 cm for men)	70

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
498	Sirtori, 1997, 9174486	58.8 (8.99)	62.2	nd
499	Sirtori, 1997, 9174486	58.8 (8.99)	62.2	nd
500	Soares, 2014, 24652053	51.6 (13.4)	28.6	nd
501	Soares, 2014, 24652053	51.6 (13.4)	28.6	nd
502	Soares, 2014, 24652053	51.6 (13.4)	28.6	nd
503	Soares, 2014, 24652053	51.6 (13.4)	28.6	nd
504	Soares, 2014, 24652053	51.6 (13.4)	28.6	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
498	Sirtori, 1997, 9174486	nd
499	Sirtori, 1997, 9174486	nd
500	Soares, 2014, 24652053	134.4 (35.1)/85.3 (21.2)
501	Soares, 2014, 24652053	134.4 (35.1)/85.3 (21.2)
502	Soares, 2014, 24652053	134.4 (35.1)/85.3 (21.2)
503	Soares, 2014, 24652053	134.4 (35.1)/85.3 (21.2)
504	Soares, 2014, 24652053	134.4 (35.1)/85.3 (21.2)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
498	Sirtori, 1997, 9174486	nd
499	Sirtori, 1997, 9174486	nd
500	Soares, 2014, 24652053	nd/nd/47.3 (14.1)/199.6 (126.3)
501	Soares, 2014, 24652053	nd/nd/47.3 (14.1)/199.6 (126.3)
502	Soares, 2014, 24652053	nd/nd/47.3 (14.1)/199.6 (126.3)
503	Soares, 2014, 24652053	nd/nd/47.3 (14.1)/199.6 (126.3)
504	Soares, 2014, 24652053	nd/nd/47.3 (14.1)/199.6 (126.3)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
498	Sirtori, 1997, 9174486	weight 73.7 (10.08)	nd	nd
499	Sirtori, 1997, 9174486	weight 73.7 (10.08)	nd	nd
500	Soares, 2014, 24652053	32.8 (8.1)	nd	nd
501	Soares, 2014, 24652053	32.8 (8.1)	nd	nd
502	Soares, 2014, 24652053	32.8 (8.1)	nd	nd
503	Soares, 2014, 24652053	32.8 (8.1)	nd	nd
504	Soares, 2014, 24652053	32.8 (8.1)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
498	Sirtori, 1997, 9174486	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
499	Sirtori, 1997, 9174486	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
500	Soares, 2014, 24652053	EPA+DHA vs EPA	g/d	Trial: Randomized Factorial Design	HDL-c
501	Soares, 2014, 24652053	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
502	Soares, 2014, 24652053	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
503	Soares, 2014, 24652053	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	HDL-c
504	Soares, 2014, 24652053	EPA+DHA vs Placebo	g/d	Trial: Randomized Factorial Design	SBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
498	Sirtori, 1997, 9174486	6.56 (6.30, 6.83)	2.57	2.552529
499	Sirtori, 1997, 9174486	-37.17 (-37.84, -36.50)	2.57	-14.46303
500	Soares, 2014, 24652053	1.70 (-3.87, 7.26)	2.4	0.7083333
501	Soares, 2014, 24652053	9.30 (1.17, 17.43)	2.4	3.875
502	Soares, 2014, 24652053	-0.90 (-2.89, 1.09)	2.4	-0.375
503	Soares, 2014, 24652053	7.60 (5.36, 9.84)	2.4	3.166667
504	Soares, 2014, 24652053	0.6 (-1.5, 2.7)	3	0.2

Causality Table: Comparative Studies

Row	Study	Outcome classification
498	Sirtori, 1997, 9174486	Primary (implied)
499	Sirtori, 1997, 9174486	Primary (implied)
500	Soares, 2014, 24652053	Secondary
501	Soares, 2014, 24652053	Secondary
502	Soares, 2014, 24652053	Secondary
503	Soares, 2014, 24652053	Secondary
504	Soares, 2014, 24652053	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
505	Soares, 2014, 24652053	2011	Brazil	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
506	Tardivo 2015 25394692	nd	Brazil	Primary Prevention, Healthy
507	Tardivo 2015 25394692	nd	Brazil	Primary Prevention, Healthy
508	Tardivo 2015 25394692	nd	Brazil	Primary Prevention, Healthy
509	Tardivo 2015 25394692	nd	Brazil	Primary Prevention, Healthy
510	Tardivo 2015 25394692	nd	Brazil	Primary Prevention, Healthy
511	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
512	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
513	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
514	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
515	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
516	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
517	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
518	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
519	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
520	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
521	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
505	Soares, 2014, 24652053	Diabetes and/or metabolic syndrome ; Hypertension (systolic arterial pressure (SAP) of \geq 130 mmHg and a diastolic arterial pressure of \geq 85 mmHg); Dyslipidemia (a triglyceride level of \geq 150 mg/dL, and a high-density lipoprotein cholesterol (HDL-C) level of $<$ 40 mg/dL for men and $<$ 50 mg/dL for women); Obesity/Overweight (abdominal circumference (AC) of $>$ 88 cm for women and $>$ 102 cm for men)	70
506	Tardivo 2015 25394692	na	87
507	Tardivo 2015 25394692	na	87
508	Tardivo 2015 25394692	na	87
509	Tardivo 2015 25394692	na	87
510	Tardivo 2015 25394692	na	87
511	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
512	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
513	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
514	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
515	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
516	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
517	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
518	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
519	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
520	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
521	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
505	Soares, 2014, 24652053	51.6 (13.4)	28.6	nd
506	Tardivo 2015 25394692	55.1 (6.9)	0	100 Hispanic
507	Tardivo 2015 25394692	55.1 (6.9)	0	100 Hispanic
508	Tardivo 2015 25394692	55.1 (6.9)	0	100 Hispanic
509	Tardivo 2015 25394692	55.1 (6.9)	0	100 Hispanic
510	Tardivo 2015 25394692	55.1 (6.9)	0	100 Hispanic
511	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
512	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
513	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
514	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
515	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
516	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
517	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
518	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
519	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
520	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
521	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
505	Soares, 2014, 24652053	134.4 (35.1)/85.3 (21.2)
506	Tardivo 2015 25394692	137.2 (13.4)/85.8 (7.9)
507	Tardivo 2015 25394692	137.2 (13.4)/85.8 (7.9)
508	Tardivo 2015 25394692	137.2 (13.4)/85.8 (7.9)
509	Tardivo 2015 25394692	137.2 (13.4)/85.8 (7.9)
510	Tardivo 2015 25394692	137.2 (13.4)/85.8 (7.9)
511	Tatsuno, 2013, 24314359	nd
512	Tatsuno, 2013, 24314359	nd
513	Tatsuno, 2013, 24314359	nd
514	Tatsuno, 2013, 24314359	nd
515	Tatsuno, 2013, 24314359	nd
516	Tatsuno, 2013, 24314359	nd
517	Tatsuno, 2013, 24314359	nd
518	Tatsuno, 2013, 24314359	nd
519	Tatsuno, 2013, 24314359	nd
520	Tatsuno, 2013, 24314359	nd
521	Tatsuno, 2013, 24314359	nd

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
505	Soares, 2014, 24652053	nd/nd/47.3 (14.1)/199.6 (126.3)
506	Tardivo 2015 25394692	220.3 (36.4)/134.6(32.3)/45.3 (7.3)/190.6 (61.6)
507	Tardivo 2015 25394692	220.3 (36.4)/134.6(32.3)/45.3 (7.3)/190.6 (61.6)
508	Tardivo 2015 25394692	220.3 (36.4)/134.6(32.3)/45.3 (7.3)/190.6 (61.6)
509	Tardivo 2015 25394692	220.3 (36.4)/134.6(32.3)/45.3 (7.3)/190.6 (61.6)
510	Tardivo 2015 25394692	220.3 (36.4)/134.6(32.3)/45.3 (7.3)/190.6 (61.6)
511	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
512	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
513	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
514	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
515	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
516	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
517	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
518	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
519	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
520	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
521	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
505	Soares, 2014, 24652053	32.8 (8.1)	nd	nd
506	Tardivo 2015 25394692	32.4 (4.7)	nd	nd
507	Tardivo 2015 25394692	32.4 (4.7)	nd	nd
508	Tardivo 2015 25394692	32.4 (4.7)	nd	nd
509	Tardivo 2015 25394692	32.4 (4.7)	nd	nd
510	Tardivo 2015 25394692	32.4 (4.7)	nd	nd
511	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
512	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
513	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
514	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
515	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
516	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
517	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
518	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
519	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
520	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
521	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
505	Soares, 2014, 24652053	EPA+DHA vs EPA	µg/mL	Trial: Randomized Factorial Design	SBP
506	Tardivo 2015 25394692	EPA+DHA (0.9) vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
507	Tardivo 2015 25394692	EPA+DHA (0.9) vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
508	Tardivo 2015 25394692	EPA+DHA (0.9) vs Placebo	g/d	Trial: Randomized Parallel	Tg
509	Tardivo 2015 25394692	EPA+DHA (0.9) vs Placebo	g/d	Trial: Randomized Parallel	SBP
510	Tardivo 2015 25394692	EPA+DHA (0.9) vs Placebo	g/d	Trial: Randomized Parallel	DBP
511	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
512	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
513	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
514	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
515	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL:HDL-c ratio
516	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
517	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
518	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	Total:HDL-c ratio
519	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	HDL-c
520	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	HDL-c
521	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	HDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
505	Soares, 2014, 24652053	3.8 (1.2, 6.4)	3	1.266667
506	Tardivo 2015 25394692	0 (-3.48, 3.48)	0.9	0
507	Tardivo 2015 25394692	-5.7 (-20.72, 9.32)	0.9	-6.33
508	Tardivo 2015 25394692	-26 (-50.91, -1.09)	0.9	-28.89
509	Tardivo 2015 25394692	-13.9 (-20.92, -6.88)	0.9	-15.44
510	Tardivo 2015 25394692	-5.7 (-8.52, -2.88)	0.9	-6.33
511	Tatsuno, 2013, 24314359	1.8 (-2.4, 5.9)	NA	
512	Tatsuno, 2013, 24314359	-0.9 (-4.5, 2.8)	NA	
513	Tatsuno, 2013, 24314359	1.8% (-2.4, 5.9)	NA	
514	Tatsuno, 2013, 24314359	-0.9% (-4.5, 2.8)	NA	
515	Tatsuno, 2013, 24314359	2.6% (-1.5, 6.7)	1.68	
516	Tatsuno, 2013, 24314359	-0.5% (-3.9, 2.9)	NA	
517	Tatsuno, 2013, 24314359	-1.4 (-4.9, 2.1)	NA	
518	Tatsuno, 2013, 24314359	-0.9 (-3.9, 2.2)	NA	
519	Tatsuno, 2013, 24314359	0.30 (-1.72, 2.32)	NA	
520	Tatsuno, 2013, 24314359	1.30 (-0.74, 3.34)	NA	
521	Tatsuno, 2013, 24314359	1.00 (-0.98, 2.98)	1.68	0.5952381

Causality Table: Comparative Studies

Row	Study	Outcome classification
505	Soares, 2014, 24652053	Secondary
506	Tardivo 2015 25394692	Secondary
507	Tardivo 2015 25394692	Secondary
508	Tardivo 2015 25394692	Secondary
509	Tardivo 2015 25394692	Secondary
510	Tardivo 2015 25394692	Secondary
511	Tatsuno, 2013, 24314359	Secondary
512	Tatsuno, 2013, 24314359	Secondary
513	Tatsuno, 2013, 24314359	Secondary
514	Tatsuno, 2013, 24314359	Secondary
515	Tatsuno, 2013, 24314359	Secondary
516	Tatsuno, 2013, 24314359	Secondary
517	Tatsuno, 2013, 24314359	Secondary
518	Tatsuno, 2013, 24314359	Secondary
519	Tatsuno, 2013, 24314359	Secondary
520	Tatsuno, 2013, 24314359	Secondary
521	Tatsuno, 2013, 24314359	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
522	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
523	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
524	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
525	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
526	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
527	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
528	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
529	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
530	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
531	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
532	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
533	Tatsuno, 2013, 24314359	2009	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
534	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
535	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
536	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
522	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
523	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
524	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
525	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
526	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
527	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
528	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
529	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
530	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
531	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
532	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
533	Tatsuno, 2013, 24314359	Dyslipidemia (fasting triglyceride level \geq 150 mg/dL and $<$ 750 mg/dL at weeks 4 and 2 during the screening period)	611
534	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
535	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
536	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
522	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
523	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
524	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
525	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
526	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
527	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
528	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
529	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
530	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
531	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
532	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
533	Tatsuno, 2013, 24314359	55.6 (10.5)	80.5	nd
534	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
535	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
536	Tavazzi, 2008, 18757090	67 (11)	78.8	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
522	Tatsuno, 2013, 24314359	nd
523	Tatsuno, 2013, 24314359	nd
524	Tatsuno, 2013, 24314359	nd
525	Tatsuno, 2013, 24314359	nd
526	Tatsuno, 2013, 24314359	nd
527	Tatsuno, 2013, 24314359	nd
528	Tatsuno, 2013, 24314359	nd
529	Tatsuno, 2013, 24314359	nd
530	Tatsuno, 2013, 24314359	nd
531	Tatsuno, 2013, 24314359	nd
532	Tatsuno, 2013, 24314359	nd
533	Tatsuno, 2013, 24314359	nd
534	Tavazzi, 2008, 18757090	126 (18)/77 (10)
535	Tavazzi, 2008, 18757090	126 (18)/77 (10)
536	Tavazzi, 2008, 18757090	126 (18)/77 (10)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
522	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
523	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
524	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
525	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
526	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
527	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
528	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
529	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
530	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
531	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
532	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
533	Tatsuno, 2013, 24314359	nd/130.1 (30.5)/ /271.8 (91.53)
534	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
535	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
536	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
522	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
523	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
524	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
525	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
526	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
527	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
528	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
529	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
530	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
531	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
532	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
533	Tatsuno, 2013, 24314359	26.3 (3.6)	ALA: 195 (nd) µg/mL, EPA: 73 (nd) µg/mL, DHA: 184 (nd) µg/mL	plasma
534	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
535	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
536	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
522	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	LDL-c
523	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	LDL-c
524	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	LDL-c
525	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	Tg
526	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	Tg
527	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	Tg
528	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	SBP
529	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	SBP
530	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	SBP
531	Tatsuno, 2013, 24314359	EPA+DHA vs EPA+DHA	g/d	Trial: Randomized Parallel	DBP
532	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	DBP
533	Tatsuno, 2013, 24314359	EPA+DHA vs EPA	g/d	Trial: Randomized Parallel	DBP
534	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Atrial fibrillation
535	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause
536	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, CVD (total)

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
522	Tatsuno, 2013, 24314359	3.40 (-2.58, 9.38)	NA	
523	Tatsuno, 2013, 24314359	4.70 (-1.08, 10.48)	NA	
524	Tatsuno, 2013, 24314359	1.30 (-4.40, 7.00)	1.68	0.7738096
525	Tatsuno, 2013, 24314359	-24.80 (-42.22, -7.38)	NA	
526	Tatsuno, 2013, 24314359	-35.00 (-53.35, -16.65)	NA	
527	Tatsuno, 2013, 24314359	-37.20 (-53.86, -20.54)	1.68	-22.14286
528	Tatsuno, 2013, 24314359	2.6 (nd)	NA	
529	Tatsuno, 2013, 24314359	1.0 (nd)	NA	
530	Tatsuno, 2013, 24314359	1.6 (nd)	1.68	0.952381
531	Tatsuno, 2013, 24314359	0.4 (nd)	1.68	0.2380952
532	Tatsuno, 2013, 24314359	-0.8 (nd)	NA	
533	Tatsuno, 2013, 24314359	-1.2 (nd)	NA	
534	Tavazzi, 2008, 18757090	HR 1.10 (0.96, 1.25)	0.866	1.116343
535	Tavazzi, 2008, 18757090	Adj HR 0.91 (0.833, 0.998)	0.866	0.8968167
536	Tavazzi, 2008, 18757090	Adjusted HR 0.90 (0.81-0.99) ^b	0.866	0.8854464

Causality Table: Comparative Studies

Row	Study	Outcome classification
522	Tatsuno, 2013, 24314359	Secondary
523	Tatsuno, 2013, 24314359	Secondary
524	Tatsuno, 2013, 24314359	Secondary
525	Tatsuno, 2013, 24314359	Secondary
526	Tatsuno, 2013, 24314359	Secondary
527	Tatsuno, 2013, 24314359	Secondary
528	Tatsuno, 2013, 24314359	Secondary
529	Tatsuno, 2013, 24314359	Secondary
530	Tatsuno, 2013, 24314359	Secondary
531	Tatsuno, 2013, 24314359	Secondary
532	Tatsuno, 2013, 24314359	Secondary
533	Tatsuno, 2013, 24314359	Secondary
534	Tavazzi, 2008, 18757090	Secondary
535	Tavazzi, 2008, 18757090	Primary (stated)
536	Tavazzi, 2008, 18757090	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
537	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
538	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
539	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
540	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
541	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
542	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
543	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
544	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
545	Tavazzi, 2008, 18757090	2002	Italy	Secondary Prevention (history of CVD event)
546	Tierney, 2011, 20938439	2004	Netherlands, Norway, Sweden, UK, Ireland, France, Poland, Spain	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
547	Tierney, 2011, 20938439	2004	Netherlands, Norway, Sweden, UK, Ireland, France, Poland, Spain	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
537	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
538	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
539	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
540	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
541	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
542	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
543	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
544	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
545	Tavazzi, 2008, 18757090	Cardiac disease (symptomatic heart failure of any cause and with any level of left ventricular ejection fraction (LVEF))	6975
546	Tierney, 2011, 20938439	Diabetes and/or metabolic syndrome	206
547	Tierney, 2011, 20938439	Diabetes and/or metabolic syndrome	206

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
537	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
538	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
539	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
540	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
541	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
542	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
543	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
544	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
545	Tavazzi, 2008, 18757090	67 (11)	78.8	nd
546	Tierney, 2011, 20938439	54.7 (SE 0.91)	80	nd
547	Tierney, 2011, 20938439	54.7 (SE 0.91)	80	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
537	Tavazzi, 2008, 18757090	126 (18)/77 (10)
538	Tavazzi, 2008, 18757090	126 (18)/77 (10)
539	Tavazzi, 2008, 18757090	126 (18)/77 (10)
540	Tavazzi, 2008, 18757090	126 (18)/77 (10)
541	Tavazzi, 2008, 18757090	126 (18)/77 (10)
542	Tavazzi, 2008, 18757090	126 (18)/77 (10)
543	Tavazzi, 2008, 18757090	126 (18)/77 (10)
544	Tavazzi, 2008, 18757090	126 (18)/77 (10)
545	Tavazzi, 2008, 18757090	126 (18)/77 (10)
546	Tierney, 2011, 20938439	139.53 (SE 1.46)/85.50 (SE 0.87)
547	Tierney, 2011, 20938439	139.53 (SE 1.46)/85.50 (SE 0.87)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
537	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
538	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
539	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
540	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
541	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
542	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
543	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
544	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
545	Tavazzi, 2008, 18757090	nd[median 1.42 (1.05, 1.98)]
546	Tierney, 2011, 20938439	[5.22 (SE 0.10)]/[3.17 (SE 0.11)]/[1.09 (SE 0.03)]/[1.67 (SE 0.10)]
547	Tierney, 2011, 20938439	[5.22 (SE 0.10)]/[3.17 (SE 0.11)]/[1.09 (SE 0.03)]/[1.67 (SE 0.10)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
537	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
538	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
539	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
540	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
541	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
542	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
543	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
544	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
545	Tavazzi, 2008, 18757090	27 (5)	EPA: 0.85 (0.77) mol%, DPA: 0.78 (0.32) mol%, DHA: 3.4 (1.2) mol%	plasma
546	Tierney, 2011, 20938439	32.51 (SE 0.42)/91.96 (SE 1.38)	nd	nd
547	Tierney, 2011, 20938439	32.51 (SE 0.42)/91.96 (SE 1.38)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
537	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Death, stroke
538	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	MACE
539	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
540	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Stroke
541	Tavazzi, 2008, 18757090	ALA+DHA+EPA vs Placebo	g/d	Trial: Randomized Parallel	Sudden cardiac death
542	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
543	Tavazzi, 2008, 18757090	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
544	Tavazzi, 2008, 18757090	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
545	Tavazzi, 2008, 18757090	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
546	Tierney, 2011, 20938439	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
547	Tierney, 2011, 20938439	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
537	Tavazzi, 2008, 18757090	OR 1.13 (0.75, 1.71)	0.866	1.151573
538	Tavazzi, 2008, 18757090	HR 0.92 (0.85, 0.999)	0.866	0.9082064
539	Tavazzi, 2008, 18757090	Adj HR 0.82 (0.63-1.06)	0.866	0.7952028
540	Tavazzi, 2008, 18757090	HR 1.16 (0.89, 1.51)	0.866	1.186948
541	Tavazzi, 2008, 18757090	OR 0.94 (0.79, 1.1)	0.866	0.9310431
542	Tavazzi, 2008, 18757090	"no differences"	0.866	
543	Tavazzi, 2008, 18757090	"no differences"	0.866	
544	Tavazzi, 2008, 18757090	nd		
545	Tavazzi, 2008, 18757090	nd		
546	Tierney, 2011, 20938439	0.77 (-2.439, 3.983)	1.2	0.6416667
547	Tierney, 2011, 20938439	-5.41 (-17.72, 6.91)	1.2	-4.508333

Causality Table: Comparative Studies

Row	Study	Outcome classification
537	Tavazzi, 2008, 18757090	Secondary
538	Tavazzi, 2008, 18757090	Secondary
539	Tavazzi, 2008, 18757090	Secondary
540	Tavazzi, 2008, 18757090	Secondary
541	Tavazzi, 2008, 18757090	Secondary
542	Tavazzi, 2008, 18757090	Secondary
543	Tavazzi, 2008, 18757090	Secondary
544	Tavazzi, 2008, 18757090	Secondary
545	Tavazzi, 2008, 18757090	Secondary
546	Tierney, 2011, 20938439	Secondary
547	Tierney, 2011, 20938439	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
548	Tierney, 2011, 20938439	2004	Netherlands, Norway, Sweden, UK, Ireland, France, Poland, Spain	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
549	Tierney, 2011, 20938439	2004	Netherlands, Norway, Sweden, UK, Ireland, France, Poland, Spain	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
550	Tierney, 2011, 20938439	2004	Netherlands, Norway, Sweden, UK, Ireland, France, Poland, Spain	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
551	Vazquez 2014 24462043	2011	Spain	Primary Prevention
552	Vazquez 2014 24462043	2011	Spain	Primary Prevention
553	Vazquez 2014 24462043	2011	Spain	Primary Prevention
554	Vazquez 2014 24462043	2011	Spain	Primary Prevention
555	Vazquez 2014 24462043	2011	Spain	Primary Prevention
556	Vecka, 2012, 23183517	2010 (approx)	Czech Republic	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
557	Vecka, 2012, 23183517	2010 (approx)	Czech Republic	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
558	Vecka, 2012, 23183517	2010 (approx)	Czech Republic	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
559	von Schacky, 1999, 10189324	1992	Canada	Secondary Prevention (history of CVD event)
560	von Schacky, 1999, 10189324	1992	Canada	Secondary Prevention (history of CVD event)
561	von Schacky, 1999, 10189324	1992	Canada	Secondary Prevention (history of CVD event)
562	von Schacky, 1999, 10189324	1992	Canada	Secondary Prevention (history of CVD event)
563	von Schacky, 1999, 10189324	1992	Canada	Secondary Prevention (history of CVD event)
564	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
565	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
548	Tierney, 2011, 20938439	Diabetes and/or metabolic syndrome	206
549	Tierney, 2011, 20938439	Diabetes and/or metabolic syndrome	206
550	Tierney, 2011, 20938439	Diabetes and/or metabolic syndrome	206
551	Vazquez 2014 24462043	Healthy	273
552	Vazquez 2014 24462043	Healthy	273
553	Vazquez 2014 24462043	Healthy	273
554	Vazquez 2014 24462043	Healthy	273
555	Vazquez 2014 24462043	Healthy	273
556	Vecka, 2012, 23183517	Diabetes and/or metabolic syndrome	60
557	Vecka, 2012, 23183517	Diabetes and/or metabolic syndrome	60
558	Vecka, 2012, 23183517	Diabetes and/or metabolic syndrome	60
559	von Schacky, 1999, 10189324	nd	223
560	von Schacky, 1999, 10189324	nd	223
561	von Schacky, 1999, 10189324	nd	223
562	von Schacky, 1999, 10189324	nd	223
563	von Schacky, 1999, 10189324	nd	223
564	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
565	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
548	Tierney, 2011, 20938439	54.7 (SE 0.91)	80	nd
549	Tierney, 2011, 20938439	54.7 (SE 0.91)	80	nd
550	Tierney, 2011, 20938439	54.7 (SE 0.91)	80	nd
551	Vazquez 2014 24462043	57.3 (10.2)	52.4	nd
552	Vazquez 2014 24462043	57.3 (10.2)	52.4	nd
553	Vazquez 2014 24462043	57.3 (10.2)	52.4	nd
554	Vazquez 2014 24462043	57.3 (10.2)	52.4	nd
555	Vazquez 2014 24462043	57.3 (10.2)	52.4	nd
556	Vecka, 2012, 23183517	52.4	65	nd
557	Vecka, 2012, 23183517	52.4	65	nd
558	Vecka, 2012, 23183517	52.4	65	nd
559	von Schacky, 1999, 10189324	58.9 (8.1)	78.6	nd
560	von Schacky, 1999, 10189324	58.9 (8.1)	78.6	nd
561	von Schacky, 1999, 10189324	58.9 (8.1)	78.6	nd
562	von Schacky, 1999, 10189324	58.9 (8.1)	78.6	nd
563	von Schacky, 1999, 10189324	58.9 (8.1)	78.6	nd
564	Yokoyama, 2007, 17398308	61 (9)	31	nd
565	Yokoyama, 2007, 17398308	61 (9)	31	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
548	Tierney, 2011, 20938439	139.53 (SE 1.46)/85.50 (SE 0.87)
549	Tierney, 2011, 20938439	139.53 (SE 1.46)/85.50 (SE 0.87)
550	Tierney, 2011, 20938439	139.53 (SE 1.46)/85.50 (SE 0.87)
551	Vazquez 2014 24462043	140.5 (18.6)/83.9 (10.3)
552	Vazquez 2014 24462043	140.5 (18.6)/83.9 (10.3)
553	Vazquez 2014 24462043	140.5 (18.6)/83.9 (10.3)
554	Vazquez 2014 24462043	140.5 (18.6)/83.9 (10.3)
555	Vazquez 2014 24462043	140.5 (18.6)/83.9 (10.3)
556	Vecka, 2012, 23183517	nd
557	Vecka, 2012, 23183517	nd
558	Vecka, 2012, 23183517	nd
559	von Schacky, 1999, 10189324	129.6 (17.8)/79.8 (9.6)
560	von Schacky, 1999, 10189324	129.6 (17.8)/79.8 (9.6)
561	von Schacky, 1999, 10189324	129.6 (17.8)/79.8 (9.6)
562	von Schacky, 1999, 10189324	129.6 (17.8)/79.8 (9.6)
563	von Schacky, 1999, 10189324	129.6 (17.8)/79.8 (9.6)
564	Yokoyama, 2007, 17398308	135 (21)/79 (13)
565	Yokoyama, 2007, 17398308	135 (21)/79 (13)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
548	Tierney, 2011, 20938439	[5.22 (SE 0.10)]/[3.17 (SE 0.11)]/[1.09 (SE 0.03)]/[1.67 (SE 0.10)]
549	Tierney, 2011, 20938439	[5.22 (SE 0.10)]/[3.17 (SE 0.11)]/[1.09 (SE 0.03)]/[1.67 (SE 0.10)]
550	Tierney, 2011, 20938439	[5.22 (SE 0.10)]/[3.17 (SE 0.11)]/[1.09 (SE 0.03)]/[1.67 (SE 0.10)]
551	Vazquez 2014 24462043	197.6 (41.3)/119.8 (39.0)/46.2 (12.9)/170.6 (94.3)
552	Vazquez 2014 24462043	197.6 (41.3)/119.8 (39.0)/46.2 (12.9)/170.6 (94.3)
553	Vazquez 2014 24462043	197.6 (41.3)/119.8 (39.0)/46.2 (12.9)/170.6 (94.3)
554	Vazquez 2014 24462043	197.6 (41.3)/119.8 (39.0)/46.2 (12.9)/170.6 (94.3)
555	Vazquez 2014 24462043	197.6 (41.3)/119.8 (39.0)/46.2 (12.9)/170.6 (94.3)
556	Vecka, 2012, 23183517	/[3.22]/[1.19]/[3.23]
557	Vecka, 2012, 23183517	/[3.22]/[1.19]/[3.23]
558	Vecka, 2012, 23183517	/[3.22]/[1.19]/[3.23]
559	von Schacky, 1999, 10189324	[6.10 (1.13)]/[4.00 (0.91)]/[1.30 (0.36)]/[2.16 (1.10)]
560	von Schacky, 1999, 10189324	[6.10 (1.13)]/[4.00 (0.91)]/[1.30 (0.36)]/[2.16 (1.10)]
561	von Schacky, 1999, 10189324	[6.10 (1.13)]/[4.00 (0.91)]/[1.30 (0.36)]/[2.16 (1.10)]
562	von Schacky, 1999, 10189324	[6.10 (1.13)]/[4.00 (0.91)]/[1.30 (0.36)]/[2.16 (1.10)]
563	von Schacky, 1999, 10189324	[6.10 (1.13)]/[4.00 (0.91)]/[1.30 (0.36)]/[2.16 (1.10)]
564	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
565	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
548	Tierney, 2011, 20938439	32.51 (SE 0.42)/91.96 (SE 1.38)	nd	nd
549	Tierney, 2011, 20938439	32.51 (SE 0.42)/91.96 (SE 1.38)	nd	nd
550	Tierney, 2011, 20938439	32.51 (SE 0.42)/91.96 (SE 1.38)	nd	nd
551	Vazquez 2014 24462043	32.6 (4.4)	nd	nd
552	Vazquez 2014 24462043	32.6 (4.4)	nd	nd
553	Vazquez 2014 24462043	32.6 (4.4)	nd	nd
554	Vazquez 2014 24462043	32.6 (4.4)	nd	nd
555	Vazquez 2014 24462043	32.6 (4.4)	nd	nd
556	Vecka, 2012, 23183517	weight 89.6	nd	nd
557	Vecka, 2012, 23183517	weight 89.6	nd	nd
558	Vecka, 2012, 23183517	weight 89.6	nd	nd
559	von Schacky, 1999, 10189324	weight 78.3 (11.1)	nd	nd
560	von Schacky, 1999, 10189324	weight 78.3 (11.1)	nd	nd
561	von Schacky, 1999, 10189324	weight 78.3 (11.1)	nd	nd
562	von Schacky, 1999, 10189324	weight 78.3 (11.1)	nd	nd
563	von Schacky, 1999, 10189324	weight 78.3 (11.1)	nd	nd
564	Yokoyama, 2007, 17398308	24 (3)	nd	nd
565	Yokoyama, 2007, 17398308	24 (3)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
548	Tierney, 2011, 20938439	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
549	Tierney, 2011, 20938439	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
550	Tierney, 2011, 20938439	ALA+EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
551	Vazquez 2014 24462043	EPA+DHA 0.64 vs Placebo	g/d	Trial: Randomized Cross-over	HDL-c
552	Vazquez 2014 24462043	EPA+DHA 0.64 vs Placebo	g/d	Trial: Randomized Cross-over	LDL-c
553	Vazquez 2014 24462043	EPA+DHA 0.64 vs Placebo	g/d	Trial: Randomized Cross-over	Tg
554	Vazquez 2014 24462043	EPA+DHA 0.64 vs Placebo	g/d	Trial: Randomized Cross-over	SBP
555	Vazquez 2014 24462043	EPA+DHA 0.64 vs Placebo	g/d	Trial: Randomized Cross-over	DBP
556	Vecka, 2012, 23183517	EPA+DHA vs Placebo	g/d	Non-randomized cross-over study	HDL-c
557	Vecka, 2012, 23183517	EPA+DHA vs Placebo	g/d	Non-randomized cross-over study	LDL-c
558	Vecka, 2012, 23183517	EPA+DHA vs Placebo	g/d	Non-randomized cross-over study	Tg
559	von Schacky, 1999, 10189324	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
560	von Schacky, 1999, 10189324	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
561	von Schacky, 1999, 10189324	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	Tg
562	von Schacky, 1999, 10189324	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	SBP
563	von Schacky, 1999, 10189324	EPA+DHA vs Placebo	g/d	Trial: Randomized Parallel	DBP
564	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Angina, unstable
565	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Death, all cause

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
548	Tierney, 2011, 20938439	-19.47 (-44.12, 5.18)	1.2	-16.225
549	Tierney, 2011, 20938439	0.1 (-, -4, 4.2)	1.2	0.0833333
550	Tierney, 2011, 20938439	0.7 (-1.7, 3.1)	1.2	0.0833333
551	Vazquez 2014 24462043	-0.69 (-2.16, 0.78)	0.64	-1.08
552	Vazquez 2014 24462043	-3.01 (-7.15, 1.13)	0.64	-4.7
553	Vazquez 2014 24462043	-3.96 (-15.08, 7.16)	0.64	-6.19
554	Vazquez 2014 24462043	-0.28 (-2.63, 2.07)	0.64	-0.44
555	Vazquez 2014 24462043	-1.32 (-2.5, -0.14)	0.64	-2.06
556	Vecka, 2012, 23183517	1.9 (-25.4, 29.2) [difference of final values]	2.58	0.9363636
557	Vecka, 2012, 23183517	10.4 (9.8, 11.1) [difference of final values]	2.58	
558	Vecka, 2012, 23183517	-82.3 (-852.6, 688) [difference of final values]	2.58	-31.89923
559	von Schacky, 1999, 10189324	3.1 (-1.0, 7.2)	3.3	
560	von Schacky, 1999, 10189324	5.79 (-5.66, 17.24)	3.3	1.754545
561	von Schacky, 1999, 10189324	-49.56 (-81.42, -17.70)	3.3	-15.01818
562	von Schacky, 1999, 10189324	-0.1 (-5.0, 4.8)	3.3	-0.030303
563	von Schacky, 1999, 10189324	0.2 (-2.8, 3.2)	3.3	
564	Yokoyama, 2007, 17398308	HR 0.76 (0.62, 0.95)	0.9	0.7371751
565	Yokoyama, 2007, 17398308	HR 1.09 (0.92, 1.28)	1.8	

Causality Table: Comparative Studies

Row	Study	Outcome classification
548	Tierney, 2011, 20938439	Secondary
549	Tierney, 2011, 20938439	Secondary
550	Tierney, 2011, 20938439	Secondary
551	Vazquez 2014 24462043	Secondary
552	Vazquez 2014 24462043	Secondary
553	Vazquez 2014 24462043	Primary (stated)
554	Vazquez 2014 24462043	Primary (stated); Secondary in registry record (NCT01758601)
555	Vazquez 2014 24462043	Primary (stated)
556	Vecka, 2012, 23183517	No data; unclear
557	Vecka, 2012, 23183517	No data; unclear
558	Vecka, 2012, 23183517	No data; unclear
559	von Schacky, 1999, 10189324	Secondary
560	von Schacky, 1999, 10189324	Secondary
561	von Schacky, 1999, 10189324	Secondary
562	von Schacky, 1999, 10189324	Secondary
563	von Schacky, 1999, 10189324	Secondary
564	Yokoyama, 2007, 17398308	Secondary; Primary in registry record (NCT00231738)
565	Yokoyama, 2007, 17398308	Secondary

Causality Table: Comparative Studies

Row	Study	Study years (start date)	Country	Population
566	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
567	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
568	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
569	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
570	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
571	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
572	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
573	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
574	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
575	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
576	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
577	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)
578	Yokoyama, 2007, 17398308	1996	Japan	Primary Prevention, Increased CVD Risk (ie, diabetes, metabolic syndrome*, hypertension, dyslipidemia, or chronic kidney disease)

Causality Table: Comparative Studies

Row	Study	Risk type	Sample size (total)
566	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
567	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
568	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
569	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
570	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
571	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
572	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
573	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
574	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
575	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
576	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
577	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319
578	Yokoyama, 2007, 17398308	Dyslipidemia (total cholesterol concentration of 6.5 mmol/L or greater, which corresponded to a LDL cholesterol of 4.4 mmol/L or greater)	9319

Causality Table: Comparative Studies

Row	Study	Age mean (SD) [median] years	Sex (% male)	Race
566	Yokoyama, 2007, 17398308	61 (9)	31	nd
567	Yokoyama, 2007, 17398308	61 (9)	31	nd
568	Yokoyama, 2007, 17398308	61 (9)	31	nd
569	Yokoyama, 2007, 17398308	61 (9)	31	nd
570	Yokoyama, 2007, 17398308	61 (9)	31	nd
571	Yokoyama, 2007, 17398308	61 (9)	31	nd
572	Yokoyama, 2007, 17398308	61 (9)	31	nd
573	Yokoyama, 2007, 17398308	61 (9)	31	nd
574	Yokoyama, 2007, 17398308	61 (9)	31	nd
575	Yokoyama, 2007, 17398308	61 (9)	31	nd
576	Yokoyama, 2007, 17398308	61 (9)	31	nd
577	Yokoyama, 2007, 17398308	61 (9)	31	nd
578	Yokoyama, 2007, 17398308	61 (9)	31	nd

Causality Table: Comparative Studies

Row	Study	Blood pressure SBP/DBP mmHg
566	Yokoyama, 2007, 17398308	135 (21)/79 (13)
567	Yokoyama, 2007, 17398308	135 (21)/79 (13)
568	Yokoyama, 2007, 17398308	135 (21)/79 (13)
569	Yokoyama, 2007, 17398308	135 (21)/79 (13)
570	Yokoyama, 2007, 17398308	135 (21)/79 (13)
571	Yokoyama, 2007, 17398308	135 (21)/79 (13)
572	Yokoyama, 2007, 17398308	135 (21)/79 (13)
573	Yokoyama, 2007, 17398308	135 (21)/79 (13)
574	Yokoyama, 2007, 17398308	135 (21)/79 (13)
575	Yokoyama, 2007, 17398308	135 (21)/79 (13)
576	Yokoyama, 2007, 17398308	135 (21)/79 (13)
577	Yokoyama, 2007, 17398308	135 (21)/79 (13)
578	Yokoyama, 2007, 17398308	135 (21)/79 (13)

Causality Table: Comparative Studies

Row	Study	Lipids: Total cholesterol/LDL/HDL/Triglycerides mean (SD) mg/dL [mmol/L]
566	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
567	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
568	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
569	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
570	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
571	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
572	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
573	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
574	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
575	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
576	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
577	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]
578	Yokoyama, 2007, 17398308	[7.11 (0.68)]/[4.70 (0.75)]/[1.51 (0.44)]/[median 1.74 (1.25,2.49)]

Causality Table: Comparative Studies

Row	Study	BMI mean (SD) Kg/m ² /Weight mean (SD) Kg	Baseline n-3 intake	n-3 source (Baseline)
566	Yokoyama, 2007, 17398308	24 (3)	nd	nd
567	Yokoyama, 2007, 17398308	24 (3)	nd	nd
568	Yokoyama, 2007, 17398308	24 (3)	nd	nd
569	Yokoyama, 2007, 17398308	24 (3)	nd	nd
570	Yokoyama, 2007, 17398308	24 (3)	nd	nd
571	Yokoyama, 2007, 17398308	24 (3)	nd	nd
572	Yokoyama, 2007, 17398308	24 (3)	nd	nd
573	Yokoyama, 2007, 17398308	24 (3)	nd	nd
574	Yokoyama, 2007, 17398308	24 (3)	nd	nd
575	Yokoyama, 2007, 17398308	24 (3)	nd	nd
576	Yokoyama, 2007, 17398308	24 (3)	nd	nd
577	Yokoyama, 2007, 17398308	24 (3)	nd	nd
578	Yokoyama, 2007, 17398308	24 (3)	nd	nd

Causality Table: Comparative Studies

Row	Study	n-3 type(s)	n-3 measure	Study design	Outcome
566	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Death, cardiac
567	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Death, CHD
568	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	MACE
569	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
570	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Myocardial infarction
571	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Revascularization
572	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Stroke
573	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Sudden cardiac death
574	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	HDL-c
575	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	LDL-c
576	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	Tg
577	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	SBP
578	Yokoyama, 2007, 17398308	EPA vs Placebo	g/d	Trial: Randomized Parallel	DBP

Causality Table: Comparative Studies

Row	Study	Reported effect Size	Dose/intake difference	Dose-corrected effect size
566	Yokoyama, 2007, 17398308	HR 0.87 (0.46, 1.64)	1.8	0.9255494
567	Yokoyama, 2007, 17398308	HR 1.10 (0.47, 2.60)	1.8	1.054377
568	Yokoyama, 2007, 17398308	HR 0.81 (0.69, 0.95)	1.8	0.8895254
569	Yokoyama, 2007, 17398308	HR 0.79 (0.52, 1.19)	1.8	0.8772556
570	Yokoyama, 2007, 17398308	HR 0.75 (0.47, 1.19)	1.8	0.8522943
571	Yokoyama, 2007, 17398308	HR 0.86 (0.71, 1.05)	1.8	0.9196239
572	Yokoyama, 2007, 17398308	HR 1.08 (0.95, 1.22)	1.8	
573	Yokoyama, 2007, 17398308	OR 1.24 (0.36, 4.28)	1.8	1.12694
574	Yokoyama, 2007, 17398308	-0.4 (-0.9, 0.1)	1.8	
575	Yokoyama, 2007, 17398308	0 (-0.9, 0.9)	1.8	
576	Yokoyama, 2007, 17398308	-8.9 (-11.0, -6.7)	1.8	
577	Yokoyama, 2007, 17398308	0 (-0.9, 0.9)	1.8	
578	Yokoyama, 2007, 17398308	0 (-0.4, 0.4)	1.8	

Causality Table: Comparative Studies

Row	Study	Outcome classification
566	Yokoyama, 2007, 17398308	Secondary
567	Yokoyama, 2007, 17398308	Primary (stated)
568	Yokoyama, 2007, 17398308	Secondary
569	Yokoyama, 2007, 17398308	Secondary; Primary in registry record (NCT00231738)
570	Yokoyama, 2007, 17398308	Secondary; Primary in registry record (NCT00231738)
571	Yokoyama, 2007, 17398308	Secondary; Primary in registry record (NCT00231738)
572	Yokoyama, 2007, 17398308	Secondary
573	Yokoyama, 2007, 17398308	Secondary; Primary in registry record (NCT00231738)
574	Yokoyama, 2007, 17398308	Secondary
575	Yokoyama, 2007, 17398308	Secondary
576	Yokoyama, 2007, 17398308	Secondary
577	Yokoyama, 2007, 17398308	Secondary
578	Yokoyama, 2007, 17398308	Secondary